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Between May 1992 and June 2001, 309 epidermolysis bullosa (EB) sufferers were identified
in Scotland (EB simplex [EBS] 175, dystrophic EB [DEB] 130, junctional EB [JEB] 4). The
point prevalences ofEB per million in June 2001 were: EBS (all variants) 33.2, the Dowling-
Meara subtype of EBS (EBS-DM) 1.2, JEB 0.3, DEB (all subtypes) 24.6, dominant DEB
(DDEB)l 7.4, DEB of uncertain inheritance (DEB-unc) 4.6, the Hallopeau-Siemens subtype of
recessively inherited DEB (RDEB-HS) 1.4, localised RDEB (RDEB-loc) 1.0, and the inverse
pattern of RDEB (RDEB-inv) 0.2. Incidences per million live births were EBS (all subtypes)
34.4, JEB 3.2, and DEB (all subtypes) 26.4. Although the prevalence figures for EBS and DEB
are the highest ofany yet reported, extrapolation ofaccurate data for the Lothians suggests that
the prevalences of EBS and DEB in Scotland are underestimates.
Detailed clinical information on 130 EBS patients revealed considerable overlap between EBS-
WC and EBS-Kb. As both phenotypes were frequently seen within the same pedigree and in
patients bearing identical mutations, EBS-WC is best regarded as a mild variant of EBS-Kb
rather than as a separate disorder. Improvement with age was common in EBS but not
invariable. Nail involvement and aplasia cutis congenita were seen in all subtypes of EBS.
Seasonal variation was confirmed as being common in EBS-Kb/EBS-WC and absent in EBS-
DM. In contrast to previously held views, substantial minorities of those with EBS-Kb/EBS-
WC experienced oral blisters (17%) and blisters at sites in addition to the palms and soles
(43%). Oral blisterswere previously thought to occuronly in EBS-DM. Laryngeal involvement,
usually associated with JEB, also occurred in EBS-DM.
Clinical features ofDEB were recorded in 97 patients. Scarring, gastrointestinal involvement,
albopapuloid lesions and EB-pruriginosa each occurred in both DDEB and RDEB. External ear
involvement, a feature not often reported in DEB, was common in RDEB and also occurred in
a minority of those with DDEB. With increasing age, squamous cell carcinoma was a major
cause ofmortality. Most of those with DDEB had relatively mild disease, their QOL scores
reflecting less impairment ofQOL than EBS sufferers. Whilst patients with RDEB-HS reported
a greater impairment ofQOL than patients with any other skin disease, EBS caused more pain
than DDEB and had a greater effect on friendships, physical and non-leisure activities.
Twenty different keratin gene mutations (15 novel) were found amongst EBS patients,
increasing the number of reported pathogenic keratin mutations by 23%. Disease severity was
determined by the position of the mutation, but was also influenced by the nature of the amino
acid substitution. Failure to detect keratin mutations in two families with classical EBS,
suggests that abnormalities of genes other than KRT5 and KRT14 may cause an identical
phenotype in a minority. In DDEB, 3 glycine substitution mutations ofCOL7A1,2 novel, were
found in 5 families. G2043R was confirmed as being a common cause of DDEB. Two novel
mutations were found in patients with RDEB-HS, but identification of mutations in DEB
patients proved difficult. The reasons for marked inter and intra familial phenotypic variation
in both EBS and DEB are unknown.
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The collective term "epidermolysis bullosa" (EB) refers to a group ofinherited disorders
in which blistering of the skin and mucous membranes occurs in response to minor
mechanical trauma. Three major types ofEB are recognized (Fine 2000), each defined
according to the level of the cleavage plane at the dermoepidermal junction. In EB
simplex (EBS), cleavage occurs through the subnuclear portion of basal keratinocytes;
in junctional EB (JEB) the split is either through the lamina lucida or, rarely, through the
lowermost part ofbasal keratinocytes (Mellerio and Pulkkinen 1998); in dystrophic EB
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Figure 1. The dermoepidermal junction and EB.
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❖ = blister cavity, d = lamina densa, 1 = lamina lucida
(Magnifications : A = x 18,000; B = x 28,000; C = x 15,000)
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1.2. EB simplex.
EB was regarded as a variant ofpemphigus (von Hebra 1870, Fox 1879) until Valentin
(1885) used the term "hereditare dermatitis bullosa" to describe what we would now
recognize as EBS. The following year, for the first time, Kobner (1886) introduced the
phrase "epidermolysis bullosa hereditaria" when reporting another family with the same
disorder. The patients described all experienced dominantly inherited seasonal non-
scarring blisters which occurred predominantly on the palms and soles during the
warmer months (Figure 3). As both Valentin and Kobner pointed out, blisters also
occurred at sites offriction from clothing, especially under "garters, braces and corsets".
Blisters in similarly affected patients were observed on light microscopy to occurwithin
the epidermis (Siemens 1921). A more localised variant ofEBS in which blisters were
confined to the feet, was described by both Weber (1926) and Cockayne (1938) under
the title "recurrent bullous eruption ofthe feet". Both authors regarded this as an atypical
variant ofEB. It has since become customary to use the term "EBS Weber-Cockayne"
(EBS-WC) to indicate localised EBS, in which only the palms and soles are involved
and to refer to EBS- Kobner (EBS-Kb) when describing more widespread blistering.
Some authors have preferred to reserve the title "EBS-Kb" for rare recessively inherited
EBS with severe widespread blistering. In the literature there has been a tendency to use
these terms interchangeably, sometimes without an accompanying clear clinical
description. There remains confusion as to whether EBS-WC and EBS-Kb are identical
conditions.
Dowling and Meara (1954) described four unrelated children who developed non-
13
seasonal spontaneous or trauma-induced blisters which were present at birth or appeared
during the next 72 hours. Blisters were numerous, appearing on any body site including
mucousmembranes. Scarringwas not a feature. The clinical picture resembled "juvenile
dermatitis herpetiformis", blisters healing at the centre but spreading peripherally to
produce "a circinate pattern of bullae" (Figure 4). The eldest child also had
hyperkeratosis of the palms and soles. This disorder was recognized by Dowling and
Meara as a form ofEB, but they were unable to place it into the existing classification.
Light microscopy ofskin from their patients appeared to show subepidermal bullae, but
more recently, electron microscopy of skin from similarly affected patients has shown
that the split occurs through the subnuclear portion of basal keratinocytes (Anton-
Lamprecht 1979), confirming this to be a variant ofEBS. It is now well recognized and
known as EBS-Dowling Meara (EBS-DM). In the neonate, blistering can occasionally
be so extensive as to be fatal, but if this early period is survived, there is usually some
improvement ofthe blistering tendency during childhood and adolescence and a normal
life expectancy (McGrath 1992). Most patients have no preceding family history, but
ifmore than one generation is affected, inheritance is autosomal dominant.
In all subtypes of EBS, the ultrastructural appearance is of a subnuclear split through
basal keratinocytes and the hemidesmosomes appear normal. In EBS-DM, there is
characteristic clumping of keratin tonofilaments which is not usually seen in other
variants of EBS (Figure 5).
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Figure 3. Blisters on the sole in EBS WC/Kb.
Figure 4. Herpetiform blisters
ofEBS-DM.
Figure 5. Tonofilament clumping within a suprabasal keratinocyte in EBS-DM.
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1.3. Molecular basis of EBS
During the last decade, spectacular progress has been made in elucidating the causes of
EB and it is now well established that EBS-WC, EBS-Kb and EBS-DM are due to
mutations of genes on chromosomes 12 or 17 encoding keratin 5 (KRT5) or keratin 14
(KRT14) (Bonifas, Lane 1992). Both keratins are expressed within basal keratinocytes,
forming heterodimers which are assembled into intermediate filaments. These form a
dense network, acting as a cytoskeleton which imparts strength and rigidity to the cell.
Keratin tonofilaments also provide cell to cell interconnections via desmosomes and
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Figure 6. Attachment of keratin tonofilaments to desmosomes and hemidesmosomes
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Both the site and nature of keratin gene mutations influence the phenotype. EBS-DM,
the most severe subtype of EBS, is due to mutations occurring within the highly
conserved helix initiation or termination motifs. Milder forms of EBS are seen when
mutations occur at other sites (Irvine 1999).
Less common variants of EBS.
Other variants ofEBS have been describedmore recently, but appear to be less common
than the Weber-Cockayne and Dowling-Meara variants.
1.4. EBS with mottled pigmentation.
EBS withmottled pigmentation (EBS-MP), also inherited in dominant fashion, was first
identified by Fischer and Gedde-Dahl (1979) and a total of eight unrelated affected
families have now been reported. (Irvine 2001). Patients have non-scarring seasonal
blisters occurring predominantly on the extremities and mottled macular pigmentation
on the trunk and limbs. They also develop punctate keratoses ofthe palms and soles and
most have nail abnormalities. The histological and ultrastructural appearances are
similar to EBS-WC, EBS-Kb and EBS-DM, showing a sub-nuclear cleavage plane
through basal keratinocytes and clumping ofkeratin tonofilaments. In seven ofthe eight
families an identical causative point mutation of keratin 5 (P25L) has been reported
(Irvine 2001).
1.5. Recessively inherited subtypes of EBS.
A small number of patients with homozygous mutations of keratin 14 have been
reported (Hovnanian 1993, Rugg 1994, Chan 1994, Jonkman 1996, Corden 1998, Batta
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2000). Most have severe widespread blistering but although Batta's patient was shown
to have a complete absence of functional keratin 14, blistering in this patient was
relatively mild. Recessive inheritance of EBS has to date been reported only in
consanguineous families. In one large family, there is a clear dominant pattern of
inheritance inmost individuals, associatedwithmild disease. Themore severely affected
daughter of first cousins in this pedigree was shown to be homozygous for the same
keratin 14 mutation responsible for mild blistering in each of her heterozygous parents
(Hu 1997).
1.6. Plectin
1.6a EBS with muscular dystrophy.
EBS associated with muscular dystrophy (EBS-MD) is a rare autosomal recessive
variant ofEBS ofwidely varying severity (Niemi 1988, Shimizu and Takizawa 1999).
Generalised blisters are usually present at birth or shortly thereafter. Occasionally
blisteringmay be seasonal and atrophic scarring sometimes occurs. There is usually nail
involvement and teeth are often abnormal. Some patients develop urethral strictures or
scarring alopecia and a few infants have experienced respiratory difficulty (Mellerio
1997). Extensive cerebral and cerebellar atrophy has also been identified in some
patients (Smith 1996). The age ofonset ofmuscle weakness ranges widely from as early
as 1 year to as late as 35 years. Mutations of varying disruptive potential have been
described in these patients in the gene encoding plectin (Smith 1996, Shimizu and
Takizawa 1999). Plectin is expressed in awide variety of tissues, including skin,muscle
and the central nervous system where it is found in association with the membrane
18
attachment sites of a variety of intermediate filaments. Within keratinocytes, it is
localised to the inner plaques of hemidesmosomes (Figure 7) (Smith 1996, Pulkkinen
and Uittol 999.) The cleavage plane in EBS-MD lies closer to the basement membrane
than in other variants of EBS and hemidesmosomes appear abnormal. Like other
subtypes of EB, the nature of the underlying mutations influences the severity of the






Figure 7. Localisation of the major components of the dermoepidermal junction.
Because the clinical features ofEBS-MD vary so much, it is likely that many patients
with this subtype of EBS have been mis-classified, especially those with minimally
disruptive mutations or patients in whom weakness has yet to develop.
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1.6b. Ogna variant of EBS
This variant ofEBS was originally described in a single Norwegian family (Gedde-Dahl
1970). In addition to seasonal blistering ofthe palms and soles, sufferers had generalised
non-seasonal skin fragility. This resulted in the occurrence of small erosions of a few
days duration, on the extremities, limbs, face and occasionally on the trunk. Healing
occurred without subsequent scarring. Many affected members of this large family also
had dystrophic great toe nails. A second similarGerman family has since been identified
and in both, inheritance is autosomal dominant. Recently, both families have been
shown to carry an identical dominantly inherited mutation of plectin (Koss-Harnes
2002). In contrast to patients having recessively inherited mutations ofplectin, muscle
weakness has not occurred in any affected individuals in these two families.
1.7. Dystrophic EB.
Scarring variants of EB with clinical features distinct from EBS were described by
Tilbury Fox (1879), Brocq (1890), Herzfeld (1892) and Hallopeau (1898). Both
Cockayne (1933) and Touraine (1942) described larger clinical series of such patients
with identical clinical features and who clearly had dominantly inherited disease.
Patients experienced blisters particularly over their knees, elbows, hands and feet which
left atrophic scars as they healed. Nails were missing or thickened and milia were
common, especially in children (Figure 8). Patients with these clinical features would
now be classified as having dominantly inherited DEB (DDEB) but mildly affected
patients who showed only subtle scarring and minimal nail dystrophy were until quite
recently often considered to have EBS. Pasini (1928) described two patients, who in
20
addition to the clinical features ofDDEB, also had numerous small ivory-white papules
on the trunk and limbs. He termed these "albo-papuloid lesions" (Figure 9). DDEB was
traditionally sub-divided into two types - one in which albopapuloid lesions were
present, termed Pasini-DEB, and a second, Cockayne-Touraine DEB, in which
albopapuloid lesions were absent and which was thought to be less severe. The current
classification recognises that both these variants of DDEB can occur within an
individual pedigree and recommends that the distinction between them should be
abandoned (Fine 2000). The cause and significance of albopapuloid lesions is
unknown. They consist of collagen bundles and amorphous material within the upper
dermis, the latter staining positively with Alcian blue (Nomura 1997).
Another group ofpatients show similar butmore severe clinical features which Siemens
(1921) pointed out were associated with recessive inheritance. Blisters are more
widespread than in DDEB and are present from birth or the succeeding few hours. Like
the more mildly affected patients, these individuals also have nail loss or dystrophy and
develop scarring at sites of previous blisters. In addition, they develop anaemia,
flexion contractures of fingers and limbs, oesophageal and urethral strictures and anal
stenosis. There is extensive involvement of the oral cavity and scarring here causes
restriction ofmouth opening (microstomia) and tethering ofthe tongue (ankyloglossia).
Scalp and body hair is sparse and affected individuals do not usually undergo puberty.
A characteristic feature of this variant of recessively inherited DEB (RDEB) is the
mitten deformity of the hands and feet (Figure 10).
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Figure 8. Scarring, nail dystrophy and Figure 9. Albopapuloid lesions on the
milia on the hand in DEB. trunk in DEB.
Figure 10. Mitten deformity in RDEB-HS.
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Webs ofscar tissue form between adjacent digits, which become increasingly flexed and
ultimately encased within a covering of skin. Infants and young children are at risk of
developing septicaemia secondary to loss ofextensive areas ofskin, whilst 50% ofthose
surviving to adult life develop at least one squamous cell carcinoma by the age of 40
(Uitto 2000). These tumours behave particularly aggressively in patients suffering from
the Hallopeau-Siemens variant of RDEB (RDEB-HS), most dying within 5 years of
detection of their first tumour (Uitto 2000). Not all patients with recessively inherited
DEB have such a severe phenotype, some having a localized form of the disease and
others having predominantly flexural involvement, the so-called inverse pattern (RDEB-
inv). Gastrointestinal involvement may occur in all subtypes ofDEB (Travis 1992).
1.8. Molecular basis of dystrophic EB.
Under the electron microscope, the cleavage plane in DEB is always found just below
the lamina densa (Figures 1 and 2) and anchoring fibrils may appear reduced in number,
rudimentary or absent (Tidman 1985). Hemidesmosomes are normal.
All variants ofdystrophic EB appear to be due to mutations ofthe gene on chromosome
3 which encodes typeVll collagen (COL7A1); this is the major component ofanchoring
fibrils. The RDEB-HS phenotype is seen in the presence ofhomozygous or compound
heterozygous premature termination codon mutations, which usually cause no clinical
abnormality in the heterozygous state (Pulkkinen and Uitto 1999). Most patients with
dominantly inherited disease have been found to havemutations causing either a glycine
substitution or (less frequently) in-frame deletions of20 - 30 amino acids of the typeVll
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collagen molecule (Christiano 1994, Mellerio 1999). Not all dominantly inherited
glycine substitutions result in clinical abnormalities, some causing symptoms only in the
presence of an additional mutation which itselfmay be clinically silent when present
alone (Winberg 1997, Hammami-Hauasli 1998). The nature, position and the precise
combination of mutations in patients who are compound heterozygotes, or who have
DDEB, has a profound effect on the severity of the phenotype (Shimizu and
Masunagal999, Murata 2000, Gardella 2002).
Other variants of dystrophic EB.
1.9. EB pruriginosa and pre-tibial EB.
These terms are used to describe DEB accompanied by itching and prurigo-like or
lichenified lesions associated with scarring (Garcia-Perez 1975, McGrath 1994). The
changes are most obvious on the limbs, and clinically resemble hypertrophic lichen
planus. EB pruriginosa occurs in both DDEB and RDEB and a variety of causative
mutations ofCOL7A1 have been described. Mutations do not appear to be specific for
this clinically distinctive subset ofDEB, as family members with the same mutation and
classical features ofDEB often lack pruginous lesions and do not complain of itch.
1.10. Bart's syndrome
Many individuals in a large kindred reported by Bart (1966) had localised congenital
absence of skin; there was also dominant inheritance of blistering and nail dystrophy.
For some years this was considered to be a separate subtype type of EB, but recent
studies ofmembers of this family have shown them to have DDEB caused by a glycine
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substitution mutation of COL7A1 (Christiano 1996). Localised absence of skin is not
specific for DEB as it has been noted in each of the three major subtypes ofEB (Kanzler
1992).
1.11. Transient bullous dermolysis of the newborn
Some infants have extensive blistering at birth which resolves or dramatically improves
during the succeeding few months (Hashimoto 1985). There is usually a family history
indicating dominant inheritance. Intracytoplasmic retention of type VII collagen within
basilar and suprabasilar keratinocytes is seen at the time of disease activity, but
following cessation of blistering, collagen VII is confined to the dermoepidermal
junction, the appearance being indistinguishable from nonnal skin (Fine 1993).
Causative mutations of collagen VII, both heterozygous and compound heterozygous,
have been identified in patients with this variant of DEB (Christiano and Fine, 1997,
Hammami-Hauasli 1998).
1.12. Junctional EB
Herlitz (193 5) reported a recessively inherited non-scarring variant ofEB in which death
occurred at a few months of age. Initially, this was thought to be the same disorder as
RDEB and there was diagnostic confusion until Pearson (1974) demonstrated by
transmission electronmicroscopy that the plane ofcleavage in the Herlitz variantofJEB
(JEB-H) was through the lamina lucida; this was in contrast to the deeper cleavage plane
found in DEB. In addition to fragility ofthe skin and mucous membranes, neonates with
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JEB-H develop absent or dystrophic nails, often with paronychia, and granulation tissue
of the nail folds and nail beds. Perioral granulation tissue is a characteristic feature in
those who survive beyond 6 months ofage. Unlike RDEB, there is minimal involvement
of the hands and feet and very few milia. If survival is prolonged until eruption of teeth
occurs, pitting or hypoplasia of dental enamel is seen. Affected infants usually fail to
thrive and develop profound anaemia. Death is often due to septicaemia, but blistering
or strictures of the larynx or trachea can cause sudden death. Post mortem examination
reveals widespread involvement ofmucous membranes, including the mouth, pharynx,
oesophagus, jejunum, gall bladder, colon, anus and the urinary tract. It should be noted
that post-mortem changes in the gall bladder are not specific to EB (Smith and Miller
1992).
It became apparent that some patients with recessive inheritance, extensive non-scarring
blistering and a cleavage plane through the lamina lucida, survive to adult life. This type
of JEB was originally termed "non-lethal JEB" but it is now included under the group
heading of JEB-nEI (Fine 2000). Identification of such patients during infancy on the
basis of clinical features is usually impossible, and examination of the morphology of
hemidesmosomes does not reliably allow distinction of lethal from non-lethal forms of
JEB (Tidman 1986). The GB3 monoclonal antibody proved to be a useful aid to
diagnosis, as normal staining of the dermoepidermal junction was never seen in the
Herlitz variant of JEB (Schofield 1990). This antibody was later found to bind with the
y2chain of laminin 5 (see below).
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Another group of individuals developing blisters at the level of the lamina lucida have
a normal lifespan but their blisters heal to leave "cigarette paper-like" atrophic scarring.
Blisters occur from birth, affecting both skin and mucous membranes. Involvement of
hair follicles results in a scarring alopecia affecting all hair bearing areas of the body.
Nail dystrophy and enamel hypoplasia occur and melanocytic naevi are seen at sites of
previous blisters. This variant of JEB was initially termed generalised atrophic benign
epidermolysis bullosa (GABEB) (Hintner 1982) but it is now classified as a non-Herlitz
variant of JEB (Fine 2000).
A small number ofpatients have been described who clinically appear to have DEB but
who on ultrastructural examination, are shown to have a cleavage plane through the
lamina lucida. Until recently this was termed cicatricial JEB (Haber 1985), but it is now
grouped with other non-lethal variants ofJEB under the heading JEB-nH. Like all other
JEB subtypes, inheritance is recessive.
Another group ofpatients have blistering from birth and pyloric atresia. Ultrastructural
examination of the skin usually shows a lamina lucida cleavage plane, but occasionally
the split occurs through the lowermost portion of basal keratinocytes (Mellerio and
Pulkkinenl998, Wasel 2000). The disease is usually fatal within the first few months
of life, even after successful surgical correction of the gastrointestinal abnormality. In
those few who survive, repeated blistering within the urogenital tract can eventually
cause strictures which in turnmay lead to hydronephrosis and renal failure (Dank 1999).
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Advances in identifying molecular abnormalities in EB have led to simplification of the
classification of JEB, which now recognizes 5 clinical variants: Herlitz (JEB-H), non-
Herlitz (JEB-nH), JEB with pyloric atresia (JEB-PA), an inverse phenotype (JEB-I) and
late onset JEB (JEB-lo) (Fine 2000).
1.13. Molecular basis of junctional EB
1.13a. Herlitz and non-Heriitz variants of junctional EB
The lamina lucida is traversed by fine anchoring filaments which consist predominantly
of laminin 5 and insert into the lamina densa (Figure 7). Laminin 5 is composed of three
individual polypeptide chains - a3, [33 and y2, each encoded by a different gene -
LAMA3 (on chromosome 18q), LAMB3 (on chromosome lq32) and LAMC2 (on
chromosome 1 q25-q31) respectively (Nakano 2002). JEB-H is caused by severely
disruptivemutations, usually premature termination codons, in both alleles ofany ofthe
genes encoding laminin 5. Over 80% ofmutations identified in JEB-H have occurred
in LAMB3 (Pulkkinen and Marinkovich 1999, Nakano 2002). JEB-nH is usually due
to a premature termination codon on one allele combined with a less disruptivemutation
on the second allele (Nakano 2002).
1.13b. Generalised atrophic benign epidermolysis bullosa
Some patients withGABEB (now included under the heading JEB-nH) have less severe
mutations ofgenes encoding laminin 5, butmost (90%) havemutations ofthe COL17A1
(BPAG2) gene, found on chromosome 6pl 1-12 ( Pulkkinen and Marinkovich 1999).
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This encodes collagen XVII (the 180 kd bullous pemphigoid antigen, BPAg2), a
transmembranous protein extending from basal keratinocytes across the cell membrane
to the lamina densa (Figure 7) (Masunaga 1997). Although most identified mutations
ofCOL17A1 appear to cause premature termination codons, the resulting phenotype is
milder than JEB-H and compatible with normal life expectancy. Mis-sense mutations
in one or both alleles cause mainly acral blistering and mild atrophy of affected skin
(Schumann 1997).
1.13c. Junctional EB with pyloric atresia
JEB-PA is caused by mutations ofa different hemidesmosomal gene/protein system. The
a6(34 integrin is expressed in skin, gastrointestinal, respiratory and urogenital
tracts(Valari 1995). Like collagenXVII, it is a transmembranous protein extending from
Basal keratinocyte




Dermis Anchoring fibrils Type Vli collagen
Figure 7. Localisation of the major components of the dermoepidermal
junction.
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the cytoplasm ofbasal keratinocytes to the outer plaque ofhemidesmosomes (Figure 7).
Intracellularly, it interacts with plectin and collagen XVII; extracellular domains of the
molecule also interact with collagen XVII and additionally with laminin 5 (Jonkman
2002). Mutations of the genes (ITGA6 and ITGB4) encoding both integrin a6 and
integrin |34 have been identified and, like the other variants of EB, the site and nature
of the mutations appears to correlate with the severity ofthe phenotype. Inmost patients,
the cleavage plane is through the lamina lucida, but a small number of patients have
been reported in whom cleavage is through the lowermost portion ofkeratinocytes, close
to the basement membrane (Mellerio and Pulkkinenl998, Wasel 2000).
Diagnosis ofEB subtype by electron microscopy and a steadily increasing number of
monoclonal antibodies, has led to rapid progress in understanding the structure and
function ofthe dermoepidermal junction. Mutations ofat least 10 genes are now known
to cause disruption of the close interaction between keratin intermediate filaments,
hemidesmosomes and collagen VII (McMillan 1998) resulting in cutaneous fragility
(Table 1).
Protein Gene Variant of EB
Keratin 5 KRT5 EBS
Keratin 14 KRT14 EBS
Plectin PLEC1 EBS-MD or EBS Ogna
Laminin 5 - a3 polypeptide LAMA3 JEB-H or JEB-nH
- (33 polypeptide LAMB3 JEB-H or JEB-nH
- y2 polypeptide LAMC2 JEB-H or JEB-nH
Collagen XVII COL17A1 JEB-nH (GABEB)
a6[34 integrin - a6 polypeptide ITGA6 JEB-PA
- (34 polypeptide ITGB4 JEB-PA
Collagen VII COL7A1 DEB - all subtypes
Table 1. Proteins and genes implicated in sub-types of epidermolysis bullosa.
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Evidence has gradually emerged of the relative importance of the proteins encoded by
these genes in maintaining the integrity of the dermoepidermal junction . Complete
absence of laminin 5 or the a6p4 integrin is rapidly fatal, whilst absence of collagen
XVII, collagen VII, keratin 5 or keratin 14, is compatible with survival to adult life.
1.14. Pre-natal diagnosis
The recent exciting advances have been of practical benefit to the care of patients. By
determination ofEB subtype it is usually now possible to accurately predict a patient's
prognosis and to provide genetic counselling. Ifpregnancy occurs in a family known to
be at risk ofhaving an affected child, knowledge of the family-specific mutation allows
pre-natal diagnosis by chorionic villous biopsy at 10 to 12 weeks of pregnancy.
Termination of an affected foetus can then be offered within the first trimester. Before
mutation detection was so readily available, diagnosis relied on foetal skin biopsy, a
procedure still undertaken if mutations are unknown. This technique has the serious
disadvantage that itmust be delayed until 18-21 weeks of gestation. Before then, foetal
skin is not sufficiently well developed to allow detection of diagnostic features.
Knowledge of mutation(s) in an affected family now permits use of the alternative
technique ofpre-implantation diagnosis (Shimizu and Suzumori 1999). In this method,
which utilises in vitro fertilisation, a single cell is removed from the blastomere at the
eight cell stage and mutation detection analysis is carried out. Disease-free embryos are
then implanted into the uterus. Although this technique has the advantage of avoiding
the need for termination ofan affected foetus, it is not widely available, pregnancy rates
are relatively low and it is costly.
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In future, it may prove possible to search formutations in nucleated foetal erythrocytes
circulating in maternal blood, a technique which would have the great advantage of
posing no risk to the pregnancy (Poon 2000, Saito 2000, Beroud 2003).
1.15. Unusual inheritance
The ability to detect mutations has led to the discovery that inheritance of EB is not
always as would be predicted from the pedigree. In two families, uniparental disomy
has been detected (Uitto 1999). The affected neonate in each case was homozygous for
a severely disruptive mutation of LAMB3 and it was expected that each parent would
be heterozygous for the same mutation. This was confirmed in the case of the mother,
but the father did not carry the mutation. After non-paternity was excluded, it was
concluded that the infants had each inherited two copies of the mother's single allele.
The risk to any subsequent pregnancy would be no greater than in the general
population. Without the benefitofmutation analyses, the risk to subsequent pregnancies
in these families would have been predicted as 1:4.
Germline mosaicism in a clinically unaffected parent can also cause disease in one or
more offspring and has recently been described in both JEB-H (Cserhalmi-Friedman
2002) and DDEB (Cserhalmi-Friedman 2001). Without the benefit of DNA analysis,
which must include the affected child and both parents, no distinction can be made
between recessive inheritance, a de-novo mutation or germline mosaicism. Each mode
of inheritance is associated with very different risks to subsequent pregnancies.
Recessive inheritance carries a 1 in 4 risk of a foetus being affected. In the case of a de-
novo mutation, the risk to subsequent pregnancies is no higher than in the general
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population, but ifone parent has germline mosaicism, the likelihood ofhaving another
affected child is much higher, and depends on the ratio ofmutant to wild type germ
cells. Ifgonadal mosaicism occurs in the father, analysis ofa semen sample can give an
indication of the proportion ofmutant germ cells, but an equivalent estimation is not
possible in maternal germ cell mosaicism (Cserhalmi-Friedman 2001, 2002).
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1.16. Aims of this thesis.
1. To determine the prevalence and incidence of EB in Scotland.
2. To document the spectrum of clinical features in Scottish EB sufferers.
3. To correlate the underlying genetic mutations with the clinical features.
4. To investigate the effect of EB on quality of life.
Despite the exciting advances during the last 10 years in understanding the underlying
causes of EB, there is very little information about the epidemiology of these rare
diseases. The most comprehensive study to date is that of the Norwegian survey of
Gedde-Dahl (1970). This was an excellent survey ofEB in Norway, but patients were
classified at the time as having only either EB simplex (Weber-Cockayne or Kobner) or
dystrophic EB.NeitherjunctionalEB norEBS-DMwere recognised. Subsequently, after
electron microscopy was carried out by Anton-Lamprecht, many families were
reclassified. Although diagnostic techniques have advanced since Gedde-Dahl
completed his work and the classification ofEB has become more detailed, his study
remains the basis for comparison by any future survey of the epidemiology of EB.
Themost ambitious survey ofEB is the National EB Registry, currently being compiled
in the USA (Fine 1999). Although up to date diagnostic techniques, using both
monoclonal antibodies and electron microscopy are available to the research team, the
large size of the country and the health care system are both factors contributing to the
exclusion ofpatients with mild disease. Because of its unique characteristics, Scotland
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was selected by DEBRA for compilation of the first section of the United Kingdom EB
register. This part of Britain has the advantages of being both politically and
geographically well defined; its relatively stable population of 5 million (General
Register Office for Scotland) is small enough to permit thorough assessment whilst
being large enough to reveal the full clinical spectrum of EB.
There are numerous reports in the literature of mutations identified in a variety ofEB
subtypes, but there are very few studies which systematically examine mutations within
a defined population. Those which do exist, whilst of interest, are small (Humphries
1996, Sorensen 1999).
During the past few years, quality of life has been assessed in a number of
dermatological conditions. To those familiar with EB, it is clear that this group of
disorders has a major impact on the lives ofEB sufferers and their families, but to date
there have been no studies of quality of life in EB.
This project, which began in 1992, sets out to investigate the epidemiology ofEB and
some of the less well documented clinical aspects of this group ofdisorders. These are
subjects which have not been adequately studied, and which put into perspective the
numerous and exciting laboratory discoveries in the field ofEB during recent years.
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Chapter Two
The Prevalence of Epidermolysis Bullosa in Scotland
2.1 Introduction
The inherited forms of epidermolysis bullosa are rare disorders and there are few
published studies oftheir epidemiology (Table 2). The most detailed surveys have been
undertaken in Norway (Gedde-Dahl 1970), Northern Ireland (McKenna 1992) and
Finland (Kero 1984), countries which each have a population of fewer than 5 million
inhabitants. In several other countries, assessments ofthe prevalence ofEB have yielded
low figures, suggesting incomplete sampling, differing genetic susceptibilities or
pronounced regional variation. In the USA, an ambitious survey of American EB
sufferers is underway and has recently reported its early results (Fine 1999). A similar
register is being compiled in Italy (Tadini 1994).
Table 2. Reported prevalences of epidermolysis bullosa (per million)
EBS JEB DEB
Norwaya 24.3 - 9.3
N. Irelandb 28.0 0.7 3.3
Finland0 15.1 0.2 8.8
Croatiad 1.5 1.5 6.6
Japane 4.0 0.2 3.5
Saudi Arabiaf 1.7 0.0 3.7
S.Africa9 0.8 0.7 1.2










Scotland has the advantages of being politically and geographically well defined; its
relatively stable population ofapproximately 5 million (Registrar General for Scotland,
1991) is small enough to permit thorough assessmentwhilst being large enough to reveal
the full clinical spectrum ofEB.
2.2 Methods
Scottish patients suffering from inherited forms ofEB were identified from a diagnostic
index at the Royal Infirmary of Edinburgh, by general practitioners and by Scottish
dermatologists. All 515 Lothian general practitioners and all 38 Scottish dermatology
consultants were asked to provide, with patient consent, details of any EB sufferers
known to them. An advertisement directed at people suffering from blisters was placed
in a newspaper distributed in rural western Scotland. Further patients were identified by
probands and from routine referrals. All known affected individuals were invited to
participate in the survey. Patients were interviewed and examined either in their own
homes or at the Royal Infirmary ofEdinburgh. Whenever possible, parents and siblings
of probands were also examined. If personal contact was not feasible, patients were
interviewed by telephone.
Interviews were conducted with the help ofa detailed questionnaire previously devised
by the Dystrophic EB Research Association (DEBRA), and answers were entered into
a computerised database (Corel Quattro Pro). Classification ofEB subtype was made on
the basis of clinical features and where appropriate, by ultrastructural examination and
antibody mapping, using the criteria suggested by Fine (1991). Patients were classified
as having sporadic disease if there was no family history ofEB. Details ofall known EB
patients living in Scotland between May 1992 and June 2001 are included in this study.
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2.3 Results
Three hundred and nine patients from 103 families were identified during the study
period as suffering from EB (Table 3).
Table 3. Epidermolysis bullosa sufferers identified in Scotland from 1992 - 2001.
EBS JEB DEB
number of individuals 175 4 130
number of families 43 4 56
Enquiries to all 515 general practitioners in Lothian (population 726,010) at the onset
of the study brought replies from 340 doctors representing 93% ofpractices. They were
aware of only 20 of the 87 (23%) EB sufferers living in Lothian. One general
practitioner notified us of a previously unidentified sufferer who would subsequently
have been found by family enquiries. Of the 29 (76%) Scottish dermatologists who
replied to our enquiries, 13 were aware of37 EB sufferers. Fifteen of these patients from
12 families were not already known to us. The newspaper advertisement did not elicit
any replies. The majority ofpatients were identified from information supplied by their
affected relatives and from routine referrals to the dermatology clinic at the Royal
Infirmary of Edinburgh.
For practical reasons, fifty eight patients (29 EBS sufferers and 29 DEB sufferers) could
not be seen personally. Forty six of these individuals, (26 EBS and 20 DEB sufferers)
were identified by probands in whom the diagnosis and subtype of EB had been
confirmed. Ten had been seen at the Royal Infirmary ofEdinburgh before the onset of
the study (3 with EBS and 7 with DEB) and a further two patients (one with RDEB-HS
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and a second with DDEB) were diagnosed at other Scottish hospitals. Twelve ofthe 58
unseen patients were interviewed by telephone; the remaining 251 (81%) patients were
each interviewed and clinically assessed. The geographical distribution of all EB
sufferers is shown in Table 4 and Figure 11.








Borders 215.1 (23) 0 (0) 28.0 (3)
Central (Forth Valley) 0 (0) 0 (0) 7.1 (2)
Dumfries and Galloway 0 (0) 0 (0) 20.5 (3)
Fife 17.1 (6) 0 (0) 8.5 (3)
Grampian 34.3 (18) 0 (0) 32.4 (17)
Highland 43.1 (9) 0 (0) 4.7 (1)
Lothian 42.1 (33) 1.2 (1) 67.6 (53)
Orkney 0 (0) 51.3 (1) 0 (0)
Strathclyde 27.3 (62) 0 (0) 17.2 (39)
Tayside 36.3 (14) 0 (0) 5.1 (2)
Western Isles 0 (0) 0 (0) 36.7 (1)
Unknown - (5) - (0) - (2)
Scotland 33.2 (170) 0.3 (2) 24.6 (126)
Prevalences are per million
n = numbers of individuals








Figure 11. Location of EB sufferers within Scotland.
Large symbols represent numerous individuals; small symbols
represent single individuals or small families.
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2.3a Epidermolysis bullosa simplex
EB simplex (EBS) was diagnosed in 175 individuals ( 73 male, 102 female) from 43
families.
Eight subjects (4 male, 4 female) had the Dowling-Meara variant of EBS (EBS-DM).
Ages at interview ranged from one day to 48.7 years. The eldest had an affected son, and
the two youngestwere identical twins, but the remaining 4 patients had no family history
of EB. Examination of skin from one twin and from 4 other subjects by transmission
electron microscopy showed the characteristic ultrastructural features of this condition
(McGrath 1992). Ultrastructural examination of skin from the mother and son was not
undertaken as a causative mutation (K14Leul22Phe) had been identified prior to her
referral.
Of the remaining 167 EBS sufferers, 138 were interviewed. They were from 37
pedigrees, one with 36 and a second with 19 living affected individuals, and were aged
between 1 month and 78.3 years (average 26.4 years). Forty three (30%) of the EBS
patients interviewed had never consulted a dermatologist and twelve had no previous
family history of the disorder. No family history is available for one child who was born
in Romania and adopted by a Scottish family.
A 9 year old girl with Kobner EBS died from meningitis during the study. Two elderly
adults also died and two patients with EBS-DM moved away from Scotland.
When calculating the prevalence of EBS, the 5 patients known to have died or moved
away from Scotland were excluded from the figures, leaving a total EBS population of
170. Taking the population of Scotland as 5,114,600, (data from the General Register
Office for Scotland), the prevalence of EBS in June 2001 is calculated as 33.2 per
41
million, with the EBS-DM subtype accounting for 1.2 per million. During the period
1960 - 1999, a minimum of 103 people affected by EBS were born in Scotland (this
number excludes the child born in Romania). The total number oflive births in Scotland
during the same period was 2,995,052. Using these numbers, the incidence of EBS is
calculated as 34.4 permillion live births (Table 5).
Decade Total Scottish Number of affected live
live births births
EBS DEB
1990-1999 615,032 22 22
1980-1989 662,747 27 26
1970-1979 724,939 23 8
1960-1969 992,334 31 22
1950-1959 941,380 18 10
1940-1949 95,7934 11 11
1930-1939 893,357 16 9
1920-1929 1086,594 7 5
1910-1919 1139,535 4 2
1900-1909 1314,274 1 0
? 0 15 15
9,328,126 175 130
Table 5. Live EB births in Scotland.
2.3b Junctional epidermolysis bullosa
No sufferers of JEB were known to be living in Scotland at the outset of the study, but
four infants with 3 variants of this subtype of EB were subsequently diagnosed. Two,
who were unrelated, had the Herlitz subtype of JEB. Both were born to healthy
consanguineous parents. One, from a Pakistani family, was born in Scotland but the
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second was born in Libya to Libyan parents. Skin from each child showed a cleavage
plane through the lamina lucida and complete absence of staining with the GB3
antibody. Both children have since moved away from Scotland; one, now aged 7, is
known to be alive, but the second has been lost to follow up. A third child, born to
healthy Scottish parents not known to share a common ancestor, also had ultrastructural
findings diagnostic ofJEB. Staining with the GB3 antibody was present, but at reduced
intensity. Although blistering remains widespread, this child is growing well and is
assumed to have a non-Herlitz subtype of JEB.
A fourth child, born in England to healthy unrelated Caucasian parents, moved to
Scotland shortly after successful surgical correction of pyloric atresia. Lie had a very
mild blistering tendency. Details ofthis patient, who continues to live in Scotland, have
been published previously (Mellerio, Pulkkinen et al 1998). Briefly, ultrastructural
examination showed a cleavage plane through the lowermost portion of basal
keratinocytes close to the basement membrane. Hemidesmosomes were poorly formed
and sub-basal dense plates were absent. Staining with the GB-3 antibody was normal
but there was reduced staining of both the a6 and (34 integrin subunits. The child was
found to be a compound heterozygote formutations of ITGB4. Both he and his mother
carried a novel missense mutation in exon 3 of ITGB4 (C3 8R). The child was also found
to have a single base-pair deletion in exon 36 (4776delG), which was present in paternal
DNA and which causes a downstream premature termination codon.
The prevalence of JEB based on the two children still living in Scotland in June 2001
was 0.3 permillion (Table 4). Calculation of the incidence of JEB for the period 1990-
1999, based on two affected infants born in Scotland during this period, is 3.2 per
million. (Table 5)
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2.3c Dystrophic epidermolysis bullosa
Dystrophic EB (DEB) was identified in 130 individuals from 56 families. Four
subtypes ofDEB were seen. Dominant DEB (DDEB) occurred in 90 individuals (38
male, 52 female) from 19 families. The ages of the 67 interviewed patients (73%) with
this subtype ofDEB ranged from 2 days to 76 years (average 27 years). By the end of
the study period, one patient with DEB had moved away from Scotland. Localized
recessive DEB (RDEB-loc) was seen in 5 patients (2 male, 3 female) from 2 families.
Four, aged between 36 and 48 years (average age 40.8 years) were interviewed. Two
unrelated females, aged 47 years and 56 years suffered from the inverse variant of
recessive DEB (RDEB-inv). The elder, then aged 60, died during the study from a
squamous cell carcinomaofthe oesophagus. The severe generalised Hallopeau-Siemens
form of recessive DEB (RDEB-HS) occurred in 9 unrelated patients (3 males, 6
females). Eight, aged 3 days to 34.5 years (average age 11.4 years) were clinically
assessed. Two adults in this group died during the study period; one, aged 23, died from
metastatic squamous cell carcinoma and the second, aged 20, died as a result of gastric
aspiration which occurred during a 'flu-like illness. Twenty thee patients (13 male, 10
female) with DEB ofmild to moderate severity had unaffected parents and siblings and
their inheritance pattern could not be accurately classified. Twenty patients (87%) in this
group, aged from 2 months to 70 years (average 16.7 years), were interviewed. There
was insufficient information to allow determination of disease inheritance in one un-
interviewed child
The parents ofone patient with RDEB-inv, who lived in the rural Western Isles,
were shown to share a common ancestor, but consanguinity was not known in any other
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families affected by DEB. One patient withmild localized DEB but unaffected parents
and siblings had a cousin with severe RDEB-HS, as previously reported by Kemmett
(1990). Twenty eight (41%) interviewed DDEB patients had never been seen by a
dermatologist.
The prevalence of all forms ofDEB in Scotland in June 2001 is calculated as 24.6 per
million (DDEB 17.4, DEB-unc 4.7, RDEB-HS 1.4, RDEB-loc 1.0, RDEB-inv 0.2 per
million), and the incidence of DEB between 1960 and 1999, when 78 new DEB
sufferers were born in Scotland, was 26.4 per million (Table 5).
2.4 Discussion
Comparison ofall studies which have reported on the prevalence ofEB (Tables 2 and
6) shows the highest figures for all three major variants to be in Scotland. Some caution
is necessarywhenmaking such comparisons; the Norwegian survey (Gedde-Dahl 1970)
was undertaken before the widespread use ofelectron microscopy or antibody mapping.
Consequently, some patients were mis-classified. When ultrastructural examination of
skin from many of the Norwegian patients was later undertaken by Anton Lamprecht
(Gedde-Dahl 1990), two, originally classified as having DEB, had ultrastructural
features ofEBS-DM. A further 14 individuals or families thought initially to have DEB
were found to have JEB, a subtype ofEB which had not been recognized at the time of
Gedde-Dahl's original study. In both Finland (Kerol984) and Northern Ireland
(McKenna 1992), electron microscopy and antibody mapping were used. Although
detection of Irish EBS patients appears to be almost as complete as in Scotland, very
few Irish DEB sufferers were identified. The particularly high Scottish figure for DEB
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is accounted for by the large group suffering from DDEB; it is probable that many
patients with this often mild subtype of EB have gone unrecognized in other studies.
Some patients with DDEB are so mildly affected that they regard their skin as normal.
As the physical signs can be very subtle, careful clinical examination ofall relatives of
a proband is necessary if the more mildly affected family members are to be detected.






All EBS 33.2 4.6 34.4 10.75
EBS WC/Kb 32.0 - 32.1 -
EBS DM 1.2 - 2.3 -
JEB COd 0.4 3.2* 2.0
All DEB 24.6 2.38 26.4 5.72
DDEB 17.4 0.99 16.7 2.9
All RDEB 2.6 0.92 3.0 2.04
RDEB-HS 1.4 0.42 3.0 0.41
RDEB-inv 0.2 - - -
RDEB-loc 1.0 - - -
DEB-unc 4.6 0.47 6.0 0.82
t based on 2,.995,052 live births in Scotland from 1960-1999
* based on 615,032 live births in Scotland from 1990-1999
(Scottish population data from the General Register Office for Scotland)
The most ambitious EB register being compiled to date is in the USA. It is not yet
complete but has data on 2,214 patients (Fine 1999) (Table 6).
As in Scotland, just over 50% of their patients have EBS, but 9.2% (compared to 0.1%
in Scotland) suffer from JEB and 12.8% (compared to 5.1 % in Scotland) suffer from the
various RDEB subtypes. Only 12.3% of their patients suffer from DDEB, whilst this
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subtype accounts for 29% of our study population. These differences probably reflect
the relative ease with which the most severely affected people are traced, and will
become less marked as people with milder EB are included in the American register.
If the prevalence of EB in the USA is similar to that in Scotland, ten thousand more
American EB sufferers are yet to be traced. With the exception of Croatia (Pavicic
1990), where there is a surprisingly high prevalence ofRDEB-HS, the prevalences of
the recessive subtypes ofEB in Scotland are broadly similar to those reported from other
countries (Tables 2 and 6).
We have found a particularly high prevalence ofEBS in the Borders Region (Table 4),
where there are 4 apparently unrelated affected pedigrees, one having 19 affected living
members. Although consanguinity might be expected in this rural areaofScotland, it has
been excluded in the two families whose DNA has been studied. DNA from the
remaining two families has not yet been analysed.
In other rural areas of Scotland, the prevalence of EB is consistently lower than in
regions where the major cities are located (Table 4). Perhaps EB sufferers tend to
gravitate towards major centres to avail themselves of medical services and
opportunities for non-manual employment.
In the Lothians, there is a particularly high prevalence ofEB (EBS 42.1, DEB 67.6). Part
of this figure is probably accounted for by more thorough searching on our home
territory where we have the benefit of an EB database and where our interest is known
to local general practitioners. It seems reasonable to assume that the prevalence ofEB
in other urban areas of Scotland should be similar to that in Lothian, and if this is so,
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many Scottish EB patients distant from Edinburgh remain undetected. Previously
unknown adults suffering from EB come to light each year, confirming that these figures
are undoubtedly underestimates.
The only other studies to comment on the sex ratio in EB are the British Medical
Research Council study (Davison 1965) and Fine (1999) who both found a ratio of 1:1
for all EB subtypes. The slight excess of females in the Scottish study (EBS 1.4:1,
DEBUT) is probably due to incomplete sampling.
The Scottish study, although not the largest, appears be the most comprehensive
population survey of EB yet published. It demonstrates that a large proportion of
sufferers with the less severe forms ofEB are unknown to both general practitioners and
dermatologists, illustrating how difficult it is to achieve accurate estimates of the
prevalence of EB. Increased use of computer databases in both hospitals and general
practice will allow easier tracing of patients who do present to the medical profession,




The Clinical Spectrum of Epidermolysis Bullosa Simplex
3.1 Introduction.
Perhaps because it is often regarded as the least severe form ofEB, there is relatively
little documentation of the clinical features of EBS. Clinical descriptions in papers
reporting newly identified mutations are often very brief and standard dermatology
textbooks contain some inaccuracies. During compilation ofthe EB Register, it became
clear that within individual pedigrees there are often marked differences in severity of
disease and some variation of clinical features which cannot be accounted for by age
differences. This study is an attempt to record the complete clinical spectrum of EBS
within the Scottish population.
In this paper, the term "EBS-Kb" is used to describe patients who fit Kobner's (1886)
original description of seasonal blistering, predominantly on the palms and soles, but
occurring in addition at other sites of friction such as beneath sock garters, in the groins
and under corsets."EBS-WC" is used to describe blistering confined exclusively to the
palms and soles (Weber1926, Cockayne 1933). This study was completed in 1999.
3.2 Patients and Methods.
In 1999, one hundred and sixty eight individuals in Scotland were known to suffer from
EBS. One hundred and forty nine were identified and assessed during compilation ofthe
EB Register (Horn1997), and a further 19 were subsequently referred to the Department
ofDermatology at the Royal Infirmary ofEdinburgh (RIE). Detailed clinical information
was recorded on 130 patients from 33 families. Of the remaining 38 patients, 30 were
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affected relatives, identified by the probands but not yet interviewed. Information on a
further 5 unrelated patients was incomplete. The remaining 3 patients were diagnosed
at other Scottish hospitals as suffering from EBS, but not seen by the author. This study
reports the clinical features in the group of 130 patients for whom information was
complete.
3.3 Results
The three commonest sub-types of EBS were encountered in this group of Scottish
patients - namely Dowling-Meara (5%), Weber Cockayne (42%) and Kobner (53%).
3.3a The Dowling-Meara subtype ofEBS.
This was the most severe variant ofEBS and was identified in 7 patients aged between
three weeks and 49 years at initial interview. The two youngest were identical twins, but
the remaining five patients were unrelated. None had an affected parent. The eldest (and
only patient over 18 years ofage) had an affected son, for whom no clinical information
is available and who was therefore not included in the study. Blisters were congenital
in four, and appeared during the first week after birth in the other three (Table 7). One
of the seven was born with an area of absent epidermis on one leg. All experienced
widespread blistering which, after the first few months of postnatal life, took on the
clustered herpetiform appearance characteristic of EBS-DM (McGrath 1992). The
severity of blistering lessened during childhood and adolescence in all patients. The four
infants in the study had intraoral blistering and hoarse cries. Two have been followed
up for several years; their hoarseness resolved during their third year. All subjects had
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nail involvement. In the case ofthe infants, this consisted ofperiodic shedding of finger
and toe nails which subsequently regrew. The adults had thickened great toe nails. None
experienced any seasonal variation ofthe blistering tendency. Mild hyperkeratosis ofthe
weight-bearing areas of the soles was seen in the two eldest patients, aged 17 and 49
years. Although friction from close fitting clothing was an important cause of blisters
in all patients with EBS-DM, many blisters appeared to arise spontaneously. Scarring
was not seen in any subjects, though widespread post inflammatory pigmentation was
present in one of the two adolescents. This patient also had several atypical naevi,
apparently at the sites of previous blisters.
Table 7. Age at onset of blistering in epidermolysis bullosa simplex
Age of onset All patients WC Kb DM
Birth 9 1 4 4
1-7 days 16 3 10 3
1-4 weeks 10 2 8 0
1-6 months 22 2 20 0
7 months-2 years 34 20 14 0
2-5 years 8 7 1 0
6-10 years 6 4 2 0
11-20 years 2 2 0 0
adult 0 0 0 0
unknown 23 13 10 0
Total 130 54 69 7
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Ultrastructural examinations of fresh blisters from one twin and four others showed in
each case characteristic cytolysis of basal and suprabasal keratinocytes and clumping
ofkeratin tonofilaments (McGrath 1992). Identical changes were seen in a biopsy taken
from the vocal cord of one infant (Shemanko 2000). The seventh and oldest patient, for
whom no ultrastructural information is available, has been shown to carry a mutation
(K14Leul22Phe) identified previously in other EBS-DM sufferers (Yamanishi 1994).
Analysis of keratin genes has been undertaken in the remaining patients and in each
case a causative mutation has been identified (K5Serl81Pro, a novel mutation
[Shemanko 2000]; K14Argl25Cys [Coulombe, Stephens, Umeki, Chen, Hachisuka]
found in both twins and an unrelated patient, and K14Argl25His [Coulombe, Stephens,
Chan], found in two patients).
3.3b The Kobner subtype of EBS.
Sixty nine individuals, whilst experiencing blisters predominantly on the palms and
soles, also blistered at other sites. Seventeen families were represented. Four patients
had parents who had never blistered. Patients were aged between 1.3 and 75.5 years at
interview (average 29.2 years, median 29.45 years). All experienced blisters of the feet
and other sites. Sixty three (91%) suffered blisters on the palms. Intraoral blisters
occurred in 17 subjects (24%) and the great toe nails were thickened in 10 patients
(14%) aged between 1.5 and 57.1 years.Mild hyperkeratosis ofthe weight bearing areas
of the soles was present in 8 adults (12%), 4 of whom were members of one family.
Sixty subjects (87%) indicated that their blistering tendencywas worst inwarm weather.
Only eleven (16%) were completely free of blisters during the winter. Three patients
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(4%), two of whom were mildly affected, denied seasonal variation in severity of
blistering. Six children (9%) were too young to allow assessment of seasonal variation.
Friction from clothing and jewellery was identified by patients as an important cause of
blisters, with heat a contributory factor, sometimes apparently causing blisters even in
the absence offriction. Improvementwith age was noted by 20 patients (29%), only two
ofwhom (aged 3 and 11 years) were under 20 years old. Fourteen patients (20%), aged
5 to 57 years, felt there had been no improvement of blistering as they had grown older.
Of these, seven were over 20 years old. Eight children were too young to allow any
assessment of improvement and no information is available for the remaining 27
patients (39%) whose ages range from 4 to 67 years (average 26.8 years). Whilst the age
of onset of blistering in the Kobner subtype ofEBS varied between birth and 10 years
of age, 81% developed their first blisters before the age of 2 years (Table 7).
Two patients, mother and daughter, were each born with a single absent area of
epidermis on one leg, which subsequently healed leaving subtle atrophic scarring. In
one family, all 3 affected children experienced blisters in the ano-genital region. There
were 6 families, none exceeding 4 sufferers, in which all affected individuals had the
EBS-Kb pattern of blistering. In each of the remaining 11 pedigrees, ranging in size
from 2 to 25 affected individuals, there was a mixed pattern of blistering, with both
EBS-WC and EBS-Kb phenotypes represented.
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3.3c The Weber-Cockayne subtype of EBS.
EBS-WC was seen in 54 patients from 20 families. Patients were aged between 1.3 and
78.3 years (average 27.8 years, median 24.6 years) at interview. Six patients had
unaffected parents. Blisters were confined to the hands and feet, although 4 individuals
(7%) from 3 families also experienced intra-oral blistering. Only two sufferers did not
have sole involvement; one, (aged 15.5 years) had mild involvement of the palms in
early childhood and the other, aged 24 years, experienced palmar blisters which were
exacerbated by his manual occupation. Palmar blistering was a feature in only 31
patients (57%). Thickened great toe nails were present in seven individuals (12%), three
of whom were aged under four years. No fungus was found in any nail clippings
submitted for mycological examination. Five patients (9%), all adults, had mild
hyperkeratosis of the soles. Seasonal variation of blistering, worst during the summer,
was noticed by all but 4 very mildly affected adults (93%). Twenty seven individuals
(50%) continued to experience blisters to a lesser extent during the winter, whilst 11
(20%) were completely free of blisters during the colder months. Three children were
too young to allow assessment of seasonal variation and information is incomplete for
the remaining 13 (24%) patients.
As in the Kobner variant of EBS, blisters were attributed to friction and heat. In
nineteen patients (35%), the blistering tendency had improved with age, all but one
being over 20 years old. Seventeen (31%) had not improved, though only 3 were over
the age of 20. One child (aged 1.3 years) was too young to allow assessment of
improvement and no information was available for the remaining 17 patients (31 %),
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aged 3.5 to 51 years. The age of onset of blistering was slightly later than that seen in
Kobner EBS, varying between birth and the teenage years (Table 7). Fifty three percent
had experienced their first blisters by the age of two years. One child was born with a
localized area of absent epidermis on one leg.
There were 9 pedigrees, none exceeding 4 patients, in which all affected individuals
demonstrated exclusively the EBS-WC phenotype.
3.3d Effect of EBS on lifestyle
In both EBS-WC and EBS-Kb, foot blisters frequently resulted in pain sufficient to
require transport even over short distances, and to limit walking during the summer
months. At home, it was common for affected children and teenagers to avoid walking;
they preferred to crawl or "bottom shuffle". One adult EBS-Kb patient used a
wheelchair during the summer months. Some parents carried their affected children to
primary school. Teenagers often found coping with frequent changes of classroom
during their school day difficult, the less motivated regularly missing school because of
pain due to blisters. Two families had persuaded their local education authorities to
provide taxis to take their affected children to school. Fourteen sufferers (8%) ( nine
with EBS-Kb, 4 with EBS-WC and one with EBS-DM), were receiving social security
benefits which in eleven cases was a mobility allowance. Seven of 67 adults of
employable age (10%), were unemployed, 5 ofwhom suffered from EBS-Kb and 2 from
EBS-WC. Both adults affected by EBS-DM were in full time employment.
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3.4 Discussion
Comparison of Scottish data with reported EB databases (chapter2) demonstrates that
this population based study is equally if not more rigorous than other national surveys
(Table 8).
Table 8. Reported prevalences of epidermolysis bullosa simplex (per million)
Country All EBS subtypes
Scotland* 33.2
Norway a 24.3




Saudi Arabia f 1.7
S. Africa 9 0.8
USA h 4.6









We have tried to minimise any bias towardsmore severely affected patients by actively
seeking out EBS sufferers, approximately one third ofwhom proved to be previously
unknown to dermatologists (Horn 1997).
Localised areas of congenital aplasia cutis, originally termed "Bart's syndrome"
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(Bartl966) and since recorded in all major EB subtypes (Amichai 1995) were seen in
all three variants ofEBS. Early onset and intraoral blisters, features typically associated
with recessive dystrophic and junctional EB (Fine 1991), all occur in each variant of
EBS. Widespread blistering during infancy in those few affected by EBS-DM
necessitates intensive nursing care, but over the longer term, pain has a greater andmore
prolonged effect on the lifestyle of those affected by EBS-Kb and EBS-WC.
EBS is a spectrum, being a potentially life threatening condition for those few affected
by EBS-DM, a painful disability for many and little more than an inconvenience for
some. There is considerable overlap within this spectrum, to such an extent that EBS-
WC and EBS-Kb should perhaps no longer be considered different disorders. Both
phenotypes are seen in family members carrying identical causative mutations and this
is apparent in all Scottish families of 5 or more EBS sufferers. Thus both EBS-Kb and
EBS-WC appear to represent variations of the same condition. Similar as yet
unexplained phenotypic variation is seen in other single gene disorders e.g. cystic
fibrosis, neurofibromatosis and ichthyosis bullosa ofSiemens (Stern 1995, Huson 1999,
Basarab 1999). It appears the causative mutation, though important, is not the only
factor determining clinical severity.
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Chapter Four
The clinical spectrum of dystrophic epidermolysis bullosa
4.1 Introduction
The clinical features of RDEB-HS have long been known and are well described in
standard dermatology textbooks (Rook 1999). Descriptions of the milder subtypes of
DEB are less detailed, perhaps because sufferers do not come to the attention of the
medical profession. As a result, there may be a tendency amongst those less familiar
with EB to regard all subtypes ofDEB as severe. During compilation of the EB register,
many patients were encountered who hadmild disease; indeed, some regarded their skin
as normal. This study is an attempt to document the clinical features of DEB in all
patients living within Scotland. It was completed in April 2001.
4.2 Patients and methods
Since 1992, 128 Scottish individuals have been identified as suffering from DEB.
Methods of identification and assessment of patients have been described previously
(Chapter 2). Diagnosis was made on the basis ofclinical features, family history and in
cases ofdoubt by antibody mapping and ultrastructural examination using the recently
published revised classification system ofFine et al (2000). DDEB was diagnosed when
typical clinical features were present in two or more individuals spanning at least two
generations. All patients with severe clinical features and many with milder disease,
underwent skin biopsy and ultrastructural assessment. Nine patients with very mild
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disease and lacking a family history did not have skin biopsies and were classified as
having DEB ofuncertain inheritance (DEB-unc). Within the group of 128 patients, four
clinical variants ofDEB were identified. DDEB occurred in 88 patients (68%). Twenty
four patients (19%) had no family history of DEB and clinical features of mild to
moderate severity (DEB-unc). On the basis ofindividual pedigrees, recessive inheritance
was judged to have occurred in 16 patients (13%), 9 (7%) having RDEB-HS and 7 non-
Hallopeau-Siemens RDEB (RDEB-nHS). DNA from selected patients was analysed by
Professor J. McGrath for the presence of COL7A1 mutations. We continue to record
newly diagnosed EB sufferers, both those referred to our department and those
diagnosed at other Scottish hospitals.
Ninety seven DEB sufferers from 50 families have been examined on at least one
occasion and their clinical findings at initial presentation systematically recorded. Ofthe
remaining 31 patients, 20, who have not been clinically assessed, were identified by
affected relatives in whom the diagnosis of DEB had been confirmed. Nine were
diagnosed at the Royal Infirmary ofEdinburgh (RIE) as suffering from DEB but clinical
information is incomplete. No clinical information is available for two patients
diagnosed at other Scottish hospitals - one an adult suffering from DDEB and the
second a neonate suffering from RDEB-HS. This study reports the clinical findings of
97 patients at their initial assessment.
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4.3 Results
4.3a Dominant dystrophic epidermolysis bullosa
Detailed clinical information is available for 64 individuals from 18 families. Subjects
were aged between 2 days and 76 years at interview (average age 27 years). Thirty six
were female. Age at onset of blistering was known in 43 of the 64 patients and varied
between birth and five years (Table 9).














birth 7 3 1 6 4 21
1-7 days 1 0 0 12 5 18
1-4 weeks 0 1 1 0 2 4
1-6 months 0 0 0 11 6 17
7-24 months 0 0 0 10 0 10
2-5 years 0 0 0 4 0 4
unknown 0 0 0 21 2 23
Clinical features are summarised in Table 10 . With the exception of 7 children, four of
whom were under 1 year old, scars were present over boney prominences in all patients.
Miliawere noted in 17 subjects (27%), both adults and children. Nail dystrophy, present
in 44 patients (69%), was not seen below the age of3 years. Ofthe 22 individuals (34%)
with significant dental abnormalities i.e. excessive dental caries or its sequelae, 3 were
under twenty years old and 13 reported oral blistering. A further 9 patients with oral
blisters had normal dentition. Only two ofthe 12 (19%) subjects with anal fissures were
children, the youngest being 2 years old.
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Nine adults and one child aged nine years (16%) complained of dysphagia. All but one
also had anal fissures (7 patients) and/or constipation (5 patients). A further six patients
complained of troublesome constipation and 2 had some restriction ofmouth opening.
A recent barium examination in one adult with longstanding dysphagia and who
intermittently produces oesophageal casts, did not reveal any abnormality. Although
pseudosyndactyly was not observed in any individuals, flexion contractures of the
fingers were seen in 4 adults (6%). No patients had eye involvement. Two adults (3%)
had EB pruriginosa and albopapuloid lesions were apparent in 23 (36%) patients. Two
heterozygous glycine substitution mutations of COL7A1 (one reported previously
[Mellerio and Salas-Alanis et al 1998]) were detected in patients from 3 families.
Table 10. Clinical features of dominant dystrophic epidermolysis bullosa.
Children aged 12 years or under (n=25) Adults (n=39)
% %





Nail loss/dystrophy 44 85
Otitis externa 8 8
Constipation 12 21
Anal fissures 12 21
Dysphagia 4 23
Oral blisters 28 36
Dental disease 8 51
Microstomia 0 5
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4.3b Dystrophic epidermolysis bullosa of uncertain inheritance
Clinical information is available for nineteen unrelated subjects. One man with mild
DEB limited to the skin and oral mucosa, is the cousin ofa patient with RDEB-HS who
died before analysis of COL7A1 mutations was available (Kemmett 1990). The
remaining patients in this group had no family history ofDEB. Ages at interview ranged
from 6 months to 39 years (average age 13.9). Nine (47%) had mild DEB whilst the
remainder had more troublesome DEB ofvarying severity. All had scars, 13 (63%) had
milia and 11 (58%) had nail loss or dystrophy. The youngest child to have abnormal
nails was 21 months old. She was the only individual in this group born with a localised
areaofabsent skin ("Barts syndrome") and the only one to suffer from recurrent corneal
erosions. Pseudosyndactyly was not observed but mild flexion contractures of the
fingers were seen in one adult. Nine subjects (47%) had albopapuloid lesions and two
(11%) had EB pruriginosa. Both these individuals also had involvement of the external
ear. Ten patients (53%) experienced oral blisters. Dental disease was present in 5 (26%),
all but one ofwhom suffered oral blistering. One adult with normal dentition had both
restriction ofmouth opening and limitation of tongue protrusion (ankyloglossia). Anal
fissures occurred in 5 individuals (26%), both adults and children, and were associated
with constipation in 4. A further 3 subjects also complained of constipation.
Oesophageal strictures were demonstrated in two of the four patients (21%) who
experienced dysphagia, which in a third was associated with the regular production of
oesophageal casts.
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4.3c Recessive dystrophic epidermolysis bullosa of Hallopeau-Siemens subtype
Clinical information is available for 8 individuals who were unrelated and had
unaffected parents. The cousin of one patient suffered from mild localised DEB of
uncertain inheritance; details of this family have been reported previously (Kemmett
1990). The parents of one child are cousins but there was no evidence of consanguinity
in the other families. Patientswere aged between 3 days and 34 years at interview. Three
were under 1 year old, two were children aged 3 and 10 years and three were adults
aged 20, 23 and 34 years. Blisters were present at birth in all but one in whom they
appeared during the following 24 hours. Two neonates also had congenital localised
areas of absent skin. Though not a prominent feature, milia were visible in all patients
and scars were seen on all but the youngest infant. Some features typical ofRDEB-HS,
including dysphagia, dental disease and the consequences of scarring (i.e. flexion
contractures of the limbs, microstomia, ankyloglossia and mitten deformity of the
hands), were age related, being present in all adults and the eldest child but not the
younger child nor the infants. Mild flexion contractures of the fingers and some loss of
inter-digital web spaces were present in the 3 year old child. All subjects, including the
infants, had nail loss or dystrophy. Each adult had very sparse scalp hair and none had
experienced puberty. Involvement of the external ear was seen in 3 patients. Five
subjects, infants and adults, experienced corneal erosions and one adult had ectropion.
Constipation proved troublesome in 6 patients, being associated in 3 with anal fissures.
Only one subject, an infant, did not have oral blisters. Neither EB pruriginosa nor
albopapuloid lesions were observed. Barium studies in two adults confirmed the
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presence of oesophageal strictures. Analysis ofDNA from one patient has identified
compound heterozygous mutations ofCOL7A1. Since the onset ofthis study, the effects
of scarring are becoming more apparent in the infants and dysphagia has become
troublesome to such an extent that two have now received gastrostomies. Two adults
have died during the study period - one frommetastatic squamous cell carcinoma (SCC)
arising in the skin and the second from aspiration of gastric contents during an
influenza-like illness. The eldest adult has recently developed her first cutaneous SCC.
Non-Hallopeau-Siemens recessive dystrophic epidermolysis bullosa subtypes
4.3d Localised recessive dystrophic epidermolysis bullosa
Clinical information is available for 3 of 4 siblings and one unrelated patient in whom
the clinical features were relatively mild and the pedigrees suggestive of recessive
inheritance. The siblings have been previously reported (Marsden 1974). There is no
evidence ofconsanguinity in either family. In each, blisters had been present at birth and
there had been congenital absence of a localised area of skin in three. All blistered
readily in response to minor trauma during childhood and the teenage years but reported
marked improvement ofskin fragility during adult life. When interviewed for this study,
the four subjects were aged between 36 and 47 years. They had all experienced normal
puberty and had unaffected children. All had atrophic scars over boney prominences and
either nail loss or dystrophy. Milia, mild finger flexion contractures, albopapuloid
lesions and external ear involvement were each seen in individual patients.
Pseudosyndactyly and corneal erosions did not occur. Two sisters experienced pruritus,
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which in the first was accompanied by pruriginous change over the pretibial areas and
posterior shoulders and in the second affected the perineum. A number of contact
sensitivities had been identified by the referring hospital in this latter patient. Oral
blisters, dental disease and anal fissures were present in every patient and constipation
was troublesome in 3 of the 4. Two had some restriction of mouth opening and
protrusion ofthe tongue. Oesophagoscopy and barium swallows had previously revealed
the presence of oesophageal webs in all four and in addition, oesophageal strictures had
been seen in two (Marsden 1974). The siblings had required repeated oesophageal
dilatations from the late teenage or early adult years, but after ten years, dysphagia
resolved in two, then aged 26 and 36.
4.3e Inverse recessive dystrophic epidermolysis bullosa
Two unrelated females aged 48 and 57 years at interview were affected by flexural
erosions in addition to blisters and scarring over boney prominences. The parents of the
elder, an only child, shared a common ancestor from a remote part of Scotland. Milia,
finger flexion contractures, loss of nails and oral blisters were seen in both patients.
They also both had dental disease, ankyloglossia, mild microstomia and anal fissures.
Constipation was troublesome in only one. Both patients experienced dysphagia as a
consequence ofoesophageal strictures and underwent repeated oesophageal dilatations.
Both also suffered blistering of the pinnae and one had bilateral stenosis of the external
auditory meatus associated with deafness. The elder of the two patients died during the
study from a SCC arising in the oesophagus.
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4.4 Albopapuloid lesions
In a significant minority of patients with DDEB (20 patients (31%) from 10 families),
examination of the lumbar area revealed multiple slightly depressed areas resembling
subtle atrophic scars, each measuring about about one centimetre in width and having
a finely wrinkled surface (Figure 12). These were found in DDEB of all severities but
were not universally present in adult members of any pedigree. They were also seen in
DEB-unc (8 unrelated patients) and in one patient with RDEB-loc. The youngest subject
in whom they were present was 6 years old.
In some cases, albopapuloid lesions were represented by small ivory-white papules
(Pasini 1928) (Figure 13), which occurred on the upper trunk, arms and buttocks of four
patients, one with mild DEB-unc and 3 unrelated individuals suffering from DDEB of
a wide range of severity. Two children, one with DDEB and a second with DEB-unc,
later went on to develop Pasini albopapuloid lesions during their mid teens. The
youngest affected was 14 years old. Two patients complained of associated itching.




Figure 12. Atrophic albopapuloid lesions on the Figure 13. Classical Pasini
lumbar area. albopapuloid lesions on the
trunk.
*
Figure 14. Hypertrophic linear plaques on pretibial skin in EB pruriginosa.
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4.5 EB pruriginosa
Intense itching associated with the formation of pre-tibial lichenified nodules or
plaques, is a distinctive clinical picture which is genetically diverse (McGrath 1994,
Mellerio and Ashtonl999). In our study it was seen in DEB ofdominant, recessive and
uncertain inheritance. The appearancemay be confused clinically with both hypertrophic
lichen planus and nodular prurigo. Amongst the Scottish families, itchy pre-tibial lesions
were present in two unrelated adults with DDEB, and two with DEB-unc. In each of
these latter patients, the lesions were remarkably extensive and linear (Figure 14). Onset
of hypertrophic scarring was delayed until adult life. Perineal itching in DEB has been
reported previously (Naeyaert 1995), and was seen in one Scottish adult female with
RDEB-loc. Her affected sister also experiences itching but the clinical appearance in her
case is that of nodular prurigo.
4.6 Discussion.
By actively seeking EB sufferers within a population we have found the prevalence of
DEB in Scotland (now 24 per million) to far exceed any previous reports. The high
Scottish prevalence ofDDEB, although undoubtedly an underestimate, is particularly
striking when compared to data from the USA (Fine 1999) (Table 11) where it is likely
that the large population and different health care system may hinder full detection of
EB sufferers.
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Table 11. Prevalences of dystrophic EB subtypes permillion in the USA (unadjusted figures) and
Scotland.
DDEB DEB-unc All RDEB RDEB-HS RDEB-nHS
(n) (n) (n) (n) (n)
Scotland 17.4 (89) 4.7 (24) 2.54 (13) 1.4(7) 1.2(6)
USA 0.87 (216) 0.37 (91) 0.8 (98) 0.36 (90) 0.43(108)
Despite these apparent differences, our clinical findings are broadly in agreement with
those of the USA National EB Registry. Milia, a nonspecific feature of most sub¬
epidermal blistering disorders, were less common in Scottish DDEB sufferers, perhaps
reflecting inclusion in the UK EB Register of patients with mild disease who were not
actively blistering at the time of clinical examination. Otitis externa was found more
frequently in all subtypes ofDEB in Scotland, but the difference was particularly marked
in those with RDEB-HS (37% in Scotland, 9% in the USA)and RDEB-loc (25% in
Scotland and 4.1% in the USA). Other clinical features(corneal erosions, nail
involvement, scarring, contractures, pseudosyndactyly, constipation, dysphagia, oral
blistering, ankyloglossia and microstomia) occurred with similar frequencies to those
reported from the USA (Fine 1999, Fine 2000).
With the exception of one individual, all Scottish RDEB-HS sufferers had blisters at
birth, the remaining patient developing blisters within the following 24 hours. However,
early blistering does not inevitably indicate either recessive inheritance or a poor
prognosis. Eighteen of the 43 DDEB patients in whom the age at onset of blistering is
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known, started to blister within the first week postpartum (Table 9). Although 8 (44%)
of this early onset group experienced a variety oftroublesome extra cutaneous features,
the remaining 10 (56%) had mild disease confined to the skin. At least 37 (58%)
Scottish DDEB sufferers had no blisters at birth, and 25 (39%) did not develop blisters
until after the fourth week of life. This finding contrasts with the recently published
revised classification of EB, which states that in DDEB it is usual for blisters to be
present at birth (Fine 2000). This apparent discrepancy probably reflectsmore complete
sampling of Scottish DDEB patients and inclusion ofmore patients with mild disease.
For most sufferers, DDEB does not impose serious difficulties, and many experience
improvement of the blistering tendency during early adult life; some even consider their
skin to be normal. Consequently there is considerable under-reporting leading to the
misleading impression that DEB is inevitably a severe disorder. For many the cosmetic
consequences of scarring are the most troublesome aspect of their disease, causing
psychological difficulties and social embarrassment rather than physical disability. A
significant minority ofDDEB sufferers, in both Scotland and the USA (Fine 1999), do
suffer amore severe phenotype, experiencing contractures,microstomia, dysphagia, and
anal fissures, clinical features more often associated with RDEB. Gastrointestinal
manifestations of DEB can occur even in the absence of active blistering and unless
cutaneous signs of DDEB are sought in such patients, EB may not be apparent as the
cause of anal disease or dysphagia. Not all our patients underwent barium studies, but
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it is significant that in some with troublesome dysphagia and a history of producing
oesophageal casts, no structural abnormality could be demonstrated.
Because scarring and its sequelae become more apparent with increasing age, some of
the hallmarks ofDEB may not be found in infants or children. The mitten deformity,
a characteristic feature of RDEB-HS, was not seen in any child aged under four years
old, though finger flexion contractures and some loss of digital web spaces were
apparent by the age of three years. Nail loss or dystrophy, one of the commonest
physical signs in DEB, was absent in those DDEB sufferers under 3 years old and
occurred in only 15% of children with this sub-type aged 5 years or under (data not
shown). Contractures, uncommon in DDEB, occurred solely in adults and dysphagia
was present in only one child with this subtype.
Dental disease due to caries occurs in all subtypes ofDEB and is preventable. The teeth
are structurally normal (Kirkham 1996), but restricted access as a result ofmicrostomia
and pain from oral blisters both contribute to poor oral hygiene. In those suffering from
dysphagia, a high carbohydrate dietmay also contribute to dental decay. It is reassuring
to note that of those with DDEB in this study, none of the 15 children under 5 years old
and only three subjects under 20 years old have evidence of dental disease.
Albopapuloid lesions (figures 12 and 13) are a striking clinical finding in DEB, but they
do not appear to be of diagnostic or prognostic significance. Although commonest in
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DDEB, they also occur in other subtypes ofDEB and have been reported in JEB (Eady
1983).
As yet there is no explanation for the development of the EB pruriginosa phenotype.
Molecular studies have revealed a range of both heterozygous and compound
heterozygous COL7A1 mutations in this distinctive clinical variant (Mellerio, Ashton
et al 1999). Identical mutations have been found in DEB sufferers with a non-
pruriginous phenotype, indicating that additional genetic or environmental factors,
perhaps atopy, may be implicated (Mellerio, Ashton et al 1999).
The explanation for improvement ofthe blistering tendency or dysphagia with age is not
known. Phenotypic variation within individual pedigrees is also difficult to explain.
Analysis ofCOL7A1 mutations orofgenes encoding structurally or functionally related
proteins may provide some of the answers.
This study, like others, has demonstrated overlapping of clinical features between the
subtypes ofDEB and other variants ofEB, illustrating that clinical features alone are not
sufficient for diagnosis. Ultrastructural studies and antibody mapping are both useful
diagnostic aids, but ultimately determination of COL7A1 mutations is essential if
accurate genetic counselling is to be given to families, especially those at risk ofhaving
a severely affected child and those patients who have moderately severe DEB of
uncertain inheritance. These latter patients usually prove to have mild RDEB or, less
commonly, de-novo sporadic dominant mutations. More unusual inheritance patterns
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such as uniparental disomy, have been reported (Uitto 1999) with profound implications
when assessing risks to future pregnancies.
Challenges for the future (Uitto 2000) include preventing the devastating effects of
scarring in the small proportion of severely affected DEB sufferers and also in those
with milder disease for whom scars are a cosmetic embarrassment. Prevention and better
treatment of SCCs, the major cause of death in RDEB (Fine 2000), are of great
importance and frequent total skin inspections are an essential part of the management
of those with severe DEB.
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Chapter Five
Genotype-phenotype correlations in epidermolysis bullosa simplex
5.1 Introduction
Since the discovery that EBS is a keratin disorder (Bonifas 1991, Coulombe 1991, Lane
1992), over 50 different pathogenic mutations have been described in the genes
encoding keratin 5 (KRT5) and keratin 14 (KRT14) (Tables 12 and 13). Most are
missense point mutations, identified in unrelated pedigrees and resulting in dominantly
inherited disease. Rarely, premature stop codons have also been reported (Gu 2002,
Muller 1999). Recessively inherited EBS, due to missense or premature stop codons,
has been described in a small number of consanguineous families (Hovnanian 1993,
Rugg 1994, Chan 1994, Jonkman 1996, Corden 1998, Batta 2000).
Keratins are proteins which assemble to form 10 nm diameter filaments, intermediate
in size between micro filaments such as actin (6nm in diameter) and microtubules such
as tubulin (23 nm diameter). More than thirty different keratins have now been
identified. They are expressed in the cytoplasm ofepithelial cells where type I (acidic)
keratins form heterodimers with compatible type II (basic) keratins. These assemble into
chains which form ameshwork of filaments within the cytoplasm (Irvine 1999).Within
basal keratinocytes, these filaments consist of keratins 5 and 14. After appropriate
staining, they are visible on light microscopy as tonofilament bundles which weave
through the cell cytoplasm. On transmission electron microscopy, tonofilaments are
seen inserting into both desmosomes and hemidesmosomes. This keratin network
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imparts strength and rigidity to individual keratinocytes, the epidermis and the
dermoepidermal junction (Lane 1993,Uitto 1997).
Keratin 14 (K14), which is a type I acidic keratin, and keratin (K5), a type II basic
keratin, are both expressed in the basal cells of stratified epithelia. Like all keratins,
they share a common structure, comprising four conserved predominantly a-helical rod
domains( 1 A, 1B, 2A, 2B) connected by non-helical linker regions (L1, L12, and L2) and
flanked by non-helical globular head and tail domains (Figure 15) (Lane 1993).
Stutter region
H1 and H2 -highly conserved regions of head and tail domains (type II keratins only)
shaded regions -helix initiation and termination motifs
L, L12 and L2 -linker regions
stutter region -an area of reversed polarity within the 2B a-helical rod
Figure 15. Diagrammatic keratin molecule
The amino acid sequences at the beginning and end of the central keratin rod domains
(helix initiation and helix termination motifs, Figure 15), are remarkably consistent
throughout the animal kingdom. In addition, helix initiation motif sequences show
conservation throughout subtypes of intermediate filaments. Alterations to amino acids
at these critical sites can result in abnormal filament assembly which in turn may have
profound effects on cell resilience (Irvine 1999). This has been borne out by the
observation that EBS-DM, the most severe subtype ofEBS, is due to mutations which
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alter amino acids within the helix boundary motifs ofboth K5 and K14. Point mutations
at other sites cause either EBS-Kb or EBS-WC (Tables 12 and 13).
Table 12. Reported keratin 5 mutations in dominantly inherited EBS











2 Moog, 1999 *
EBS-MP Yes 2 Irvine, 2001
EBS-DM Yes K5:V164del22 1 Rugg, 1999
EBS-WC NR K5:P152L 1 Muller, 1998*
EBS-WC Yes (mild) KR-I1R1Q Chan, 1993
EBS-WC NR
i\0.1 10 I o
Erlich, 1995
EBS-Kb No K5:K173N 1 Stephens, 1995
EBS-DM Yes K5:L175F 1 Nomura, 1996
EBS-DM No 1 Stephens, 1997
EBS-DM Yes
rw.lN 1 / Do
1 Sorensen, 1999
EBS-DM Yes K5:F179S 1 Stephens, 1997
EBS-DM Yes K5:S181P 1 Shemanko, 2000
EBS-Kb Yesd K5:V186L 1 Liovic,2001
EBS-WC ? K5:N193K 1 Humphries, 1996
EBS-Kbe NR K5:V323A 1 Galligan, 1998




EBS-WC ? 1 Humphries, 1996
EBS-WC NR K5:M327K 1 Muller, 1998
EBS-WC NR K5:D328V 1 Matsuki, 1995
EBS-WC NR K5:D328H 1 Muller, 1998
EBS-WC ? K5:D328E 1 Liovic, 2000
EBS-WC Yes (mild) K5:N329K 1 Chan, 1994
EBS-WC No K5:R331C 1 Rugg, 1993
EBS-Kb NR K5:L463P 1 Dong, 1993
EBS-DM K5:I467T 1 Irvine, 1997*
EBS-Kb Yes (mild) K5:K472X 1 Livingstone, 2001
EBS-DM Yes K5:E475G 1 Lane, 1992
EBS-DM Yes K5:E477K 2 Stephens, 1997
EBS-DM Yes K5:E477X 1 Muller, 1999
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EBS-DMb No 1 Cummins, 2001
EBS-Kb NR K14:M119V 1 Cummins, 2001
EBS (acral only) NR K1A-M11QI 1 Chen, 1995
EBS-WC, (DM)0 Yes (Mild)0 1 Hu, 1997
EBS (generalized) NR K14:Q120R 1 Chen, 1995
EBS-Kb ? K141122F 1 Yamanishi, 1994
EBS-DM Yes K14:N123S 1 Sorensen, 1999
EBS-DM Yes 1 Coulombe, 1991
EBS-DM Yes 1 Stephens, 1993
EBS (generalized) NR Chen 1995







EBS-DM Yes Rugg, 2000
EBS-DM Yes 1 Ning, 2001
EBS-DM NR Hut, 2000
EBS-DM ? 1 Premaratne 2002
EBS-DM Yes 1 Coulombe, 1991
EBS-DM Yes
WAA&WRU Stephens, 1993
EBS-DM Yes 1 Shemanko, 2000
EBS-DM NR 1 Hut, 2000
EBS (generalized) NR K14:R125S 1 Chen, 1995
EBS-DM Yes K14:Y129D 1 Chan, 1996
EBS-Kb No K14:R134P 1 Rugg, 2000
EBS-Kb NR K141143P 1 Sorensen, 1999
EBS-WC No K14:V270M 1 Rugg, 1993
EBS-Kb NR K14:M272R 1 Humphries, 1993
EBS-WC NR K14:D273G 1 Muller, 1998
EBS (mostly acral) NR K14:A274D Chen, 1995
EBS-WC NR K14: 375del 1 Chen, 1993




EBS-Kb ? 2 Hachisuka 1995

























NR Not reporteda The three families share a common haplotype.
b Diagnosis of EBS-DM based on clinical phenotype but not supported by ultrastructural findings.
cThis mutation shows partial dominance. Severe keratin aggregates were seen in a skin biopsy from a
patient homozygous for the mutation.
d Abnormal filaments detected when mutant keratin is expressed in cultured keratinocytes
e Some family members had an EBS-WC phenotype.
* Denotes residue number has been changes from the original publication
Although there are numerous reports ofpathogenic EBS mutations (Tables 12 and 13),
most document clinical findings in only single individuals from a small number of
pedigrees. A few authors have looked in detail at multiple individuals within kindreds
to determine if they exhibit identical phenotypes (Sorensen (1999), Sasaki (1999)).
Some have observed that the location of a mutation is not the only factor to determine
the severity of the phenotype and that the specific amino acid substituted also plays an
important role (Cummins 2001, Sorensen 1999, Shemanko 1998). None attempt to
comprehensively document the range of mutations occurring within a complete
population. This chapter reports all the pathogenic K5 and K14 mutations identified
within the Scottish population and assesses the correlation between phenotype and the
site and nature of mutations.
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5.2 Methods
During assessments of patients for the EB Register, blood samples were taken from
adult EBS patients and at least one unaffected relative for extraction of DNA. In the
case of two children, mouthwashes were obtained instead of blood. Initially, samples
were taken only from individuals belonging to large pedigrees, but after the introduction
ofautomated sequencing ofDNA, blood samples were taken from at least one affected
adult in every newly diagnosed EBS family. All samples were sent to the laboratories
ofDr. David Baty and Professor E. Birgit Lane in Dundee, where DNA was extracted
from peripheral lymphocytes or, in the case ofmouthwashes, from buccal keratinocytes.
The regions ofKRT5 and KRT14 encoding the helix initiation and termination motifs
were then screened for mutations. If no mutation was found, each entire gene was
sequenced. By June 2002, DNA from EBS sufferers belonging to 27 (63%) of the 43
known Scottish EBS families had been extracted and sequenced. Affected members of
these 27 families account for 146 (82%) of the 179 Scottish EBS sufferers identified
since the onset of the study. DNA from one further family is currently undergoing
sequencing.
5.3 Results
Mutations of keratin genes were found in 25 of the 27 families whose DNA was
sequenced (Table 14). Twenty different mutations were identified. The majority (13)
affected K14 and the remainder (7) altered amino acids in K5. Fifteen mutations were
novel; three ofthese have formed the subjects ofprevious published reports (K5:R331C
and K14:V270M- Rugg 1993, and K5:S181P - Shemanko 2000). One hundred and
twenty affected individuals from the 27 families whose DNA has been sequenced have
been clinically assessed. Their clinical features are summarized in Table 14.
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(number of individuals affected)
16 K14:K116E* WC&Kb 4(4) Feet, hands, other (3) oral (4), nails (1), analfissures
31 K14:L122F DM 1(2) Feet, hands, other, nails
30 K14:R125C DM 1(1) Feet, hands, other, nails
35 K14:R125Ca DM 2(2) Feet, hands, other, nails
5 K14:R125H DM 1(1) Feet, hands, other, oral
6 K14:R125H DM 1(1) Feet, hands, other sites, nails
21 K14:Y129C* Kb 6(6) Feet, hands, other (6), oral (2), nails (1)
12 K14:V133A* WC&Kb 4(4) Feet, hands, other (4), nails (1).
11 K14:V133M* WC 4(5) Feet, hands
17 K14:V133M* WC&Kb 3(4) Feet, hands, other (1)
20 K14:V133L* WC&Kb 5(6) Feet, hands, other (4), oral (1)
34 K14:R148C* WC 1(1) Feet, nails
7 K14:V270M* WC&Kb 4(4) Feet, hands (2), other (2), nails (3)
3 K14:V270M* WC&Kb 25 (37) Feet, hands(21), other(17), oral(4), nails (8)
39 K14:I377T* WC 1(3) Feet, hands
8 K14:R388C WC 4(5) Feet, hands (1)
29 K14:L418V* WC&Kb 2(4) Feet, hands, other (2), oral (1)
28 K5: E170G* Kb 2(2) Feet, hands (1), other (2), oral(1), nails(1)
22 K5: S181P DM 1(1) Feet, hands, other, oral, nails
9 K5: N193K WC&Kb 18(18) Feet, hands (16), other (16),
15" K5: N329S* WC&Kb 7(7) Feet, hands (3), other (2) oral (3), nails (1)
1 K5: R331C WC&Kb 6(6) Feet, hands (3), other (3), nails (1)
33 K5: R331C WC 1(1) Feet, hands
26 K5: A428V* Kb 1(2) Feet, hands, other, oral
19 K5:1467L* WC&Kb 10(14) Feet, hands (7), other (2), nails (1)
13 not found Kb 2(2) Feet, hands, other, oral, localized absence ofskin at birth
32 not found WC 3(3) Feet, hands (1)
Total: 120 (146)
* novel mutation a Monozygotic twins.
b Mutation only present in the two most severely affected individuals.
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Nomutation could be found in two families despite complete sequencing ofboth KRT5
and KRT14. The first of these two pedigrees comprised a mother and daughter (aged
39 and 20 years respectively) who each experienced typical seasonal blistering of the
palms and soles, with minor blistering occurring at other sites of friction. Oral blisters
also occurred in both. An unusual feature seen at birth in these patients was the presence
of a localized area of absent skin on the shins. In each case, the defects healed rapidly,
leaving subtle atrophic scarring. Studies of this family continue.
Each of 3 affected members of the second pedigree in which a keratin mutation could
not be found, had typical seasonal blistering of the soles. The father (aged 36 years),
but not his two children (aged 7 and 13 years) also developed occasional blisters on his
hands. The nails were normal and there were no oral blisters or hyperkeratosis. These
patients appeared clinically to have classical EBS.
5.3a EBS-DM
EBS-DM occurred in six pedigrees (Table 14). In each, amutationwas identifiedwithin
the highly conserved helix initiation motif of either K14 or K5 (Figure 16). Four
unrelated families were found to have mutations of codon 125 in K14. In two, this
caused the change of arginine to cysteine (families 30 and 35 and in the remaining two,
arginine was changed to histidine (families 5 and 6). In family 17, a novel mutation







JH1A — 1B 2A -
LI L12 L2
1 J|1A 1B 2A iB
Mutations resulting in the EBS-DM phenotype
—> Mutations resulting in the EBS Kb/WC phenotype
Figure 16. Diagrammatic keratin 5 and 14 molecules, showing the position and
severity of keratin mutations in Scottish patients.
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5.3b EBS Kb and EBS-WC
All other mutations occurred outside the helix initiation motifs. In nine pedigrees
(families 16, 21, 11, 17, 20, 29, 28, 19 and 12) the mutation altered conserved amino
acids close to these critical areas or within the helix termination motif. In family 21,
blistering was particularly severe. The mutation in this family ( K14:Y129C, novel
mutation) lay on the boundaryofhelix 1A and caused a phenotype intermediate between
EBS-DM and EBS-Kb. Like EBS-DM, blisters werewidely distributed and herpetiform,
particularly in the children. Features more in keeping with EBS-Kb and EBS-WC were
the late onset of blistering (six weeks of age) and marked seasonal variation.
In family 16 (K14:K116E, novel mutation,) the phenotype was milder, although still
relatively severe. This mutation also lies on the boundary of helix 1A. Blisters were
extensive and easily provoked, with involvement of both the oral mucosa and genital
region. A similar phenotype, though without genital involvement, was seen in family
28, which also carried amutation in the boundary region ofhelix 1A (K5 :E170G, novel
mutation).
Four families had keratin 14 mutations within codon 133, which lies within the helix
boundary region. In two, (families 11 and 17, K14:V133M, novel mutation), the
phenotypewas consistently mild and typical ofEBS-WC. Oral blisters did not occur and
only the youngest, a child aged 20 months, experienced any blistering at sites other than
the palms and soles. Haplotype analysis of polymorphisms in exon 1 ofK14 indicated
that the mutation had arisen independently in each family (E. L. Rugg, personal
communication). The remaining two pedigrees with mutations of this codon (families
20 and 12) were more severely affected, all but one of the adults blistering at sites in
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addition to the palms and soles; some also experienced oral blisters. In the first of these
families, valine was altered to leucine(K14:V133L, novel mutation) and in the second
valine was altered to alanine.
Blistering was relatively severe in family 29 and clumping of tonofilaments was seen
on ultrastructural examination. The mutation in this family (K14:L418V, novel
mutation), lay within the helix termination motif of keratin 14. Although the mutation
in family 19 was also within the highly conserved helix terminationmotif (K5:I467L,
novel mutation), the phenotype was relatively mild; oral blisters did not occur and only
the two youngest children ofthis family of 10 blistered at sites other than the palms and
soles.
All other mutations occurred away from the helix boundary areas. The least severe
phenotype resulting from a mutation in helix 1A was seen in family 34 (K14:R148C,
novel mutation). The single affected individual had typical EBS-WC, blisters occurring
only on the hands and feet. In family 9, the mutation was also within helix 1A
(K5:N 193K), but in contrast to family 34, the phenotype was relatively severe. For such
a large pedigree (18 affected individuals), the phenotype was surprisingly consistent;
there was no improvement with age and oral blisters did not occur.
A variety ofphenotypes were seen in those pedigrees (families 15, 7, 3, 1 and 33) who
had mutations within the LI 2 linker region. Two adult members of family 15 (Figure
17) were particularly severely affected and were found to carry a novel mutation of
KRT5 (K5:N329S).Ultrastructural examination ofthe skin of one showed clumping of
keratin tonofilaments. Their 5 affected relatives had a very mild phenotype, blisters
occurring on only the feet in 3, with additional involvement of the oral mucosa in 2 and
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the hands in 1. Despite complete sequencing ofKRT5 and KRT14, no keratinmutations














Figure 17. Pedigree of EBS Family 15
(a = severely affected individual)
The remaining four families with mutations in the LI2 linker region had a mixed
phenotype. Two apparently unrelated pedigrees (families 1 and 33), carried an identical
novel mutation (K5:R331C). Family 1 has been described previously (Rugg 1993).
Some members of this family had typical EBS-WC, whilst others, including the eldest
adult, also experienced blisters at additional sites (Table 14). A mixed phenotype of
similar severity was seen in the two families found to have a mutation of the K14 LI 2
linker region (families 7 and 3, K14:V270M, novel mutation). In family 3, which has
been reported previously (Rugg 1993), four of the more severely affected patients were
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over 60 years of age. Haplotype analysis indicates that the families are unrelated and
that the mutations have arisen independently (Rugg, personal communication).
Mutations close to the stutter region within helix 2B were found in three pedigrees. One
(K5:A428V, novel mutation) was associated with a relatively severe phenotype in the
single individual available for clinical assessment (Table 14). In K14, each mutation
(K14:R388C and K14:I377T, novel mutation) caused EBS-WC.
5.4 Discussion
Although not yet complete, this is the largest reported series of pathogenic KRT5 and
KRT14mutations. The Scottish population is relatively small (approximately 5 million,
General Register Office for Scotland), yet a surprisingly high number (20) ofdifferent
keratin mutations were found, of which 15 were novel. Addition of the Scottish
mutations to the 50 previously published, increases the number of keratin mutations
known to cause EBS by 23%. When all reported mutations are assessed, it is clear that
whilst a few occur repeatedly in geographically widely separated areas, most are family
specific. This observation has important implications when devising possible
therapeutic options, including gene therapy.
Scottishmutations were clustered at known mutation "hotspots" - i.e. at the ends ofthe
1A and 2B rod domains, within the LI2 linker region and within helix 2B close to the
stutter region. Although mutations of the stutter region of K14 have been recorded
previously, the mutation identified in family 26 (K5:A428V) is the first to be reported
adjacent to the stutter region of K5. In keeping with published reports, alterations to
amino acids within the highly conserved helix initiation motifs ofK5 (codon 181) and
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K14 (codons 122 and 125) caused EBS-DM, with less severe phenotypes being caused
by mutations in more central areas of the rod domains. It is surprising that the mutation
causing EBS-DM in family 31 (K14:L122F) has been previously reported as causing
EBS-Kb (Yamanishil994). Disruption at this highly conserved site would be expected
to cause EBS-DM. However, insufficient clinical information was given in this paper
describing a 24 year old patient to permit confirmation of the diagnosis ofEBS-Kb and
exclusion ofEBS-DM.
Although the site of a mutation is critical, the nature of the amino acid substitution is
also important in determining disease severity (Sorensen 1999, Cummins 2001). This
is confirmed by the four Scottish families carrying mutations of codon 133 in K14.
V133M was associated with predominantly acral blistering, whilst both VI33A and
V133L resulted in a more severe phenotype. A mutation of codon 129 in K14
(K14:Y129D) has been reported to cause severe EBS-DM (Chan 1996), but in Scotland
(family 21), a differentmutation ofthe same codon (Y129C) resulted in an intermediate
phenotype showing features of both EBS-DM and EBS-K. In the literature, a range of
phenotypes have been observed due to a variety ofmutations within codon 119 in K14.
One (K14:M119T, Shemanko 1998, Cummins 2001), caused EBS-DM, whilst a
second (Ml 19V) resulted in mild EBS-K (Cummins 2001). A third mutation in the
same codon (Ml 191) produced only acral blistering (Chenl995).
Most members of family 19 experienced blisters on only the palms and soles, but were
found to carry a mutation within the highly conserved helix termination region of
keratin 5 (K5:I467L). A more severe phenotype might be expected from a mutation at
this site and there is indeed a report of EBS-DM occurring as a result of a different
mutation within the same codon (I467T - Irvine 1997).
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Mutations within the highly conserved helix initiation motif of helix 1A do not
inevitably cause EBS-DM. This is demonstrated by family 16 (K14:K116E), whose
phenotype would be best classified as EBS-Kb. A different mutation in the same codon
(K14:K116N ) has previously been reported as causing EBS-WC (Sorensen 1999).
Two mutations at the stutter region of helix 2B in K14 each caused EBS-WC. That
found in family 8 (K14:R388C) has been previously reported as causing EBS-WC
(Chen 1995). The second mutation, identified in family 39 was novel (K14:I377T), but
a differentmutation within the same codon has also been reported as causing EBS-WC
(Chen 1995).
Differences between observed and previously reported phenotypes were noted for one
further Scottish pedigree (family 9). The mutation in this large family (K5:N193K)
caused predominantly EBS-Kb, which appears to be in contrast to a previous report of
EBS-WC due to the same mutation (Humphries 1996). Some caution in interpretation
is necessary as mild EBS-Kb (i.e. blisters on the palms and soles and at other sites of
friction) is sometimes labeled in the literature as EBS-WC. No clinical informationwas
provided in the paper by Humphries et al in support of the diagnosis of EBS-WC.
Observation of large pedigrees reveals considerable intrafamilial variation in severity
of phenotype. Although seldom commented on in the literature, this was noted in all
Scottish families of 5 or more affected individuals. Some of the variation is accounted
for by improvement with age, but many adults over 60 years old still experienced
blisters at sites of friction. Perhaps the most profound intra-familial variation reported
occurred in one family carrying K14.-R125C. The phenotype in this family varied from
EBS-DM to EBS-WC (Sasaki 1999). As such marked clinical variation can occur
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between individuals with identical keratinmutations, conclusions regarding phenotype-
genotype correlations should be cautious if only single individuals or small pedigrees
are available for assessment.
The failure to findmutations ofeither KRT 5 or KRT14 in some families who clinically
have classical EBS suggests that mutations of other genes, perhaps plectin (Koss-
Harnes 2002) or the (34 integrin (Jonkman 2002 ), might cause an identical phenotype.
This theory might also explain the mild phenotype seen in the less severely affected
members of family 15. The mutation ofthe L12 linker region ofKRT5 found in the two
worst affected family members (K5:N329S), is not predicted to cause severe disease.
Indeed, a differentmutation of the same codon has caused EBS-WC (Chan 1994). The
variation ofdisease severity in this family could be explained by all affected individuals
carrying amutation ofa non-keratin gene, e.g. plectin or the (34 integrin, causing amild
phenotype; the two severely affected family members would then be compound
heterozygotes, carrying both the unidentified mutation and the known KRT5 mutation.
Studies of this family's DNA continue.
Analysis ofDNA from Scottish EBS sufferers confirms that mutations of KRT5 and
KRT14 are the cause ofEBS in the majority. The failure to find keratin mutations in a
small number of individuals with classical EBS indicates that mutations ofone or more
other genes can cause an identical phenotype in a minority. Disease severity is
determined by the position of the mutation, but is also influenced by the nature of the




Genotype-phenotype correlations in dystrophic epidermolysis bullosa
6.1 Introduction
Dystrophic epidermolysis bullosa occurs as a result ofmutations in COL7A1, the gene
which encodes collagen VII. This protein is accepted as being the major, ifnot the only
component of anchoring fibrils. It is synthesised as procollagen VII by basal
keratinocytes and fibroblasts and is a homotrimer formed from three proa 1 (VII)
monomers. Each proa 1 (VII) molecule consists ofa central triple-helical domain flanked
by non-collagenous globular N-terminal (NC-1) and C-terminal (NC-2) domains.
Monomers ofprocollagen VII associate to form anti-parallel dimers which then align to
form anchoring fibrils (Figure 18, Bruckner-Tuderman 1999).
Under the electron microscope, anchoring fibrils appear as cross-banded fan-shaped










2. Anti-parallel dimers 3. Lateral association of dimers to
form anchoring fibrils
NC-1 and NC-2 are globular non-collagenous domains flanking the central collagenous triple helix.
Figure 18. Diagrammatic assembly of anchoring fibrils
(adapted from Bruckner-Tuderman 1999)
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down into the dermis and back to the lamina densa or embedding into anchoring plaques
in the upper dermis (Bruckner-Tuderman 1999). Ultrastructural examination of skin
fromDEB patients shows that anchoring fibrils can appear abnormal, reduced in number
or absent (Tidman 1985, McGrath 1993). To date, over 200 mutations ofCOL7A1 have
been identified in both RDEB and DDEB (Christiano 1993, Bruckner-Tuderman 1999,
Dunnill 1996, Pulkkinen and Uitto 1999, Nordal 2001, Gardella 2002). Mutations
resulting in homozygous or compound heterozygous premature stop codons cause the
most severe disease, either by production of truncated polypeptides which are
functionally abnormal, or by decay ofmRNA with consequent severely reduced levels
of transcripts (Christiano and Amano 1997, Hovnanian 1997). These mutations are
usually silent in the heterozygous state (Pulkkinen and Uitto 1999). Less disruptive
mutations either causemild disease ormay have no clinical effect unless in the presence
of a second mutation on the other allele (Shimizu and Hammamai-Hauasli).
DDEB is occasionally caused by in-frame deletions of20-30 amino acids ofthe collagen
VIImolecule (Christiano 1994,Mellerio 1999) butmost patients with DDEB have been
found to carry a glycine substitution on one COL7A1 allele (Christiano 1994, Mellerio
1999). Heterozygous glycine substitutions do not inevitably cause disease; an additional
mutation on the second allele may be necessary for skin fragility to occur (Winberg
1997, Hammami-Hauasli 1998, Pulkkinen and Uitto 1999, Nordal 2001). Conversely,
mutations expected to cause a severe phenotype can sometimes result in surprisingly
mild disease (McGrath, 1999).
COL7A1 containsmore exons (118) than any other gene,making detection ofmutations
time consuming and costly. Limited resources and a tendency to investigate mutations
in only more severely affected patients have led to identification of fewer mutations in
DDEB than in recessively inherited subtypes. Most dominantly inherited mutations
91
have been found within the triple helical collagenous domain but it appears that the site
of a glycine substitution along the length of the collagen VII molecule is not related to
disease severity (Pulkkinen and Uitto 1999). With the increasing number of identified
mutations, some exons, particularly exon 73, have emerged inDDEB as being common
sites ofpathogenic mutations (Mellerio and Salas-Alanis 1998, Mecklenbeck 1999). In
recessively inherited disease, a few mutations have been detected in more than one
pedigree and there appears to be some geographical clustering; R2814X, R578X and
7786delG are common in Britain (Mellerio and Dunnill 1997,Mellerio and Salas-Alanis
1998, Mohammedi 1999), 5818delC and E2857X in Japan (Tamai 1999), 2470insG in
Mexico (Salas-Alanis 2000) and 497insA, 4783-1G -► A , 7344G -»A, 425 A-»G,
G1664A and 8441-14del21 in Italy (Ashton 1998, Gardella and Castiglia 2002). With
these exceptions, most mutations of COL7A1 in both DDEB and RDEB appear to be
family specific (Figure 19).
6.2 Methods
Patients with DEB were identified during compilation of the EB Register or in the
epidermolysis bullosa clinic at the Royal Infirmary of Edinburgh. Blood samples for
DNA extraction were taken from members of 15 unrelated families. In five families
there was a dominant pattern of inheritance spanning at least two generations. Details
of one of these families (family 35) have been published previously (Mellerio, Salas-
Alanis et al, 1998). Three infants with no family history ofskin disease or consanguinity,
each had the severe RDEB-HS phenotype. A recessive pattern of inheritance also
occurred in two adults. The first (family 5), had no affected relatives and predominantly
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flexural disease; there was also oesophageal involvement. The second adult (family 8)
had relatively mild but generalised disease with oesophageal involvement. His two
affected siblings were not available for assessment. Two teenagers (families 7 and 41)
had disease of uncertain inheritance and varying severity. The parents from family 41
and the mother from family 7 were clinically examined and found to have normal skin.
Other relatives were not available for assessment. Three adults, whose relatives were not
available for clinical assessment, also had disease ofuncertain inheritance (families 23,
29 and 52). Two of the three, aged 33 and 72, both had the EB pruriginosa phenotype.
Skin biopsies were taken from the ten patients who did not have clearly defined
dominant inheritance. Biopsy specimens were submitted to transmission electron
microscopy and also, in recent years, to monoclonal antibody studies, using LH7:2 (NC-
1 domain ofcollagen VII,) GB3 (y2 chain ofLaminin 5) and COL94 (type IV collagen).
Extraction ofDNA and mutation analyses were kindly undertaken in the laboratories of
Professor J. McGrath at the St. John's Institute Dermatology, London.
6.3 Results
6.3a Dominant dystrophic epidermolysis bullosa
All 5 families with DDEB were found to carry a glycine substitution mutation in exon
73 (Table 15). In three unrelated pedigrees, the mutations were identical (G2043R).
Differing novel mutations were found in each ofthe two remaining pedigrees (G2026R
and G2046R).
93
6.3b The G2043R mutation of COL7A1
There was considerable variation ofphenotype both within and between the 3 pedigrees
carrying this mutation. In each, individuals from three generations were affected. No
scarring was visible on the skin of the youngest when she was first assessed at the age
of2 months, but by the age ofthree years scars were visible at the classical sites (knees,
ankles, elbows and knuckles) and were seen in all remaining patients (Table 15).
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11 (4-65) G2043R 10(12) 8 10 3 5 1 0 1 0 0 3 5 1 9 0 0 1
14(11-76) G2043R 4 (9) 3 4 3 0 0 3 3 2 1 3 2 4 4 1 0 0
35 (0.2-50) G2043R 3 (3) 3 2 1 2 0 2 0 2 0 2 1 2 2 0 1 0
12(41-71) G2026R 4 (5) 3 4 0 1 1 1 2 2 0 3 2 0 4 1 0 0
28 (7-35) G2046V 3 (6) 2 3 1 2 0 0 0 0 1 2 2 1 3 1 1 0
Total 23 (35)
Abbreviations:
A APL -atrophic albopapuloid lesions
P APL -Pasini albopapuloid lesions
Nail dystrophy -includes those with nail loss
All adults and children, with the exception of the two youngest, had one or more
dystrophic nails, usually the great toe nail. Dysphagia occurred in 4 of 5 adult members
of two of the three families (families 14 and 35). With the exception of the youngest
child and eldest adult, all individuals from these two families also experienced anal
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fissures. Atrophic albopapuloid lesions were seen in two ofthe three pedigrees (families
11 and 35), affecting 7 of 9 adults and the typical ivory-white papules described by
Pasini appeared in one child as she reached adolescence. Although oral blisters occurred
in adults and children from all 3 families, not every patient was affected. Finger flexion
contractures and microstomia were present simultaneously in a single individual but
were not seen in any other patients with this mutation. Otitis externa also occurred in
one adult. One patient with the G2043Rmutation showed the EB pruriginosa phenotype
which clinically resembled hypertrophic lichen planus. She also experienced persistent
blistering of the natal cleft.
6.3c The G2026R mutation of COL7A1
Nail dystrophy and scarring were the only features seen in every member of the single
family found to carry this mutation. Skin fragility in the three eldest subjects (aged 61-
71), was mild and had improved with age. One patient developed anal stenosis but none
ofher affected relatives experienced anal symptoms. She and her nephew (aged 41) both
suffered from dysphagia which did not occur in the two remaining members of the
family. Both atrophic and Pasini albopapuloid lesions were present in the nephew,
whose skin blisteredmuchmore readily than that ofhis older relatives. He was the only
member of the family to have finger flexion contractures.
6.3d The G2046V mutation of COL7A1
In two members of this family, aged 7 and 35, blistering was infrequent, causing little
practical difficulty and only subtle scarring. The third member of the family (aged 28)
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blistered readily and had finger flexion contractures, otitis externa and microstomia. In
addition to involvement of acral sites and bony prominences, there was persistent
blistering ofthe natal cleft. Like his 7 year old nephew, this patient also experienced oral
blisters. Atrophic albopapuloid lesions were visible on the lower backs of the two adults.
6.3e Recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens subtype
Novel mutations ofCOL7A1 were found in two infants who presented with widespread
blistering at birth or within the following 24 hours. One of the two (family 43) also had
a congenital localized area ofabsent skin. Both children went on to develop the typical
RDEB-HS phenotype (Table 16).
Table 16. Scottish C0L7A1 mutations in RDEB-HS
Family No. Mutation Exon sub-lamina densa
cleavage
LH7:2 monoclonal antibody
37 879G-»T 7 confirmed staining absent
43 8697 del 11 117 confirmed staining absent
Biopsies offreshly blistered skin were taken from each child within 1 month ofbirth and
revealed localization of the GB3 antigen to the roofof the blister and complete absence
ofstaining with the LH7:2 antibody. On ultra-structural examination, the cleavage plane
was confirmed to be below the lamina densa.
The mutation found in family 37 (879G -T) causes an amino acid substitution. It is a
missense rather than a nonsense mutation and may be a polymorphism rather than a
pathogenicmutation (personal communication, Dr. G. Ashton).No other mutations were
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found in this family.
In the second child (family 43), a pathogenic mutation (8697 del 11) was found in exon
117. Deletion of 11 base pairs at this site in the gene causes disruption of the reading
frame and would be predicted to result in a premature termination codon within
exonl 18. Such a mutation is likely to lead to nonsense-mediated decay of messenger
RNA and production of little or no functional protein (personal communication, Dr. G.
Ashton). Although the presence of an additional mutation on the second allele is
predicted in this severely affected patient, none was found.
6.3f EB pruriginosa
One patient (family 52) with no family history of skin disease presented at the age of66
with a 20 year history of itchy hypertrophic nodules and papules over the pretibial areas
and forearms. Blisters and milia were also present, but were confined to the same sites;
both great toe nails were dystrophic. The skin was reported to have been normal until
the age of 46 years. Light microscopy showed no evidence of lichen planus and
immunofluorescence (both direct and indirect) was negative. Ultrastructural examination
of the skin showed a cleavage plane through the lamina lucida. The LH7:2 and GB3
antibodies each localised to both the roof and floor ofa blister, confirming a junctional
split. However, analysis of COL7A1 showed a novel glycine substitution mutation
G1522E which is predicted to be pathogenic (personal communication, Professor John
McGrath) and whichwould be expected to cause sub-lamina densa cleavage, rather than
the lamina lucida split observed in this patient. Because of uncertainty regarding
classification ofthis patient's skin disorder, details ofthis patient have not been included
in other chapters.
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6.3g Patients in whom no mutation was found
Mutations of COL7A1 were unsuccessfully sought in 7 patients who clinically had a
variety of subtypes ofDEB (Table 17).
Table 17. DEB patients in whom no COL7A1 mutation was found
Family subtype Distinctive clinical features
No.
































6.4a Dominant dystrophic epidermolysis bullosa
Examination ofCOL7A1, albeit in only a small proportion of Scottish DDEB patients,




Exon 7 Exon 45 Exon 73 Exon 117
_[> Sites of multiple previously reported mutations causing predominantly recessively
inherited DEB.
^ Sites of multiple reported glycine substitution mutations causing either dominantly




Sites of Scottish mutations
"Hinge region"
Triple helical collagenous domain
Non-collagenous domains
Figure 19. Diagrammatic collagen VII molecule showing positions of COL7A1
mutations in dystrophic epidermolysis bullosa
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Most reported DEB mutations in the literature are family specific, but 5 point mutations
(R2008, G2034W, G2043R and G2079R), all lying within exon 73, have each been
identified in more than one DDEB pedigree (Christiano 1995, Cserhalmi-Friedman
1997, Hovnanian 1997,Winberg 1997, Kon 1997, Kon 1998, Rouan 1998,Mecklenbeck
1999). The most frequently reported mutation is G2043R, which has been identified in
Italian, Hungarian, Norwegian, Mexican, Finnish and American families (Christiano
1995, Cserhalmi-Friedman 1997,Winberg 1997,Mellerio and Salas-Alanis 1998). This
study has confirmed that the same mutation is also common in Scotland. Exon 73 lies
close to a non-collagenous interruption within the triple helix, an areawhich is thought
to act as a hinge region, providing flexibility to the collagen VII molecule (Mellerio,
Salas-Alanis 1998). Replacement ofglycine residues close to this critical site by bulkier
amino acids appears to disrupt folding ofthe collagen VII molecule and its secretion by
keratinocytes (Shimizu and Hammami-Hauasli 1999).
Within each of the Scottish families bearing the G2043R mutation, the severity of skin
fragility is inconsistent, varying from very mild to a severity exceeding that seen in
many patients with localised RDEB. A similarly broad spectrum of fragility was seen
in affected members of family 28 who carry a different glycine substitution (G2046V).
It is clear from this study that some unusual and distinctive clinical features of DEB,
100
such as Pasini albopapuloid lesions and EB pruriginosa do not occur in every person
carrying a specific mutation and are often seen in only one affected family member.
The factors determining severity ofDDEB in any individual remain unknown. Further
analysis may reveal additional hitherto undetected mutations in the more severely
affected individuals. Some might prove to be compound heterozygotes for COL7A1
mutations or, alternatively, mutations ofother genes relevant to the epidermal basement
membrane may additionally be present in those with more severe disease.
6.4b Recessive dystrophic epidermolysis bullosa
The single nucleotide substitution (G -T) identified in family 37 is predicted to cause
an amino substitution rather than a premature termination codon. It is not typical of
pathogenic COL7A1 mutations found inRDEB and is unlikely to be contributing to this
patient's severe disease. The sub-lamina densa cleavage plane, absence of staining by
the LH7:2 antibody together with the phenotype all point towards a severe abnormality
of collagen VII but in this child, identification of causative mutations has been
unsuccessful.
Like most mutations underlying both DDEB and RDEB, the COL7A1 mutation found
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in family 43 appears to be family specific. It is typical ofmutations identified in RDEB
in that it is a small nonsense deletion which results in a premature termination codon.
Because the abnormality lies in exon 117 close to the 3' end of the gene, almost full
length protein should be transcribed and it is perhaps surprising that the phenotype in
this patient is so severe. There are several possible explanations. Although a second
mutation has not been identified, one is predicted to exist. It is known that the phenotype
in RDEB is profoundly affected by the position and nature of the second mutation
(Shimizu and Masunaga 1999) which in this patient may be the major disruptive
influence rather than the identified mutation. It is also known that nonsense mutations
lead to messenger-RNA decay and thus to low levels of polypeptide synthesis, reduced
numbers of anchoring fibrils (Christiano and Amano 1997) and consequently to skin
fragility. Finally, the severe phenotype in this patient could indicate that the NC-2
domain of type VII collagen is critical for correct assembly of anchoring fibrils.
It has proved frustratingly difficult to identify COL7A1 mutations inmany patients who
clinically and ultrastructurally have classical features of DEB, including some with
severe disease. In families who lack an obvious dominant or recessive pattern of
inheritance, accurate genetic counselling can be given only ifpathogenicmutations have
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been detected. When both parents ofan EB sufferer have normal skin, disease in their
child may be due to one of several modes of inheritance, each having differing
implications for future pregnancies. Recessive inheritance indicates a 1 in 4 risk, in
contrast to the negligible risk associated with uniparental disomy (Uitto 1999) or a de-
novo mutation. In this latter situation, the mutation may later be passed on in dominant
fashion by the affected child. Finally, in the case of gonadal mosaicism in one parent,
the likelihood ofhaving another affected child is much higher and depends on the ratio
ofmutant to wild type germ cells. If gonadal mosaicism occurs in the father, analysis of
a semen sample can give an indication of the proportion ofmutant germ cells, but an
equivalent estimation is not possible in maternal germ cell mosaicism (Cserhalmi-
Friedman 2001,2002). When identification ofCOL7A1 mutations proves unsuccessful,




Quality of life in epidermolysis bullosa.
7.1 Introduction
Skin disease can have a profound impact on many aspects ofdaily life. Pain may reduce
mobility and affect concentration, with implications for social activities, education and
employment. Visible areas of abnormal skin often arouse misunderstanding and
inappropriate fear of infection amongst observers, causing embarrassment, self-
consciousness and loss of confidence. Personal relationships may be affected by the
demands of time-consuming treatments or by odour associated with dressings. These
factors all affect quality of life (QOL), but to what degree is dependent on other
considerations such as an individual's personality and coping abilities. Objective
assessment of quality of life is difficult, a fact reflected by the variety of different
methods that have been used in an attempt to achieve meaningful and reproducible
results. During the past few years, the Dermatology Life Quality Index (DLQI) (Finlay
1994) and the Children's Dermatology Life Quality Index (CDLQI) (Lewis-Jones 1995)
have emerged as useful tools for assessing the QOL of those with skin diseases,
comparing severities ofdifferent disorders and judging the effectiveness of treatments
(Finlay 1994, Kurwa 1995, Lewis-Jones 1995, Emerson 1998, Badia 1999, Poon 1999,
Shum 2000, Touw 2001, Von der Worth 2001). The aim of this study, which was




Details of all EB sufferers living in Scotland were derived from the EB Register (Horn
1997). In the first of three diagnostic groups, (group A), there were 143 EBS sufferers.
One hundred and eleven adults and 27 children in this group had either EBS-WC or
EBS-Kb and five patients (three adults and two children) had EBS-DM. Adults were
aged between 16 and 86 years (mean 41 years) and children between 1 and 15 years
(mean 10 years). In group B there were 99 DEB sufferers comprising 53 adults and 20
children with DDEB, 12 adults and 8 children with DEB-unc and 6 adults with RDEB-
nHS. Adults were aged between 16 and 84 years (mean 44 years) and the ages of the
children ranged from 3.5 to 15 years (mean 10 years). Six patients with RDEB-HS were
considered in group C, an adult aged 40 years old and 5 children aged from 3.5 to 15
years (mean 6 years, median 3.5 years).
The DLQI and an explanatory letter stressing the anonymity of replies were posted in
early May to every Scottish EB sufferer aged 16 years or over. Parents of those aged
under 16 were sent a copy of the CDLQI for each of their affected children. After an
interval of two weeks, a reminder was posted to every patient. To enable correlation of
replies with subtype of EB, questionnaires were colour coded, different colours
corresponding to each of the three diagnostic groups.
The (C)DLQI (Figures 20 and 21) contains 10 questions relating to experiences during
the previous week (Finlay 1994, Lewis-Jones 1995). Each question has 5 possible
answers (very much, a lot, a little, not at all or not relevant) which score 3, 2, 1, or 0
respectively. Patients were asked to state their age and sex and to tick one answer for
each question; thus the maximum total score possible for any patient was 30 and the
minimum was 0.
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1 Over the last week, how itchy, sore, painful or stinging has your skin been?
2 Over the last week, how embarrassed or self conscious have you been because of your skin?
3 Over the last week, how much has your skin interfered with you going shopping, or looking after your
home or garden?
4 Over the last week, how much has your skin influenced the clothes you wear?
5 Over the last week, how much has your skin affected any social or leisure activities?
6 Over the last week, how much has your skin made it difficult for you to do any sport?
7 Over the last week, has your skin prevented you from working or studying?
If "No", over the last week, how much has your skin been a problem at work or studying?
8 Over the last week, how much has your skin created problems with your partner or any of your close
friends or relatives?
9 Over the last week, how much has your skin caused any sexual difficulties?
10 Over the last week, how much of a problem has the treatment of your skin been, for example by making
your home messy or by taking up time?
Figure 20. The Dermatology Life Quality Index questionnaire.
1. Over the last week, how itchy, "scratchy", sore or painful has your skin been?
2. Over the last week, how embarrassed or self conscious, upset or sad have you been because of your
skin?
3. Over the last week, how much has your skin affected your friendships?
4. Over the last week, how much have you changed or worn different or special clothes/ shoes because
of your skin?
5. Over the last week, how much has your skin trouble affected going out, playing or doing hobbies?
6. Over the last week, how much have you avoided swimming or other sports because of your skin
trouble?
7. Last week, was it either: If school time: over the last week, how much did your skin affect your
school □ school work?
or (answer only one)
holiday time □ If holiday time: how much over the last week, has your skin interfered with
your holiday plans?
8. Over the last week, how much trouble have you had because of your skin trouble, with other people
calling you names, teasing, bullying, asking questions or avoiding you?
9. Over the last week, how much has your sleep been affected by your skin problem?
10. Over the last week, how much of a problem has the treatment of your skin been?
Figure 21. The Childrens' Dermatology Life Quality Index questionnaire
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7.3 Results
Replies were received from 75 patients in group A (57 adults and 18 children), a
response of52%, (adults 50% and children 62%). In group B, there were 32 replies from
adults (45%) but only 8 replies (29%) from children, an overall response of40%. Only
one ofthe patients in group C, a child, did not reply (response rate of83%). Overall, the
response was 48%. As many patients failed to state their age or sex, no attempt was
made to correlate severity of symptoms with these parameters.
Adults
7.3a EB simplex
Themean total score in group A was 10.7 (range 0 to 26, median 10). Question 1, which
enquired about symptoms, had the highest mean score (1.6, median 2) and question 6,
relating to sport, also recorded high scores (mean 1.5, median 2, Figure 22).The lowest
mean score (0.3), was for question 9 which asked about sexual difficulties. Four
patients, aged between 23 and 39, each scored a total of zero.
3
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Question number
Figure 22. Mean DLQI scores in adult EB patients
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The question answered "very much" most often (20 patients, 35%) was number 6 ,
which related to sport (Table 18).
1 2 3
Question number
4 5 6 7 8 9 10
EBS (n=57) n 12 7 7 7 9 20 13 4 1 1
% 21 12 12 12 16 35 23 7 2 2
DEB (n=32) n 4 4 2 3 2 7 3 1 2 2
% 13 13 7 10 7 23 10 3 7 7
RDEB-HS (n=1) n 1 1 0 1 1 0 0 1 0 1
% 100 100 0 100 100 0 0 100 0 100
Table 18. Numbers of adults scoring "3" for individual questions.
7.3b Dystrophic EB
The mean total score was 7.5 (median 4, range 0 to 28). Questions 1, 2 and 4
(symptoms, embarrassment and clothing) achieved the highest mean scores of 1.2, 1.0
and 1.0 ( median scores of 1 in each case) and question 8 (relationships) had the lowest
mean score (0.4, median 0, Figure 20). Like EBS, the question awarded "verymuch" by
the greatest number of patients was number 6 (sport), which was selected by 7 (23%)
patients. Responses to each individual question varied from 0 to 3. Five patients, 3 aged
between 67 and 84 and two of unknown age, recorded total scores of zero.
Children
7.3c EB Simplex
Children with EBS recorded a mean total score of 15 (median 15, range 0 to 30).
Question 1 achieved the highest mean score (2.1, median 2), followed by question 5
(play and hobbies) (mean 1.9, median 2, Figure 21). The lowest score was for question
8,which enquired about teasing and bullying (mean 0.9, median 0.5). Only one patient





Figure 23. Mean CDLQI scores for children with EB
In keeping with the adult responses, the question awarded "very much" by the greatest
number of children (9 children, 50%) was number 6 (Table 19). The full range of
answers was seen in response to every question.
1 2 3
Question number
4 5 6 7 8 9 10
EBS (n=18) n 6 4 4 5 7 9 3 2 5 3
% 33 22 22 28 39 50 17 11 28 17
DEB (n=8) n 3 2 0 1 0 1 0 2 1 0
% 38 25 0 13 0 13 0 25 13 0
RDEB-HS (n=4) n 3 2 1 1 2 4 1 0 2 3
% 75 50 25 25 50 100 25 0 50 75
Table 19. Numbers of children scoring "3" for individual questions
109
7.3d Dystrophic EB
The mean total CDLQI score for children with DEB was 11.5 (median 12.5, range 0 to
23).Question 2 (embarrassment and sadness) recorded the highest mean score (1.7,
median 2), followed by question 1 (symptoms) (meanl.6, median 2). The lowest mean
score was for question 3, which asked about friendships (mean 0.5, median 0). Question
number 1 was awarded the maximum score by the most patients (3 patients, 37.5%).
One child, aged 8, scored a total ofzero. No patients scored higher than 2 for questions
3, 5, 7 and 10, but the remaining questions were awarded the full range of scores.
7.3e RDEB-HS in adults and children
The one adult with RDEB-HS recorded a total score of 18. Question numbers 3,6,7,and
9 were each awarded a score 0, all remaining questions scoring 3.
The four children with RDEB-HS scored a mean total of 22.0 (median 21, range 17 to
29). All patients answered "very much" to question 6 (sport). Question 3 (friendships)
recorded the lowest mean score (mean 1.0, median 1).
7.4 Discussion.
Despite the limitations of a postal survey and the possibility of a biassed response, the
results reflect the wide variety of problems encountered by EB sufferers. Adults and
children with both EBS and DEB experience an impairment ofQOL equivalent to that
caused by moderate to severe psoriasis and atopic eczema (Table 20). Like most other
skin disorders, question 1 relating to symptoms was scored most highly by all those in
groups A and B. Comparison with other studies suggests that RDEB-HS causes greater
impairment ofQOL than any skin disease previously assessed (Table 20).
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Adults Children
Atopic eczema 4.14 1-16.2 2 7.7 3 -12.7 4
Psoriasis 4.5 1-13.9 2
Hidradenitis suppurativa 8.9 5
Urticaria 7.5-15 6









5.Von der Worth (2001)
6. Poon (1999)
7. Blackford (1997)
Table 20. Mean (C)DLQI scores in skin disorders.
Inevitably, the number ofRDEB-HS patients assessed in this study was small but they
were representative of those having this rare disorder. Their high QOL scores are
unlikely to be overestimates and in some cases were artificially lowered by responses
"not at all" or "not relevant" to questions on matters entirely incompatible with the
lifestyle of RDEB-HS suffers. These include sport, sexual difficulties and domestic
duties.
The devastating effects ofRDEB-HS are obvious to observers, but the difficulties and
distress experienced by sufferers of less severe variants ofEB may not be so apparent.
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EBS is often considered to be the mildest subtype ofEB but this survey indicates that
it has a more marked effect on QOL than the non-Hallopeau-Siemens variants ofDEB.
Patients' replies reflect the greater restriction ofphysical, social and sporting activities
caused by EBS compared to DEB and also its greater impact on employment and
education. Despite the often visible skin lesions of DEB, children with EBS, whose
blisters are usually concealed by footwear, experiencemore difficultieswith friendships.
Pain prevents participation in the more physical aspects of normal childhood and can
contribute to social isolation and psychological problems. Undoubtedly, some DEB
sufferers, both those with DDEB and those with RDEB-nHS, do experience great
difficulties, but such patients are few in number, the majority of DDEB patients and
even some with RDEB-nHS having only mild disease (Horn 2002).
Although some patients with EBS experience an improvement of the blistering





Tracing EB patients in Scotland has led to compilation of the most comprehensive EB
Register of any yet reported. Although the American EB Registry includes details of a
greater number of EB sufferers, the prevalences of EBS and DEB in Scotland are far
higher, particularly amongst those with DDEB suggesting that in Scotland detection of
EB patients is more complete.
Many Scottish EB sufferers (EBS 30%, DDEB 41%) were brought to the attention of
dermatologists for the first time directly as a result ofthis study. Despite this exhaustive
attempt to accurately assess the epidemiology of EB in Scotland, previously
undiagnosed EB sufferers are still occasionally referred to clinics at the Royal Infirmary
ofEdinburgh, demonstrating that the high prevalence figures for EB in this study remain
an underestimate. Nevertheless, the data has proved to be ofpractical use in the planning
of healthcare services for EB patients not only in Scotland but also, by extrapolation,
throughout the United Kingdom. In the future, the Register should allow identification
of those Scottish EB patients who might benefit from novel treatments.
Systematic clinical evaluation ofScottish EBS patients has highlighted some differences
from traditional clinical descriptions. Oral blisters and nail dystrophy in EBS-DM have
long been recognized, but standard dermatology textbooks do not mention that these
clinical features are also found in a substantial minority of patients with the less severe
variants ofEBS. Blisters at sites other than the palms and soles were considered to occur
in only a small minority of those with non-Dowling-Meara subtypes of EBS (Rook
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1999). This study has shown that at least 43% of such patients develop blisters at other
sites of friction. Assessment of entire families with EBS has shown a spectrum of
severity which is only partially determined by the location and nature of the underlying
mutation. The occurrence of both Weber-Cockayne and Kobner phenotypes
simultaneously in all but the smallest EBS pedigrees suggests that these are one
disorder, whose severity is modified in an individual by other, currently unidentified,
factors. The terms "EBS/WC" and "EBS/Kb" are not sufficiently precise to be used
alone but should always be accompanied by a clinical description.
Similar and often marked intra familial variation ofseverity is also seen in DDEB. Some
unusual and distinctive clinical features ofDEB, such as Pasini albopapuloid lesions and
EB pruriginosa do not occur in every person carrying a specific mutation and are often
seen in only one affected family member. As in EBS, the factors determining severity
ofDDEB in an individual remain unknown. Such extensive clinical variation indicates
that unless several affected individuals can be assessed, caution is necessary when
attributing a phenotype to a newly described pathogenic mutation.
As a result of assessment of EBS patients in Scotland, the worldwide database of
pathogenic keratin mutations has been increased by 23%. A small number of patients
with classical EBS were identified in whom no keratin mutations were found, suggesting
that mutations of other genes can cause identical phenotypes to those induced by
mutations of KRT5 and KRT14.
Because analysis ofCOL7A1 is less readily available, fewer mutations were identified
in DEB patients. It is frustrating that mutation detection failed or was only partially
successful in approximately 50% of those DEB patients whose DNA was analysed,
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including some with severe disease. Further detailed examination ofCOL7A1 in these
patients may reveal additional mutations. If mutations of this gene cannot be found,
analysis ofgenes encoding other basement membrane proteins, eg.a6 or [14 integrins, or
collagen XVII, may show some of these patients to be compound heterozygotes for
mutations of two different genes. At present, there are no routine facilities in the United
Kingdom for DNA analysis of these patients, who, despite the genetic basis of their
disease, are denied the benefits of informed genetic counselling.
Examination of the QOL ofEB patients confirmed the profound impact of RDEB-HS
onQOL. Perhapsmore surprisingwas the finding that EBS, often considered themildest
EB subtype, also seriously reduces QOL, especially in children. DEB (excludingRDEB-
HS) had less impact on quality of life, and for many, was a mild disease.
This study confirms the need to investigate the mechanisms underlying scarring in DEB.
For many this is only a cosmetic problem, but in an unfortunate minority, it is
sufficiently severe to cause deformity and disability. The aggressive nature of SCO in
DEB is also not understood and current treatments are inadequate. It is to be hoped that
current research will prove constructive in both areas. There is also an unmet need to
provide a mutation screening service for those DEB patients who have severe disease
or disease of uncertain inheritance.
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Appendix 1
Numbers of Epidermolysis Bullosa patients in Scotland
EBS
Total seen 1992-2001 = 146
Total not seen = 29
175
Total died/moved = 5
Total population June 2001 =170
DEB
Total seen 1992-2001 = 101
Total not seen = 29
130
Total died/moved = 4
Total population June 2001 = 126
JEB Total seen 1992-2001 = 4
Total moved = 2
Total population June 2001 = 2
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initials m f EBS
sub¬
type




1 1 JB 0 1 Kb 6-10 yrs 23.8 Lothian
2 1 CB 0 1 WC 6-10 yrs 17.8 Lothian
3 1 MB 0 1 Kb 6-10 yrs 47.5 Lothian
4 1 AB 1 0 WC 6-10 yrs 37 Lothian
5 1 DM 0 1 WC 6-10 yrs 26 Lothian
6 1 SM 1 0 Kb 7mths-2 yrs 2.7 Lothian
7 2 AM 0 1 WC 2-5 yrs 15.5 Lothian
8 3 PK 1 0 WC 7mths-2 yrs 22.2 Lothian
9 3 KM 0 1 Kb 1 -4 wks 7.8 Strathclyde
10 3 KvM 1 0 Kb 1 -4 wks 10.1 Strathclyde
11 3 AM 1 0 WC 7mths-2 yrs 34.3 Strathclyde
12 3 LM 1 0 Kb 1-7 days 4.3 Lothian
13 3 RD 1 0 Kb birth 41.2 Lothian
14 3 Mg W 0 1 Kb 1 -4 wks 38.8 Lothian
15 3 MW 0 1 WC 1-4 wks 16.3 Lothian
16 3 stw 1 0 Kb 1 -4 wks 13.8 Lothian
17 3 Sn W 1 0 Kb 1 -4 wks 13.8 Lothian
18 3 HR 0 1 Kb ? 62.3 Lothian
19 3 AK 0 1 Kb 1-7 days 57.2 Lothian
20 3 LB 0 1 WC 7mths-2 yrs 14.8 Grampian
21 3 AB 0 1 WC ? 35.5 Grampian
22 3 VB 0 1 WC 7mths-2 yrs 16.8 Grampian
23 3 GH 1 0 Kb 7mths-2 yrs 34.3 Tayside
24 3 GrH 1 0 Kb 1-6 mths 4.3 Tayside
25 3 AH 0 1 Kb ? 61.7 Tayside
26 3 EH 0 1 Kb 1-6 mths 2.6 Tayside
27 3 RH 1 0 Kb 1-6 mths 30 Tayside
28 3 SH 1 0 Kb ? 1.9 Tayside
29* 3 ZH 0 1 ? 1 -4 wks 1.3 Tayside
30 3 IM 1 0 Kb 2-5 yrs 61.8 Fife
31 3 AS 1 0 Kb 1-7 days 50.6 Fife
32 3 AM 0 1 WC ? 67.6 Fife
33* 3 JM 0 1 ? 1-6 mths 1.1 Fife






initials m f EBS
sub¬
type




35 4 KM 1 0 WC 1 -7 days 23.7 Strathclyde
36 4 AM 0 1 Kb 1-6 mths 3 Strathclyde
37 5 DC 1 0 DM birth 0.1 Lothian
38 6 CC 0 1 DM 1 -7 days 11.5 Strathclyde
39 7 AJ 0 1 Kb 7mths-2 yrs 26.6 Lothian
40 7 WT 0 1 Kb 7mths-2 yrs 57.1 Lothian
41 7 HJ 0 1 WC 7mths-2 yrs 3.5 Lothian
42 7 SJ 0 1 WC 7mths-2 yrs 3.5 Lothian
43 8 MG 0 1 WC 7mths-2 yrs 51.5 Strathclyde
44 8 MC 0 1 WC 7mths-2 yrs 29.3 Strathclyde
45 8 PC 1 WC 7mths-2 yrs 5.3 Strathclyde
46 8 BD 1 WC 7mths-2 yrs 24.9 Strathclyde
47* 8 ED 0 1 WC ? 2.6 Strathclyde
48 9 DP 0 1 Kb 1 -6 mths 17.8 Borders
49 9 EP 0 1 Kb 1-6 mths 35.3 Borders
50 9 NL 0 1 Kb 1-6 mths 66.8 Borders
51 9 DP 0 1 Kb 7mths-2 yrs 58.5 Borders
52 9 RR 0 1 Kb ? 65.6 Borders
53 9 BA 0 1 Kb ? 30.3 Borders
54 9 CA 0 1 Kb 1 -4 wks 10.8 Borders
55
56
9 VP 0 1 Kb 7mths-2 yrs 7.8 Borders
9 BP 1 0 WC ? 38 Borders
57 9 TH 1 0 Kb ? 63.1 Borders
58 9 TH Jnr 1 0 Kb 1-7 days 34.3 Borders
59 9 CJ 0 1 Kb ? 73 Borders
60 9 AC 0 1 Kb ? 75.3 Borders
61 9 EP 0 1 Kb 1-6 mths 69.4 Fife
62 9 SH 0 1 Kb 1 -6 mths 3.8 Borders
63 d 9 AD 0 1 Kb 1 -4 wks 48 Borders
64 9 GS 0 1 WC ? 42.8 Borders
65 9 PH 0 1 Kb 1 -6 mths 32.3 Borders
66* 10 BC 0 1 WC 6-10 yrs 13.3 Borders
67* 10 GC 1 0 WC 6-10 yrs 10.3 Borders
68 11 DB 1 0 WC 7mths-2 yrs 77.3 Lothian
69 11 SD 0 1 WC 1-7 days 16.7 Lothian
70 11 JD 0 1 WC 1 -7 days 44.9 Lothian






initials m f EBS
sub¬
type




72 12 NH 0 1 Kb 7mths-2 yrs 38.3 Lothian
73 12 DF 0 1 Kb 1-6 mths 41.9 Lothian
74 12 EJF 0 1 Kb 7mths-2 yrs 19.3 Lothian
75 12 DH 0 1 Kb 1 -6 mths 7.3 Lothian
76 13 DP 0 1 Kb birth 39.1 Lothian
77 13 JR 0 1 Kb birth 19.9 Lothian
78 14 CB 0 1 WC 2-5 yrs 19.7 Borders
79 14 PB 0 1 WC 2-5 yrs 12.8 Borders
80 14 EB 0 1 WC 2-5 yrs 47.6 Borders
81 d 14 MG 0 1 WC 2-5 yrs 78.3 Borders
82 15 PM 1 0 Kb 1-6 mths 34.8 Highlands
83 15 CM 0 1 WC 7mths-2 yrs 7.5 Highlands
84 15 DM 1 0 WC ? 33.3 Highlands
85 15 CM 0 1 WC 2-5 yrs 13.9 Highlands
86 15 RM 1 0 WC 6-10 yrs 10.6 Highlands
87* 15 JM 1 0 Kb ? 60 Strathclyde
88 15 RS 0 1 WC 7mths-2 yrs 33 Strathclyde
89 16 JH 1 0 WC 7mths-2 yrs 38.7 Strathclyde
90 16 JH Jnr 1 0 Kb 1 -6 mths 13 Strathclyde
91 16 PH 1 0 Kb 1-6 mths 10.8 Strathciyde
CDK) Ol 16 Jn H 0 1 Kb 7mths-2 yrs 7.7 Strathclyde
93 17 HP 0 1 WC ? 45.7 Borders
94 17 Dv P 1 0 WC 7mths-2 yrs 24.3 Borders
95 17 KD 0 1 Kb 1 -4 wks 1.8 Strathclyde
96 18 CMc 0 1 WC birth 7.9 Strathclyde
97 19 JK 0 1 WC 7mths-2 yrs 29.3 Strathclyde
98 19 MK 0 1 Kb 1-6 mths 1.5 Strathclyde
99 19 GK 1 0 WC 1-6 mths 6.2 Strathclyde
100 19 PS 0 1 WC 7mths-2 yrs 32.8 Strathclyde
101 19 BS 1 0 WC 1 -4 wks 14.8 Strathclyde
102 19 CS 1 0 WC 7mths-2 yrs 3.5 Strathclyde
103 19 TS 1 0 WC ? 28 Strathclyde
104 19 MY 0 1 WC ? 35.8 Strathclyde
105 19 AH 1 0 Kb 7mths-2 yrs 11.9 Strathclyde
106* 19 WH 0 1 ? ? 40 Strathclyde






initials m f EBS
sub¬
type




108 20 GH 1 0 Kb ? 55.7 Grampian
109 20 PH 1 0 Kb 1-6 mths 28.6 Grampian
110 20 IM 1 0 Kb ? 57 Highlands
111* 20 MM 0 1 Kb 1-6 mths 31.5 Highlands
112 20 NH 1 0 WC ? 54.8 Highlands
113 20 YA 0 1 Kb 1-7 days 30.4 Highlands
114 21 DL 1 0 Kb 1-7 days 20.1 Strathclyde
115 21 EL 0 1 Kb 1-7 days 24.5 Strathclyde
116 21 CL 0 1 Kb 1-7 days 43.8 Strathclyde
117 21 LL 0 1 Kb 1-6 mths 1.3 Strathclyde
118 21 DcL 1 0 Kb 1-6 mths 1.5 Strathclyde
119 21 NL 0 1 Kb 1 -6 mths 1.5 Strathclyde
120 22 NK 0 1 DM birth 0.3 Tayside
121 d 23 WMc 1 0 WC ? 75.3 Strathclyde
122 24 AMc 1 0 Kb 7mths-2 yrs 7.7 Strathclyde
123 24 MMc 0 1 Kb 7mths-2 yrs 5.5 Strathclyde
124 25 DS 1 0 WC ? ! 27.3 Tayside
125 25 ES 0 1 WC 1 -6 mths 1.3 Tayside
126 26 CMc 0 1 Kb 1-7 days 18.8 Strathclyde
127 27 JMc 0 1 WC ! 11 -20 yrs 20.7 Strathciyde
128* 27 SMc 1 0 WC 11-20 yrs 18.8 Strathclyde
129 28 LD 0 1 Kb 7mths-2 yrs 28.9 Tayside
130* 28 ED 0 1 Kb 1-6 mths 1.3 ; Tayside
131 29 AB Jr 1 1 0 Kb 7mths-2 yrs 9 Strathclyde
132 29 MB 0 1 Kb 1-7 days 5.3 Strathclyde
133* 29 AB Sr 1 0 WC 7mths-2 yrs 32.3 Strathclyde
134 30 CP 0 1 DM birth 16.8 Strathclyde
135 31 MS 0 1 DM 1-7 days 48.7 Grampian
136 32 JF 1 0 WC 2-5 yrs 7.5 Strathclyde
137 32 VJF 0 1 WC 11-20 yrs 13 Strathclyde
138* 32 IF 1 0 WC ? 27.1 Strathclyde
139 33 JR 1 01 WC ? 59.9 Strathclyde
140* 34 GL 1 0 WC 7mths-2 yrs 12.3 Strathclyde
141 35 SZ 1 0 DM 1-7 days 0.1 Strathclyde
142 35 AZ 1 0 DM 1-7 days 0.1 Strathclyde
143* 39 JMc 0 1 WC ? 39 Grampian
144* 40 LI 0 1 WC ? 19 Strathclyde
145* 40 Rl 0 1
I I






initials m f EBS
sub¬
type




146* 41 PMc 1 0 ? 1 year 6 Lothian
147* 42 MR 0 1 WC 1 year 7 Strathclyde
148* 42 CR 0 1 WC ? 28 Strathclyde
149* 43 LM 0 1 WC 2 years 15 Ayrshire
*
patient not included in chapter 3
d patient died during the study
WC Weber-Cockayne subtype of EBS
Kb Kobner subtype of EBS
DM Dowling-Meara subtype of EBS
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Kb 1 1 1 0 1 1 1 0 ? 1 0
2 1 CB WC 0 1 0 0 0 1 0 0 ? 1 0
3 1 MB Kb 1 1 1 0 0 1 1 0 ? 1 0
4 1 AB WC 1 1 0 0 0 1 1 0 ? 1 0
5 1 DM WC 0 1 0 0 0 1 1 0 1 0 0
6 1 §M Kb 0 1 1 0 0 9 0 0 9 0 0
7 2 AM wc 0 0 0 0 0 0 0 0 1 1 1
8 3 PK
K14:Val270Met
WC 0 1 0 0 0 1 0 0 1 0 0
9 3 KM Kb 1 1 1 0 1 1 ? 0 ? 1 0
10 3 KvM Kb 1 1 1 0 0 1 0 0 ? 1 0
11 3 AM WC 1 1 0 0 0 1 0 0 0 1 0
12 3 LM Kb 1 1 1 0 0 1 7 0 ? 1 0
13 3 RD Kb 1 1 1 0 0 1 ? 0 ? 1 0
14 3 Mg W Kb 1 1 1 0 0 1 9 0 1 1 0
15 3 MW WC 1 1 0 0 1 1 ? 0 0 1 0
16 3 stw Kb 1 1 1 0 1 1 1 0 0 1 0
17 3 Sn W Kb 1 1 1 0 1 1 1 0 0 1 0
18 3 HR Kb 1 1 1 0 0 1 ? 0 1 1 0
19 3 AK Kb 1 1 1 1 0 1 ? 1 1
0
1 0
20 3 LB WC 0 1 0 0 0 1 1 0 0 0
21 3 AB WC 1 1 0 0 0 1 1 1 1 0 0
22 3 VB WC 0 1 0 0 0 1 1 0 0 ? 0
23 3 GH Kb 1 1 1 1 0 1 1 1 1 1 0
24 3 GrH Kb 1 1 1 0 0 1 ? 0 ? 1 0
25 3 AH Kb 1 1 1 1 1 1 1 1 1 1 0
26 3 EH Kb 0 1 1 0 0 ? 1 0 inf 1 0
27 3 RH Kb 1 1 1 0 1 1 1 1 1 1 0
28 3 SH Kb 1 1 1 0 0 1 inf 0 inf 1 0
29* 3 ZH ? ? ? ? 7 7 ? inf ? inf 0 0
30 3 IM Kb 1 1 1 1 0 1 1 0 1 0 0
31 3 AS Kb 1 1 1 0 1 0 1 0 1 1 0
32 3 AM WC 1 1 0 0 1 1 ? 0 1 0 0
33* 3 JM ? 0 1 1 0 0 0 0 0 inf 0 0









































































































































































































































































































































































































































































































































































72 12 NH Kb 1 1 1 0 o 1 0 1 1 0
73 12 DF
K14:Val133Ala
Kb 1 1 1 1 0 1 1 1 1 0 0
74 12 EJF Kb 1 1 1 1 0 1 1 ? 1 0
75 12 DH Kb 1 1 1 0 0 1 1 0 ? 0 0
76 13 DP
not found
Kb 1 1 1 1 0 1 0 0 ? 1 1
77 13 JR Kb 1 1 1 1 0 1 0 0 ? 1 0
78 14 CB WC 1 1 0 0 0 1 ? 0 ? 0 0
79 14 PB WC 0 1 0 0 0 1 1 0 ? 0 o
80 14 EB WC 1 1 0 1 0 1 0 ? 1 0
81d 14 MG WC 0 1 0 0 0 -| 9 0 1 1 0
82 15 PM K5:Asn329Ser Kb 1 1 1 1 1 1 0 0 1 0
83 15 CM WC 0 1 0 0 0 1 0 0 0 0 0
84 15 DM
not found
WC 1 1 0 1 0 1 ? 0 0 0 0
85 15 CM WC 0 1 0 1 0 1 ? 0 0 0 0
86 15 RM WC 0 1 0 0 0 ? 0 0 0 0 0
87* | 15 JM K5: Asp329Ser Kb 1 1 1 ? 0 1 0 ? 1 1 0
88 I 15 RS not found WC 0 1 0 0 0 1 ? 0 1 0 0
89a I 16 JH
K14:Lys116Glu
WC 1 1 0 1 1 1 1 0 1 1 1
90a I 16 JH Jnr Kb 1 1 1 1 0 1 1 0 ? 1 0
91 a| 16 PH Kb 1 1 1 1 0 I 1 0 ? 1 0
92 a d 16 Jn H Kb 1 1 1 1 0 1 1 0 9 1 0
93 17 HP WC 1 1 0 0 0 1 1 0 1 0 0
94 17 Dv P K14:Val133Met WC 1 1 0 0 0 1 1 0 0 0 0
95 17 KD Kb 1 1 1 0 0 ? 2 0 ? 1 0
96 18 CMC WC 1 1 Q 0 0 1 0 0 1 1
97 19 JK WC 1 1 0 0 0 1 1 0 ? 1 0
98 19 MK Kb 0 1 1 0 0 1 ? 0 inf 1 0
99 19 GK WC 0 1 0 0 0 1 1 0 0 1 0
100 19 PS WC 1 1 0 0 0 1 0 1 1 0
101 19 BS WC 1 1 0 0 0 1 1 0 0 1 0
102 19 CS K5:lle467Leu WC 0 1 0 0 1 1 1 0 ? 0 0
103 19 TS WC 1 1 0 0 0 1 1 1 1 0
104 19 MY jwc 1 1 0 0 0 1 1 1 1 0
105 19 AH Kb 1 1 1 0 0 0 0 0 1 0
106* 19 WH ?1? ? ? ? ? ? ? ? ? ? 0




































































































































































































































































































































































































































































































































































































































143* 39 JMc K14:lle377Thr WC 1 1 0 0 0 1 1 0 ? 1 1
144* 40 LI WC 1 1 0 1 o 0 0 0 ? ? 0
145* 40 Rl WC 1 1 0 1 0 0 0 0 0 0 0
146* 41 PMc ?
147* 42 MR WC 1 1 0 0 1 1 0 0
148* 42 CR blood sent WC
159* CO LM WC 0 1 0 0 0
1 feature present
0 feature absent
* patient not included in chapter 3
d patient who died during the study
a anal fissures present in all members of family 16
inf infant too young for full assessment of clinical features
WC Weber-Cockayne subtype of EBS
Kb Kobner subtype of EBS
DM Dowling-Meara subtype of EBS
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initials m f D.O.B. Region Mutation
3 MH 1 25/07/1972 Strathclyde
3 SN 1 10/09/1938 Grampian
3 KH* 1 20/10/1968 Grampian
3 SH 1 ? Grampian
3 MC 1 27/11/1933 Grampian
K14 Val270Met
3 DN 1 20/10/1968 Grampian
3 AE 1 21/07/1936 Grampian
3 JH (Snr) 1 ? Grampian
3 LH 1 ? Grampian
3 JH (Jnr) 1 ? Grampian
11 MD 1 ? ? K14 Val133Met
17 HD 1 ? Strathclyde K14 Val133Met
19 AM 1 ? Strathclyde
19 DS 1 ? Strathclyde K5:lle467Leu
19 MS 1 01/12/1935 Strathclyde
24 AMc 1 08/08/1963 Grampian
26 WMc 1 ? Strathclyde K5:Ala428Val
27 CB 1 ? Strathclyde
27 GB 1 ? Strathclyde
29 MB 1 29/09/1927 Strathclyde K14:Leu418Val
31 KS 1 14/03/1972 Grampian K14:Leu122Phe
? RT 1 03/10/1913 Lothian
36 CGd 1 ? Strathclyde
no tonofilaments
but K5 and K14
presenta
37 JMcd 1 29/07/1965 ?
38 >ZJ Q. 1 ? ?
39 FS 1 ? Tayside
K14:lle377Thr
39 cs 1 ? Tayside
40 DT 1 04/11/1955 ?
44 DK* 1 27/06/1968 Lothian blood sent
patient seen September 2002
personal communication (E. J. Rugg)
patient identified by other dermatologists
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1d 1 JH 1 0 RDEB-HS birth 23 Lothian
2 1 PB 1 0 DEB-unc 1-6 months 33 Lothian
3d 2 CL 0 1 RDEB-HS (s) birth 20 Strathclyde
4 3 AH 0 1 RDEB-HS (s) birth 3.5 Dumph + Gall
5d 4 FMcN 0 1 RDEB-inv (s) 1 -4 weeks 57 Western Isles
6 5 MMcL 0 1 RDEB-inv (s) birth 48 Lothian
7 6 SA 0 1 RDEB-unc (s) birth 6 Lothian
8 7 CC 0 1 RDEB-unc (s) 1-7 days 6 Lothian
9 8 VH 1 0 RDEB 1 -4 weeks 43 Lothian
10 9 CY 1 0 DDEB 1-7 days 1.5 Lothian
11 9 SY 1 0 DDEB ? 37 Lothian
12 10 CB 0 1 DDEB birth 0.04 Lothian
13 10 LB 0 1 DDEB 1-7 days 21 Lothian
14 10 PT 1 0 DDEB 1-6 months 10 Lothian
15 10 LT 0 1 DDEB ? 30 Lothian
16 10 JMcM 0 1 DDEB ? 31 Lothian
17 10 FW 1 0 DDEB 2-5 years 9 Lothian
18 10 DT 0 1 DDEB 7-24 months 3.25 Lothian
19 10 DN 0 1 DDEB 1-6months 5 Lothian
20 10 LN 0 1 DDEB 1-6months 3 Lothian
21 10 VN 0 1 DDEB 1-6months 25 Lothian
22 10 HMcM 0 1 DDEB ? 50 Lothian
23 10 HD 0 1 DDEB ? 27 Lothian
24 10 CD 0 1 DDEB 1-7 days 2 Lothian
25 10 JD 1 0 DDEB 7-24 months 7 Lothian
26 10 MD 1 0 DDEB 7-24 months 9 Lothian











28 11 DF 1 0 DDEB ? 65 Lothian
29 11 KF 0 1 DDEB 1 -7 days 10 Lothian
30 11 KF 1 0 DDEB 1-7 days 8 Lothian
31 11 DF 1 0 DDEB 1-7 days 40 Lothian
32 11 HD 0 1 DDEB ? 46 Lothian
33 11 HM 0 1 DDEB birth 37 Lothian
34 11 MR 0 1 DDEB ? 72 Lothian
35 11 JC 0 1 DDEB 1-6 months 4.5 Lothian
36 11 FC 1 0 DDEB 1-6 months 31 Lothian
37 11 AC 0 1 DDEB ? 54 Lothian
38 12 MG 0 1 DDEB birth 66 Lothian
39 12 GG 1 0 DDEB ? 61 Lothian
40 12 DC 1 0 DDEB 7-24 months 41 Lothian
41 12 MC 0 1 DDEB ? 71 Lothian
42 13 MD 0 1 DDEB 1-7 days 31 Lothian
43 14 GMcK 1 0 DDEB 1-7 days 47 Grampian
44 14 AMcK 0 1 DDEB 1-7 days 11 Grampian
45 14 IMcK | 0 1 DDEB ? 76 Grampian
46 15 KMcF 0 1 DEB-unc (s) 1-6 months 6.75 Central
47 16 JC 0 1 DEB-unc (s) birth 1.75 Strathclyde
48 18 MG 0 1 DEB-unc (s) 1-7 days 14 Strathclyde
49 19 MK 1 0 DEB-unc (s) 1 -4 weeks ; 2 Grampian
50 20 CG 1 0 DDEB birth 0.08 Strathclyde
51 20 SG 1 0 DDEB birth 0.08 Strathclyde
52 20 WG 1 0 DDEB 7-24 months 26 Strathclyde
53 20 CG 0 1 DDEB ? 50 Strathclyde
54 21 AG 1 0 RDEB birth 41 Grampian
55 21 RG 0 1 RDEB birth 43 Grampian
56 21 DS | 0 1 RDEB birth 36 Highland
57 22 EH 0 1 DDEB ? 51 Strathclyde
58 22 JH 0 1 DDEB 1-6 months 23 Strathclyde
59 22 AK 0 1 DDEB ? 74 Strathclyde
60 23 CC 0 1 DEB-unc (s) ? 39 Grampian
61 24 CA 1 0 DDEB 1-6 months 4 Strathclyde
62 25 KM 0 1 DEB-unc (s) 1 1-7 days 5 Strathclyde
63 26











64 27 NG 0 1 DDEB 7-24 months 31 Strathclyde
65 27 SG 1 0 DDEB 2-5 years 7 Strathclyde
66 27
L
MG 1 0 DDEB ! 7-24 months 9 Strathclyde
67 27 JG 1 0 DDEB ? 55 Strathclyde
68 28 MW 1 0 DDEB 1-7 days 28 Strathclyde
69 28 CW 1 0 DDEB ? 35 Strathclyde
70 28 JW 1 0 DDEB 1 yr 7 Strathclyde
71 29 PN 1 0 DEB-unc (s) 1-7 days 33 Strathclyde
72 30 MF 0 1 DDEB 7-24 months 27 Grampian
73 30 IF 0 1 DDEB ? 46 Grampian
74 31 SE 1 0 DEB-unc (s) 1-6 months 15 Dum + Gall
75 32 JM 1 0 DEB-unc (s) birth 4 Strathclyde
76dd 33 EMcG 0 1 RDEB-HS (s) birth 34 Strathclyde
77 34 MB 1 0 DEB-unc (s) 1-6 months 15 Strathclyde
78 35 CA 0 1 DDEB 1 -7 days 50 Fife
79 35 PA 1 0 DDEB 1-7 days 27 Fife
80 35 CA 0 1 DDEB 1- 6months 0.2 Fife
81 36 MS 1 0 DDEB ? 0.1 Grampian
82 36 AS 1 0 DDEB ? 32 Grampian
83 37 AC 1 0 RDEB-HS (s) 1-7 days 0.08 Strathclyde
84 38 DM 1 0 DEB-unc ? 33 Strathclyde
85 39 WM 1 0 RDEB-HS (s) birth 10 Strathclyde
86 40 JL 0 1 DDEB 2-5 years 32.6 Borders
87 40 AL 0 1 DDEB 2-5 years 3.8 Borders
88 41 WL 1 0 DEB-unc (s) birth 15 Strathclyde
89 42 SP 0 1 DEB-unc (s) 1-6 months 1.3 Dumph + Gall
90 43 AF 0 1 RDEB-HS (s) birth 0.01 Tayside
91 44 AF 0
I
1 DDEB birth 14.8 Central
92 45 CMcC 0 1 RDEB-HS (s) birth 0.4 Grampian
93 48 EB 0 1 DEB-unc (s) 2 weeks 0.5 Lothian
94 49 JM 1! o ! DDEB ? 61.5 Strathclyde
95 50 SMcC 0 1 DEB-unc (s) 0.25 1.5 Strathclyde
96 51 AB 0 1 DDEB 0.33 2.5 Lothian
97 | 51 ?B 0 1 DDEB 7 I >20 Lothian











99 53 FM 1 0 DDEB ? 2 Lothian
100 53 CM 1 0 DDEB ? 7 Lothian
101 53 ?M 0 1 DDEB ? >20 Lothian
^ patient who died during the studydd
patient who died during 2002
(S) sporadic inheritance

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































92 45 CMc RDEB-HS nf 0 0 1 1 1 0 1 0 0 0 1 inf 0 0 0 0 0 0 1 0 1
93 48 EB DEB-unc (s) 0 0 1 1 1 0 1 ? 0 0 1 inf 0 0 0 0 0 0 0 1 0
94 49 JM DDEB 0 1 1 1 1 0 0 0 ? 1 1 0 0 0 0 0 0 0 1 0 1
95 50 SMc DEB-unc (s) 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 ?
96 51 AB DDEB 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1
97 51 ?B DDEB 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Jo 0 0
98 52 LB DEB-unc (s) G1522E 0 0 1 1 1 0 0 ? ? 0 0 0 0 0 0 0 0 0 ? ? 1
99 53 FM DDEB ? ? ? 7 7 ? 7 ? ? ? 7 7 7 7 ? ? ? ? ? 7 ?
100 53 CM DDEB ? ? ? ? ? 7 ? ? ? ? ? 7 ? 7 ?' 7 ? 7 ? 7 7




patient who died during the study
:
patient who died during 2002










sex date of birth region mutation
LW 10 f 07/05/79 Lothian
SW 10 f 06/07/81 Lothian
CS 10 f ? Lothian
PS 10 f ? Lothian
GS 10 m 09/04/69 Lothian
MW 10 f ? Lothian






















































HL 40 f ? Borders
HmcK * 46 f 29/10/97 Grampian
JG * 47 m ? Western Isles
CG * ? M 24/02/92 Lothian
RM * ? m 12/11/65 Lothian
MW* ? m 05/04/60 ?
AM * 749 m ? Tayside
ES 79 f 11/05/34 ?
MV* 24 f Strathclyde
* identified by other dermatologists
d died during the study
* seen during 2002
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Quality of life questionnaire responses
EBS >16 age
years (years)





(n=114) ? 2 1 3 3 2 0 0 2 2 0 15
? 3 3 3 1 3 3 2 2 2 2 24
? 3 0 1 3 2 3 3 3 1 1 20
? 1 0 1 1 1 2 1 0 0 0 7
7? 1 1 1 3 1 0 0 0 0 0
39 3 0 1 1 3 3 2 0 0 1 14
>40 2 2 2 2 3 3 3 2 1 1 21
17? 2 2 2 2 2 2 2 1 0 2
36 1 3 1 1 1 2 0 0 0 1 10
? 1 0 0 1 1 0 0 0 0 0 3
? 2 3 2 3 1 3 0 1 0 2 17
16 2 1 1 1 1 0 0 1 0 0 7
? 1 1 0 1 1 0 0 0 0 0 4
27 0 0 0 0 0 0 0 0 0 0 0
62 1 0 0 0 0 0 0 0 0 0 1
25 0 0 0 0 0 0 0 0 0 0 0
42 1 0 1 1 1 1 1 0 0 0 6
? 3 0 1 1 1 3 1 1 0 1 12
023 0 0 0 0 0 0 0 0 0 0
62 0 0 1 0 1 0 0 0 0 0 2
38 3 2 2 2 2 2 3 2 0 1 19
? 1 0 0 0 0 0 0 0 0 0 1
? 2 1 1 1 2 0 0 1 0 1 9
51 2 2 2 2 3 3 3 1 1 1 20
? 3 3 1 0 0 0 0 0 0 0 7
16 3 3 3 3 3 3 3 1 0 3 25
21 1 1 2 2 1 2 1 0 0 1 11
39 0 0 0 0 0 0 0 0 0 0 0
? 2 2 3 1 1 3 2 3 0 1 18
? 2 1 2 2 2 3 3 0 0 1 16
32 2 2 2 1 2 3 0 1 3 1 17
25 2 1 1 0 1 0 1 0 1 1 8
18? 3 0 2 1 2 3 3 1 1 2
? 1 0 1 0 1 0 0 0 0 0 3
27 2 1 1 2 1 2 0 0 0 1 10
46 3 2 2 2 2 3 3 2 2 2 23
21 3 1 3 2 2 0 2 0 0 1 14
18? 2 2 2 2 3 3 1 1 1 1
? 2 3 2 2 3 3 3 3 0 2 23
? 1 0 1 2 1 1 0 0 0 1 7
? 1 1 0 2 0 0 1 0 0 1 6
45 2 3 1 3 2 3 0 0 0 0 14
71 1 0 1 0 0 0 0 0 0 0 2
? 1 0 1 1 2 2 0 0 0 0 7
45 2 2 3 3 3 3 3 3 2 2 26
63 1 0 0 1 1 1 0 0 0 0 4








question number and score




























45 1 0 0 0 0 0 0 0 0 0 1

























? 3 2 2 2 1 0 3 1 0 1 15
? 1 1 2 2 2 3 0 1 0 1 13
50 0 0 1 0 1 1 0 0 0 1 4




average 38.9 1.6 1.0 1.3 1.3 1.3 1.5 1.0 0.6 0.3 0.8 10.7
maximum 71 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 26.0
minimum 16 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0





question number and score




(n=29) 1 3 0 0 3 3 3 2 0 3 2 19
? 2 2 2 1 1 0 2 1 1 3 15
15 1 0 0 0 1 0 0 0 0 0 2
12 3 3 3 3 3 3 2 3 3 3 29
15 3 3 2 3 3 2 3 1 3 2 25
15 3 3 3 3 3 3 3 3 3 3 30
0.9 2 0 0 2 0 0 0 0 1 1 6
? 3 2 1 2 2 3 2 2 2 2 21
? 2 1 3 2 3 3 3 0 0 0 17
4 2 1 0 3 2 1 1 0 3 2 15
4 2 1 0 2 2 0 1 0 2 2 12
7 2 1 0 2 3 1 2 0 2 2 15
8.5 0 0 0 0 0 0 0 0 0 0 0
? 2 1 2 1 2 2 1 1 2 1 15
? 3 3 3 1 3 3 2 2 2 2 24
4 2 2 0 2 2 1 1 1 1 1 13
13 2 1 0 1 2 1 1 0 0 2 10
? 1 1 0 0 0 1 1 2 1 0 7
number of
replies =18
average 8.3 2.1 1.4 1.1 1.7 1.9 1.5 1.5 0.9 1.6 1.6 15.3
maximum 15 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 30.0
minimum 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0




question number and score total
DLQI
years 1 2 3 4 5 6 7 8 9 10 score
(n=71) ? 1 2 1 0 0 0 1 0 1 0 6
? 3 3 1 2 2 3 1 1 0 1 17
84 0 0 0 0 0 0 0 0 0 0 0
56 1 0 0 0 0 0 0 0 0 1 2
56 1 0 0 0 0 0 1 0 0 1 3
80 0 0 0 0 0 0 0 0 0 0 0
66 1 0 0 2 0 0 0 0 0 0 3
? 0 0 0 1 0 1 0 0 0 0 2
56 3 3 3 3 3 3 3 1 3 3 28
? 2 1 2 2 3 3 2 1 2 2 20
? 0 1 0 0 0 0 0 0 0 0 1
34 0 0 1 0 0 0 0 0 0 0 1
? 2 2 2 1 2 2 3 1 1 2 18
? 1 0 0 1 1 0 0 0 0 1 4
51 3 1 1 1 1 3 1 1 0 1 13
18 1 1 0 1 0 0 0 0 0 0 3
67 0 0 0 0 0 0 0 0 0 0 0
? 0 0 0 1 0 0 0 0 0 0 1
18 0 0 0 0 0 0 0 0 3 0 3
? 2 1 1 1 1 2 3 1 1 1 14
9 2 2 0 3 2 0 1 1 1 1 13
? 0 0 0 0 0 0 0 0 0 0 0
40 3 2 2 3 2 0 0 1 0 3 16
16 1 1 0 1 1 0 1 0 0 1 6
? 1 2 0 2 0 0 1 0 0 0 6
? 1 1 0 1 0 0 0 0 1 0 4
? 0 0 0 0 0 0 0 0 0 0 0
63 1 1 0 1 1 0 0 0 0 0 4
? 2 3 1 2 2 3 2 1 1 1 18
44 2 3 0 1 2 3 0 3 1 2 17
? 2 1 0 1 0 0 1 0 0 1 6




average 48.6 1.2 1.0 0.5 1.0 0.7 0.8 0.7 0.4 0.5 0.7 7.5
maximum 84 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 28.0
minimum 16 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0






question number and score




(n=28) 6 3 2 1 2 2 1 1 1 2 2 17
? 3 0 0 2 0 2 0 0 3 2 12
8 0 0 0 0 0 0 0 0 0 0 0
? 3 3 1 2 2 0 2 3 1 2 19
8 0 1 0 0 0 0 1 1 0 1 4
8 0 1 0 0 0 0 1 1 0 1 4
14 2 2 0 2 2 2 1 0 1 1 13




average 9.8 1.6 1.7 0.5 1.4 0.9 1.0 1.0 1.1 1.1 1.4 11.5
maximum 15 3 3 2 3 2 3 2 3 3 2 23
minimum 6 0 0 0 0 0 0 0 0 0 0 0




question number and score









question number and score




(n=5) 3.5 3 3 3 3 3 3 3 2 3 3 29
3.5 3 2 0 2 2 3 1 0 2 2 17
3.5 3 3 0 2 2 3 2 1 3 3 22




average 3.5 2.8 2.5 1.0 2.3 2.5 3.0 1.5 1.3 2.5 2.8 22.0
maximum 3.5 3.0 3.0 3.0 3.0 3.0 3.0 3.0 2.0 3.0 3.0 29.0
minimum 3.5 2.0 2.0 0.0 2.0 2.0 3.0 0.0 0.0 2.0 2.0 17.0
median 3.5 3.0 2.5 0.5 2.0 2.5 3.0 1.5 1.5 2.5 3.0 21.0
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Summary The prevalence of epidermolysis bullosa (EB) in Britain and most other countries is unknown.
Patients suffering from the inherited forms of EB and living in Scotland have been traced. Two
hundred and fifty-nine affected people from 76 families have been identified, of whom 211 were
clinically assessed. One-third of these Scottish EB sufferers had never been seen by a dermatologist. In
Lothian, where there appears to be a relatively high prevalence ofEB, 75% of patients were unknown
to their general practitioners.
The point prevalence of all forms of EB at the outset of the study was 49-0 per million, comprising
EB simplex 28-6 per million and dystrophic EB 20-4 per million. Extrapolation of accurate data
available for the Lothians suggests that the point prevalence of all forms of EB in Scotland is in excess
of these figures.
There are few reliable studies of the epidemiology of the
inherited forms of epidermolysis bullosa (EB) (Table 1).
The most detailed surveys have been undertaken in
Norway, Northern Ireland and Finland,1-3 each with
a population of less than 5 million. The prevalence ofEB
has been assessed in several other countries.4-8 but the
low figures obtained suggest either incomplete sampling
or pronounced regional variation.
A national register of EB sufferers in Britain is being
compiled under the aegis of the Dystrophic Epidermo¬
lysis Bullosa Research Association (DEBRA) with the
aim of yielding accurate information on the number of
affected individuals and the impact of this group of
disorders on the lives of sufferers and their families. It
will provide data on the medical and social require¬
ments of those affected. Similar EB registers are being
compiled in the U.S.A. and Italy.910
As part of the United Kingdom EB Register, Scotland
was selected as a politically and geographically well
defined area (population 4.998.56711), for intensive
assessment of those suffering from EB. This paper
reports on the prevalence of EB.
Methods
Scottish patients suffering from inherited forms of EB
were identified from a diagnostic index at the Royal
Infirmary of Edinburgh, and by general practitioners
and Scottish dermatologists. All 515 Lothian general
practitioners and all 38 Scottish dermatology consul¬
tants were asked to provide, with patient consent,
details of any EB sufferers known to them. An adver¬
tisement directed at people suffering from blisters was
placed by DEBRA in a newspaper distributed in rural
western Scotland. Further patients were identified by
family enquiries. All known affected individuals were
invited to participate in the survey. Patients were
interviewed and examined in their own homes or at
the Royal Infirmary of Edinburgh. Parents and siblings
were also examined whenever possible. If personal
contact was not feasible, patients were interviewed by
telephone.
Interviews were conducted with the help of a detailed
questionnaire and answers were entered on to a com¬
puterized database. Classification of EB subtype was
made on the basis of clinical features and, where
appropriate, ultrastructural examination, using the
criteria suggested by Fine et al.12 Patients were classified
as 'sporadic' if there was no family history ofEB. Details
of all known EB patients living in Scotland between May
1992 and March 1996 are included in this paper.
Results
Two hundred and fifty-nine patients from 76 families
were identified as suffering from EB (Table 2). Their geo¬
graphical distribution is shown in Fig. 1. Enquiries to
all 515 general practitioners in Lothian (population
560 © 1997 British Association of Dermatologists
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rable 1. Reported prevalences of epidermolysis bullosa (EB) (per
liillion)
EBS JEB DEB
Norway1 24-3 _ 9-3
1. Ireland2 28 0-7 3-3
^inland3 15-1 0-2 00 00
Iroatia4 1-5 1-5 6-6
apan5 4-0 0-2 3-5
3audi Arabia6 1-7 0 3-7
3. Africa7 0-8 0-7 1-2
Wester
Isles
3BS, EB simplex; JEB, junctional EB; DEB, dystrophic EB,
72 6,01011) brought replies from 340 doctors represent-
ng 93% of practices. They were aware of only 20 of the
78 documented Lothian EB patients and also notified us
jf one previously unidentified sufferer who would sub-
iequently have been found by family enquiries. Of the
29 (76%) Scottish dermatologists who replied to our
enquiries, 13 were aware of 37 EB patients. Fifteen of
:hese individuals from 12 families were previously
unknown to us. The newspaper advertisement did not
dicit any replies. One hundred and fifty-seven patients
vere identified by family enquiries or were referred to us
-outinely during the study.
Of the 259 individuals identified as suffering from EB,
211 (81%) were clinically assessed. Twelve interviewed
.objects were not examined, information being obtained
fither by telephone, or from a parent, spouse or sibling,
fhirty-six patients (20 EB simplex sufferers and 16
lystrophic EB sufferers), all relatives of people in
/vhom the diagnosis and subtype of EB was confirmed,
vere, for practical reasons, neither interviewed nor
ilinically assessed.
epidermolysis bullosa simplex
iB simplex (EBS) was diagnosed in 149 individuals (58
nale, 91 female) from 33 families. One hundred and
wenty-five patients from 30 families were interviewed
Cable 2. Numbers of Scottish individuals and families identified as
uffering from epidermolysis bullosa (EB)
EBS JEB DEB Total
lumbers of individuals 149 2 108 259
lumbers of families 33 2 41 76




Figure 1. Geographical distribution of epidermolysis bullosa in Scot¬
land. Small symbols represent individuals; large symbols represent
multiple individuals within a small area.
and 121 patients from 33 families were examined
clinically.
Four subjects (one male, three female), each of whom
were sporadic cases, had the Dowling-Meara (DM)
variant. Their ages at interview ranged from 1 month
to 16-7 years (average 5'2 years). Electron microscopic
examination of skin from all four showed the character¬
istic ultrastructural features of this condition.13
The remaining 121 interviewed EBS sufferers, aged
from 1-3 years to 78-3 years (average 30-2 years), were
from 26 pedigrees, one with 36 and a second with 19
living affected individuals. Ten patients had no family
history of the disorder. Fifty experienced blisters on only
the palms and soles, as described originally by Weber
and Cockayne,14'1' and 71, while also developing blis¬
ters predominantly on the palms and soles, experienced
blisters at additional friction sites, thus fitting Koebner's
original description of EBS."1 Other variants of EBS were
not seen.12
Thirty-eight (30%) of the EBS patients interviewed
had never consulted a dermatologist. One 9-year-old girl
with Koebner EBS died from meningitis during the
study.
The point prevalence of EBS on 1 May 1992 is
calculated as 28-6 per million, with the DM subtype
5 1997 British Association of Dermatologists. British Journal of Dermatology, 136. 560-564
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accounting for 0-6 per million. The incidence of EBS is
at least 0-43 per million per year, over 46 years.
Junctional epidermolysis bullosa
There were no known junctional EB (JEB) sufferers in
Scotland at the outset of the study. Two males were
subsequently diagnosed on the basis of the ultrastruc-
tural features and reduced or absent expression of GB3
antigen. The lirst, born to apparently unrelated parents,
had a relatively mild phenotype, but the second, born in
Libya to healthy Libyan parents who were first cousins,
had the Herlitz (letalis) subtype of JEB. Both children
were still alive at the conclusion of the study. The
incidence of JEB over 4 years was 0-05 per million per
year.
Dystrophic epidermolysis bullosa
Dystrophic EB (DEB) was identified in 108 individuals
from 41 families; 88 patients from all 41 families were
clinically assessed and 85 patients from 37 families were
formally interviewed.
Four subtypes of DEB were seen. Localized dominant
DEB (DDEB) occurred in 78 individuals (35 male,
43 female) from 14 families and 59 of these patients
were interviewed. Their ages at interview ranged from
1 month to 76'5 years (average 28-9 years). Localized
recessive DEB (LRDEB) was seen in five patients (two
male, three female) from two families. They were aged
between 36 and 48 years (average age 42-4 years).
Two unrelated females, aged 47 years and 56 years
suffered from the inverse variant of recessive DEB
(RDEB-inv). The elder has recently died (aged 60
years) from a squamous cell carcinoma of the oeso¬
phagus. The severe generalized Hallopeau-Siemens
form of recessive DEB (RDEB-HS) was seen in five
unrelated patients (two males, three females), aged
1 month to 34-5 years (average age 16-2 years). Two
died during the study period, one (aged 23 years) from
metastatic squamous cell carcinoma and the second
(aged 20 years) from gastric aspiration during a 'flu-like'
illness. Eighteen patients with localized DEB (11 male,
seven female) aged 2 months to 43-1 years (average
age 16-1 years) had unaffected parents and siblings
and their inheritance pattern could not be accurately
classified.
The parents of one patient with RDEB-inv were
shown to share a common ancestor, but consanguinity
was not known in any other families affected by DEB.
One patient with mild localized DEB but unaffected
parents and siblings had a cousin with severe RDEB-
HS, as previously reported by Kemmett et al.1'
Twenty-four (30%) interviewed DDEB patients had
never been seen by a dermatologist. The point preva¬
lence, on 1 May 1992 of all forms ofDEB is calculated as
20-4 per million (DDEB 14 6, LRDEB 1-0, RDEB-inv 0-4,
RDEB-HS 0-8, sporadic localized DEB 3-6 per million)
and the incidence of DEB since 1950 is at least 0-2 per
million per year.
Discussion
Accurate estimates of the prevalence of EB are difficult
to achieve. While the most severely afflicted EB sufferers
are well known to the medical profession, we have
shown that a large proportion of sufferers of the
milder forms of EB are unknown to both general
practitioners and dermatologists; 30% of patients with
both EBS and DDEB in Scotland had never been seen
by a dermatologist. Although these patients do not
have life threatening disease, most, particularly those
with EBS. have blistering which significantly restricts
their lives. It emerged from interviews that many felt,
based on the experiences of similarly afflicted relatives,
that there was little to be gained from consulting a
doctor. Some patients had suffered at the hands of well-
meaning but uninformed members of the medical pro¬
fession who had inflicted considerable pain by using
unsuitable dressings. Predictably, such people are reluc¬
tant to subject their children to similar trauma and
many prefer to use long established family remedies.
Comparison of the prevalence of EB in Scotland with
other countries (Tables 1-3) shows figures for EBS
similar to those of Norway and Northern Ireland. The
relatively high Scottish figure for DEB is accounted for
by the large group suffering from DDEB. It is unlikely
(though possible) that the prevalence of this often mild
subtype is higher in Scotland than elsewhere; rather it is
probable that many of these patients go unrecognized.
Table 3. Epidermolysis bullosa (EB) in Scotland
EBS JEB DEB
Point prevalence on 1/5/92 28-6 0 20-4
(xlO-6)
Period prevalence (xlO-6) 29-8 0-4 21-6
(1/5/92-1/5/96)
Incidence (xlO-6) 0-43 0-05 0-2
EBS. EB simplex; JEB. junctional EB: DEB. dystrophic EB.
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ruble 4. Point prevalences on 1 May 1992 of epidermolysis bullosa
EB) in Scottish regions (xlO-6)
EBS DDEB All DEB All EB
3orders 240-6 0 0 240-6
lentral 0 0 3-7 3-7
Oumfries and Galloway 0 0 13-5 13-5
-ife 23-4 5-8 5-8 29-2
Irampian 27-7 17-8 27-7 55-4
iighland 19-6 0 4-9 24-5
jOthian 42-6 55-0 64-7 107-3
itrathclyde 22-6 9-7 14-6 37-2
rayside 18-2 0 2-6 20-8
Orkney 0 0 0 0
Western Isles 0 0 33-7 33-7
ihetlands 0 0 0 0
Icotland 28-6 14-6 20-4 49-0
IBS, EB simplex; DDEB, localized dominant EB; DEB, dystrophic EB.
rhey will not be found unless all family members are
fiinically examined. This condition can be so mild that
he patient may regard his skin as normal and the
physical signs may be very subtle.
The most ambitious EB register being compiled to
late is in the U.S.A. It is not yet complete but have data
m 1750 patients.9 As in Scotland, just over 50% of
heir patients have EBS, but 8-1% (compared with 0-1%
n Scotland) suffer from JEB and 15-6% (compared with
1-7% in Scotland) suffer from the various RDEB sub-
ypes. Only 12-4% of their patients suffer from DDEB,
vhile this subtype accounts for 30-2% of our study
copulation. Some of these differences, probably reflect
he relative ease with which the most severely affected
people are traced, and will become less marked as people
vith milder EB are included in the American register. If
he prevalence of EB is similar in the U.S.A. to that in
Jcotland then they can expect to find between 11.000
ind 12,000 EB sufferers.
The prevalences of the recessive subtypes of EB in
Scotland are similar to those reported from other coun-
ries, with the exception of Croatia where there appears
o be a surprisingly high prevalence of RDEB-HS.4 We
lave found a high prevalence of EBS in the Borders
legion (Table 4), where there are four apparently
inrelated pedigrees, one having 19 affected living
nembers. This is a rural area with a low population
lensity, and although the families do not knowingly
hare a common ancestor, this remains a possibility. A
nutation of the keratin 5 gene has been identified in the
argest family18 and results of DNA analysis from a
econd family are awaited.
In other rural areas of Scotland, the prevalence of EB
is consistently lower than in regions where the major
cities are located (Table 4). Perhaps EB sufferers gravi¬
tate towards major centres to avail themselves of
medical services and opportunities for non-manual
employment.
The prevalence of EB in Lothian is particularly high
(EBS 42-6 per million, DEB 64-7 per million), compared
with other areas of Scotland. This is probably accounted
for by more complete searching on our home territory
where we have the benefit of an EB database and where
our interest is known to local general practitioners. It
seems reasonable to assume that the prevalence of EB
in other urban areas of Scotland should be similar to
that in Lothian, and if this is so, many Scottish EB
patients distant from Edinburgh remain undetected.
Our figures are undoubtedly underestimates. Since the
study was completed, more previously unknown
patients have come to light. This suggests that EB is a
more common condition than was hitherto thought.
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A recurrent glycine substitution mutation, G2043R, in the type
VII collagen gene (COL7A1) in dominant dystrophic
epidermolysis bullosa
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Summary Dystrophic epidermolysis bullosa (DEB) is caused by mutations in the type VII collagen gene
(COL7A1). Nearly all cases of dominant DEB are caused by glycine substitution mutations occurring
within the triple helical region of type VII collagen, and most of the mutations are unique to
individual families. In this study, we identified a patient of Hispanic-Mexican origin with a mild form
of DEB, which resulted from a de novo dominant glycine substitution, G2043R, in exon 73 of
COL7A1. We also investigated a Scottish family with a three-generation pedigree of dominant DEB,
in whom the same glycine to arginine substitution mutation was demonstrated. This particular
mutation has also been detected previously in three other families with dominant DEB: one Italian,
one Hungarian and one Norwegian. Given the widespread geographical distribution of this mutation
and the demonstration of its occurrence as a de novo event, G2043R therefore represents the first
example of a mutational hotspot in dominant DEB. Interestingly, although both the Mexican and
Scottish families we studied had some clinical features in keeping with the Pasini form of the disorder,
there was considerable interfamilial variability as well as intrafamilial diversity in the affected
individuals.
Both autosomal dominant and autosomal recessive
forms of the inherited blistering skin disorder, dys¬
trophic epidermolysis bullosa (DEB), are caused by
mutations in the type VII collagen gene (COL7A1).1"'
Mutations in dominant subtypes of DEB usually com¬
prise glycine substitutions in the triple helix of
COL7A16"8 and such mutations may impede the
normal secretion of type VII collagen from basal kera-
tinocytes into the extracellular space, disrupt anchoring
fibril assembly at the dermal-epidermal junction and
lead to a sublamina densa plane of tissue fragility
(Fig. I).9-13
Several different glycine substitution mutations
resulting in dominant DEB have been described, most
of which are unique to individual families.14-27 In this
Correspondence: Dr John McGrath. E-mail: j.mcgrath@umds.ac.uk
study we investigated the molecular basis of DEB in two
affected families, one from Mexico and one from Scot¬
land, using polymerase chain reaction (PCR) amplifica¬
tion of genomic DNA, heteroduplex analysis, direct
automated sequencing of PCR products displaying hetero¬
duplex bandshifts and verification ofmutations by restric¬
tion endonuclease digestion. In the Mexican family, we
identified a patient with a mild form of DEB and clinically
normal parents, who had a de novo glycine substitution.
G2043R, in exon 73 of COL7A1. In the unrelated family
from Scotland, we delineated the same mutation as the
cause of dominant DEB in three generations. The muta¬
tion G2043R has been described previously in one Italian,
one Hungarian and one Norwegian family, all with
dominant DEB.17'22'23 Thus, this mutation represents
the first recurrent hotspot mutation in the autosomal
dominant form of this genodermatosis.
730 © 1998 British Association of Dermatologists
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Figure 1. Diagrammatic illustration of
anchoring fibril assembly and pathology
mderlying dominant dystrophic
apidermolysis bullosa (DEB), (a) Type VII
aollagen comprises a homotrimer, with a large
lon-collagenous NC-1 domain, a central
;ollagenous triple helix and a smaller non-
xillagenous NC-2 domain. The homotrimer is
synthesized within basal keratinocytes (and
lbroblasts) and secreted into the extracellular
space, (b) Two homotrimers then align to
'orm an antiparallel dimer, with disulphide
tond formation and cleavage of part of the
4C-2 domain, (c) Several antiparallel dimers
hen aggregate laterally to form anchoring
Ibrils, which insert into the lamina densa,
lave a fan-shaped appearance and
lemonstrate central cross-banding, (d) In
lominant DEB, the mutations comprise
jlycine substitutions within the collagenous
riple helix, which disrupt the tightly coiled
brmation oi the helix, (e) The homotrimers
nay contain none, one, two or three
ibnormal type VII procollagen chains. Some
ir several of these polypeptides may not be
secreted into the extracellular space. For
irotein that is secreted, lateral aggregation of
Jimers may be compromised with consequent
lisruption of anchoring fibril morphology.
Assuming equal expression of wild-type and
nutant alleles, and similar secretion of wild-
ype and mutant protein, only one in 64
intiparallel dimers would be expected to have
i normal configuration.
a) v jrxsitntarAmb
















Pedigrees of the two families investigated are shown in
■Fig. 2. In family A (Fig. 3), the proband was a 25-year-
ald Hispanic-Mexican woman with a lifelong history of
trauma-induced skin fragility. None of her 13 siblings
-had any history of blisters or erosions. Similarly, neither
of her non-consanguineous parents had any skin or nail
abnormalities. Examination showed blisters, erosions
and scarring, particularly over bony prominences.
Nail dystrophy and loss of some fingernails and toenails
was also evident. In addition, numerous albopapuloid
lesions were detected on the trunk.
In family B (Figs 4 and 5), there were three affected
individuals in three generations. Individual II-2 (Fig. 4),
a 31 -year-old white Caucasian, had a history of trauma-
induced blisters since childhood, with thickening of
nails and loss of some nail plates. As an adult, the
Blistering tendency had been less marked with the
main feature being minor scarring over the bony
prominences. His daughter (Fig. 5), aged 3 years, had
a -a
rrnri
1 2 3 4 5 6 7 10 11 12 13 14
Family B
Figure 2. Pedigrees of the two families studied. Family A is from
Mexico and contains one affected individual (II-7) who has clinically
normal parents. Family B is from Scotland and has three affected
family members (1-1, 11-2 and III-l) in three generations.
© 1998 British Association of Dermatologists, British Journal of Dermatology, 139, 730-737
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Figure 3. Clinical appearance of the affected individual III-7) in family A. (a) Fingernails are thickened and dystrophic with loss of nail plates on some
fingers, (b) There is marked scarring and blistering over both elbows, (c) Scarring and postinflammatory hyperpigmentation are present on both
knees, (d) Most of the toenails have been lost and there is moderate scarring around the ankles, (e) Numerous albopapuloid lesions are present on the
back.
numerous recurrent blisters and milia induced by
trauma, particularly on the knees and around the
ankles. Nail dystrophy was not a prominant feature,
with only slight thickening of one great toenail.
Polymerase chain reaction amplification and heteroduplex
analysis
Genomic DNA was extracted from peripheral blood
lymphocytes using standard methods s and was used
as a template for amplification of genomic sequences of
COL7A1 (GenBank L23982, L02870). Pairs of oligonu¬
cleotide primers spanning all 118 exons of the gene
were synthesized on the basis of intronic sequences to
generate PGR products.29,30 Specifically, to amplify exons
73 and 74 (see results), the following primers were
used: sense primer 5'-CCCGTGGAGTGGGGTGTAGC-3';
antisense primer 5-TGCAGGAAACAAGAAAATGG-3'.
The expected PCR product size was 469 bp. For PCR
amplification, approximately 2 5()ng of genomic DNA
was used as the template in an amplification buffer
containing 6-2 5 pmol of the primers, 37-5 nmol MgCU.
5 mmol of each nucleotide and 1-25 U Taq polymerase
(Perkin Elmer, Warrington, U.K.) in a 25-p.L total
volume reaction in an OmniGene thermal cycler
(Hybaid, Teddington, U.K.). The amplification condi¬
tions were 94°C for 5min; then 94°C for 45 s, 5 5°C
for 45 s, 72 °C for 45 s, for 38 cycles. Aliquots of 5 (jlL of
the PCR products were analysed by 2% agarose gel
electrophoresis, and 3-8 (xL of the sample were pre¬
pared for heteroduplex analysis using conformation-
sensitive gel electrophoresis.'1 Staining with ethidium
bromide was used to visualize the heteroduplexes. PCR
products displaying altered electrophoretic patterns
1998 British Association of Dermatologists, British Journal of Dermatology, 139, 730-737
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Figure 4. Clinical appearance of une of the
affected individuals (II-2) in family B. (a)
Nail dystrophy is present in all fingernails
and there are scattered scars on the
dorsum of the hands and fingers, (b)
Toenails are either thickened or have been
shed, but there is little evidence of scarring
on the lower legs or feet, (c) A small degree
of crusting and scarring is seen on both
elbows, (d) Subtle scarring is present on the
knees with no signs of active inflammation,
(e) Minor scarring is present on the heel at
a site of previous trauma.
were sequenced directly using dye terminator labelling
in an ABI 310 genetic analyser (Perkin Elmer) and
mutations detected in the PCR products (see results)
were verified in genomic DNA by restriction endonu-
clease digestion. Digestions were performed according to




In family A, heteroduplex analysis of PCR products
spanning exons 73/74 revealed heteroduplex bands in
the affected individual's sample, but only a homoduplex
band in the parents' samples and in the control PCR
product (Fig. 6). In family 13, similar bandshifts were
present in DNA from the two affected individuals exam¬
ined (1-1 and II-2), but these were not detected in
unaffected family members (1-2 and II- 3) or in a further
sample of amplified control DNA. Automated nucleotide
sequencing of PCR products from individuals displaying
bandshifts (II-7 in family A and II-2 in family B) revealed
a heterozygous point mutation in both cases, a G-to-A
substitution at nucleotide position 6127 (GenBank
L02870) that converts a glycine residue (GGG) to argi-
nine (AGG), the mutation being designated G2043R.
This mutation results in loss of a Smal restriction site
(CCC/GGG) which was used to assess the presence or
absence of the mutation in all members of the two
families from whom DNA samples were available. In
control DNA and all unaffected individuals, the 469 bp
PCR product was digested into fragments 264, 160 and
45 bp in size, while in the affected family members, an
additional undigested band of 309 bp was present, indi¬
cating that these individuals were all heterozygous for
the mutation G2043R in exon 73 ofCOL7Al. Of note, in
family A, the mutation G2043R was not detected in
© 1998 British Association of Dermatologists, British Journal of Dermatology, 1 39. 730-737
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Figure 5. Clinical appearance of one of the
affected individuals (TII-1) in family B
(daughter of II-2 depicted in Figure 4). (a)
There is no significant fingernail dystrophy,
but prominent milia and scarring are
present over the dorsum of the
interphalangeal joints, (b) Similar changes
are present in the toes, although slight
dystrophy of the great toenail is also
present- (c) On the knee there is prominent
inflammation with focal erosions and
surface crusting, (d) Tense inflammatory
blisters are noted on and around the ankle.
either parent's DNA, indicating it had arisen as a de novo
event in the affected individual (II-7).
Discussion
In dominant DEB, pathogenic mutations usually consist
of glycine substitutions within the type VII collagen
triple helix.5-6 Glycine is the smallest amino acid and its
presence at every third residue in the form of a Gly X-Y
repeat is a characteristic feature of the coiled triple helix
of several collagens, including type VII.32'33 Substitu¬
tion of glycine by a different amino acid disrupts the
triple helix and leads to dominant-negative interference
between wild-type and mutant protein. This may inter¬
fere with the secretion of type VII collagen and perturb
anchoring fibril formation, thereby giving rise to fragi¬
lity at the dermal-epidermal junction.4-13
Several different glycine substitution mutations in
dominant DEB have now been described, and are high¬
lighted in Fig. 7. Of these, only G2034R, G2043R and
G2079R have been reported in more than one family.
Most of the glycine substitutions that underlie dominant
DEB lie within exon 73. the largest of the 118 exons that
comprise COL 7A1,2 y and most are clustered between
amino acids 2003 and 2079-3-' Our study represents
the fourth and fifth description of G2043R resulting in
© 1998 British Association of Dermatologists, British Journal of Dermatology. 139, 730-737




igurc 6. Identification of a shared COL7A1
nutation in families A and B, (a)
Ieteroduplex analysis of exons 73/74 in
amily A reveals a heteroduplex bandshift
He) in the polymerase chain reaction
PCR) product of the affected individual (II-
7). but only homoduplex bands (Ho) in the
implified DNA from both parents (1-1 and
-2) and control (C). In family B, similar
leteroduplex bandshifts are present in
ndividuals 1-1 and II-2. but not in 1-2 or 11-
3 or the control sample, (b) Nucleotide
sequencing of the PCR products spanning
2x0ns 73/74 in one of the affected
ndividuals (here illustrated with DNA from
ndividual II-2 in family B) reveals a
heterozygous single G-to-A transition that
:onverts a glycine residue (GGG) to
irginine (AGG). The mutation is designated
32043R. (c) Verification of the mutation by
'estriction endonuclease digestion with
SimiI. The control PCR products and those
from the unaffected individuals in both
families are digested into bands 264 and
160 bp in size. By contrast, the mutation
results in loss of a umul cut, site and an
additional undigested band of 309 bp is
seen in all the affected individuals (IT-7 in
family A, 1-1 and II-2 in family B),
indicating that they are all heterozygous for
the mutation G2043R in exon 73 of
COL7A1. MW, molecular weight marker.
(b)
1-1 1-2 11-7 C
Family A
Exon 73: affected individual
1-1 1-2 11-2 II-3 C
Family B
Exon 73: control





1-1 1-2 11-7 C
Family A
1-1 1-2 11-2 I1-3 C
Family B
this genodermatosis.17'22"25 Thus, this mutation has
now been found in Italian, Hungarian, Norwegian,
Mexican and Scottish families. Furthermore, we are
also aware of its occurrence in two other families with
dominant DEB, one Finnish and one American (L.Pulk-
kinen, personal communication). Although a few recur¬
rent mutations have been described in patients with
autosomal recessive forms of DEB,54-5' the mutation
G2043R represents the first hotspot mutation to be
elucidated in cases of dominant DEB. Interestingly, in
-families with this mutation, variability in the clinical
features of the affected individuals is present. In the two
families reported here, there was considerable inter-
familial and intrafamilial heterogeneity. The Mexican
Figure 7. Database of published glycine substitution mutations in type
VII collagen resulting in dominant dystrophic epidermolysis bullosa:
G1557R:14 G2003R;1' G2006D;16 G2009R;17 G2015E;16
G2034R;1618 G2034W;19 G2037E;20 G2040S;21 G2043R;17'22'23
G2055E;14 G2064R;19 G2076D;18 G2079R;18 G2079E:24
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proband had features fully consistent with the Pasini
form of dominant DEB, with numerous albopapuloid
lesions on the trunk.38 By contrast, in the Scottish
family, individual 11-2 (see family B, Fig. 2), of similar
age to the Mexican patient, had less pronounced blisters
and scarring, while his daughter (Ifl-l) had less dystro¬
phy but more extensive acral blister formation and
inflammation.
Demonstration of the mutation G2043R in the Mex¬
ican family is only the third case of de novo dominant
DEB to be reported. The rarity of de novo dominant
mutations in COL7A1 has important implications for
genetic counselling. Extensive mutation analysis in
patients with mild DEB and clinically normal parents
has shown that the overwhelming majority of these
cases represents recessive DEB with a risk of affected
children in subsequent pregnancies being one in four.
By contrast, in cases of de novo dominant disease, the
risk of having additional affected children is more
difficult to predict because the recurrence risk arising
from gonadal mosaicism is theoretically anywhere
between that of the general population and 50%. How¬
ever, in the Mexican family, none of the proband's 13
siblings was affected, ft should be remembered, how¬
ever, that for the affected individual in this family there
will be a one in two possibility of her own offspring
inheriting dominant DEB.
Although glycine substitution mutations in the triple
helical domain of type VII collagen underlie most cases
of dominant DEB, not all glycine substitutions actually
lead to dominant-negative interference between mutant
and wild-type protein. In particular, several silent gly¬
cine substitution mutations have been described.3 5 and
in individuals heterozygous for a COL7A1 allele bearing
one of these mutations and a wild-type allele, there is no
abnormal phenotype. However, if such a missense
mutation is inherited on both alleles or in trans with a
premature termination codon or splice site mutation on
the other allele, the clinical consequences are either
mild, moderate or severe recessive DEB, depending on
the nature of the second mutation.39-44 Precisely what
determines whether a particular glycine substitution
will lead to dominant-negative disruption, or alterna¬
tively function as a null allele, remains to be fully
determined. In contrast to the silent glycine mutations,
most of the substitutions that result in dominant DEB
are located close to a non-collagenous interruption
within the triple helix that may act as a hinge region,
providing flexibility to the collagen. Disruption of this
part of the protein may therefore have important impli¬
cations for the functional integrity of type VII collagen.
In summary, we have detected a recurrent glycine
substitution mutation in COL7A1. Elucidation of the
mutation has significant implications for understanding
the pathogenesis of skin fragility in dominant DEB anc
for the design of mutation detection strategies to investi
gate other patients with this mechanobullous disorder.
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Summary Junctional epidermolysis bullosa associated with pyloric atresia (EB-PA; OMIM 226730) is a rare
autosomal recessively inherited disease in which mucocutaneous fragility is associated with
gastrointestinal atresia. This disease is usually fatal within the first few weeks or months of life
even following surgical correction of the intestinal obstruction. Recently, mutations in the genes
encoding the epithelial integrin ot6[34 (ITGA6 and ITGB4) have been identified in several patients
with EB-PA. We report two unrelated patients with this disease who have survived into early
childhood with mild cutaneous involvement, in whom we have identified pathogenetic mutations in
ITGB4. The first patient was a compound heterozvgote for a splice site mutation in exon 30
(3793 + lG-to-A) and a non-sense mutation in exon 36 (W1478X). and the second was a
compound heterozygote for a missense mutation in exon 3 (C38R) and a 1 bp deletion in exon 36
(4776delG). Although the non-sense and deletion mutations are predicted to result in markedly
reduced (34 integrin mRNA levels, the presence of the missense or splice site mutation on the second
allele may enable the synthesis of some functional, albeit perturbed, (34 polypeptide. Determination of
the molecular mechanisms in these two cases increases our understanding of EB-PA and may enable
correlation between genotype and phenotype.
Junctional epidermolysis bullosa (JEB) is a group
of autosomal recessively inherited mechanobullous
diseases characterized ultrastructurally by a plane of
blister formation through the lamina lucida of the
basement membrane zone (BMZ).1'2 Defective expres¬
sion of proteins comprising the hemidesmosome-
anchoring filament complex at the cutaneous BMZ,
including laminin-5 and the 180 kDa bullous pemphi¬
goid (BP) antigen, have been demonstrated in some
forms of JEB and mutations in the corresponding
genes identified.3 Abnormal expression of integrin
a6[34, also a component of hemidesmosomes in strati¬
fied and transitional epithelia. has been identified in a
particular form of JEB associated with pyloric atresia
(EB-PA) (OMIM 226730).4-10 Other features of this
disease include urogenital tract involvement, aplasia
Correspondence: Prof. Robin A.J.Eady. E-mail: r.eady@umds.ac.uk
cutis and failure to thrive, with affected infants usually
dying within the first few months of life.11-1' Recently,
mutations in the genes encoding the a 6 and (34
integrin subunits (ITGA6 and ITGB4. respectively)
have been described in EB-PA.16-22 In this report,
we describe two unrelated children with EB-PA, aged
6 and 3 years, with unusually mild cutaneous features
of disease, although the older patient had marked
urogenital tract involvement. Both had reduced expres¬
sion of integrin ct6[34 in biopsies of uninvolved skin.
Molecular analysis of ITGB4 in the older child revealed
compound heterozygosity for a splice site mutation and
a non-sense mutation, while the younger child was a
compound heterozygote for a single base deletion and a
missense mutation. It is possible that these previously
unreported combinations of mutations may be impor¬
tant in determining the relatively mild phenotype
observed in these two patients.
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Materials and methods
linical details
fitient A. Some clinicopathological features of this case
lave been reported previously.6 6 A male infant, cur-
ently 6 years old, was the first child of non-consangui-
leous Caucasian British parents. The proband was
lelivered normally at 35 weeks gestation following a
iregnancy complicated by polyhydramnios. In the first
-lays after birth, he was noted to have scanty blisters
tnd erosions on his limbs, and dystrophic nails. He also
lad pyloric atresia and had a corrective gastroduodc-
xostomy at the age of 6 days, from which he recovered
vithout complication. Tn the third year of life, he
leveloped haematuria and dysuria. Subsequent investi-
;ations revealed the presence of bladder wall haemor-
hage and blistering, bilateral ureteric reflux, unstable
letrusor contraction and recurrent urinary tract infec-
ion. He required frequent urological intervention and
lad a vesicostomy formed at age 5 years. In general, his
;kin remained in good condition with occasional small
rlisters and no mucous membrane involvement
Fig. la). His nail dystrophy persisted and he also
lad abnormal dentition with enamel hypoplasia. Both
rarents and a younger sibling are healthy.
3atient B. A male infant, now aged 3 years, was the only
;hild of healthy Caucasian British parents who are not
cnown to be related. He was delivered by forceps at 36
veeks gestation after a pregnancy complicated by poly-
lydramnios, gestational diabetes and maternal hyper-
ension. Fetal hydronephrosis was detected antenatally.
pyloric atresia was diagnosed in the first few days after
rirth and at 6 days was corrected by pyloroplasty from
.vhich he recovered well. He had mild skin fragility to
nechanical trauma and dystrophic nails which per¬
sisted (Fig. lb). Postnatal ultrasound scans revealed
so renal tract anomaly.
Electron microscopy and immunohistochemistry
Biopsies of gently rubbed, uninvolved skin were taken
from both probands under local anaesthesia. Samples
for transmission electron microscopy were processed as
described previously,25 including primary fixation in
half-strength Karnovsky fixative (containing 2% form¬
aldehyde and 2-5% glutaraldehyde in 0-04mol/L caco-
dylate buffer), and secondary fixation in 1-3% osmium
tetroxide in distilled water. Samples were dehydrated in
ethanol and embedded in Epon resin or Araldite. Ultra-
thin sections were stained with uranyl acetate and
Figure 1. Clinical features of probands, (a) Small trauma-induced
blister on the nose of patient A. (b) Toenail dystrophy in patient B.
lead citrate and examined with a JEOL 100CX transmis¬
sion electron microscope. Skin samples from patients
A and B were processed for immunohistochemistry
as described previously.24'26 Cryostat sections were
incubated with the following optimally diluted mono¬
clonal antibodies or antisera: GB3 antilaminin-5 anti¬
body26 (Sera-Lab, Crawley Down, Sussex, U.K.); GoH3
antibody against the a6 integrin subunit2' (gift from
© 1998 British Association of Dermatologists. British Journal of Dermatology, 139, 862-871
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A.Sonnenberg); 3E1 antibody (Gibco Life Technologies,
Paisley, U.K.), G71 antibody28 (gift from J.Aplin; patient
A only) and 450-11A antibody29 (gift from S.Kennel;
patient B only) all against the (34 integrin subunit; 7A8
antiplectin antibody30 (Sigma-Aldrich, Poole, Dorset,
U.K.; patient B only); HD4-233 antibody against the
180kDa BP antigen31 (gift from K.Owaribe: patient B
only); and FP-1 antiserum against the 230kDa BP
antigen'2 (gift from J.Stanley; patient B only).
Molecular analysis and verification ofmutations
Genomic DNA from both probands, their parents and
the unaffected sibling of patient A, was extracted from
peripheral blood lymphocytes using a standard
method.3 3 Individual exons of ITGB4 (GenBank
U66529-U66541) were amplified by polymerase chain
reaction (PCR) using approximately 200 ng of genomic
DNA as a template in standard conditions including
12pmol of each primer, 200 |xmol of dNTPs, 4%
dimethyl sulphoxide, 10 x PCR buffer and 1-25 U of
AmpliTaq (Perkin Elmer Cetus. Norwalk, CT, U.S.A.) or
Expand high-fidelity amplification reagents (Boehringer
Mannheim, Indianapolis, IN. U.S.A.) in a 50 p.L reaction
volume. Specifically (see results), exons 3, 7, 30, 34 and 36
were amplified using the following pairs of primers based on
flanking intronic sequences: for exon 3, sense, 5 -GCTGAG
CACCTCCCCATTCA-3'; anti-sense, 5'-ATTCCCGACCCTTG
CGTGTT-3'; for exon 7, sense, 5'-CCTGTGACACTCTCTC
TCCC-3'; anti-sense, 5'-AGATTCCAGAACGCTAAAGC-3';
for exon 30, sense. 5'-CCTCGCCATGTCTGTCCATT-3';
anti-sense, 5'-TCCAGGGAGTGACCAAGAGC-3': for exon
34, sense, 5-GTGACCAGGAATGTGCAGGG-3'; anti-sense,
5 -CCAGGAGCTGGAAGAGAGGA-3'; and for exon 36.
sense. 5 -GGGGGCAGCACTGTGACTCC-3 : anti-sense. 5 -
AGGGACTTGGGTGGGTTCCT-3'. PCR conditions were
94 °C for 5 min followed by 35 cycles of 94 °C for 45 s.
annealing temperature for 45 s and 72 °C for 45 s.
Annealing temperatures were 64 °C for exons 3 and
36, 62 °C for exon 7 and 60 °C for exons 30 and 34. PCR
products were examined on 2% agarose gels and
then screened by heteroduplex analysis using confor¬
mation-sensitive gel electrophoresis (CSGE).34 Exons
displaying bandshifts were subjected to direct nucleotide
sequencing (ABI, Perkin Elmer).
The mutationsW1478X and C38R altered restriction
endonuclease cut sites which were used to confirm the
presence of mutations in the probands and family
members (see Results). Specifically, W1478X created a
Nhel restriction enzyme site in the exon 36 PCR product
from patient A (normal allele 32 7 bp, mutant allele
173 bp and 154 bp fragments), which was examinei
on a 2% agarose gel. C38R abolished a BbvI restrictioi
site in patient B's exon 3 PCR product (normal allel
112 bp and <40bp fragments, mutant allele 136bp
and <40 bp fragments), which was viewed on a 4°/
NuSieve agarose gel (EMC BioProducts, Rockland, ME
U.S.A.). Restriction endonucleases were used accordinj
to the manufacturer's instructions (New England Bio
labs, Hitchin, Herts, U.K.). The splice site mutation ii
exon 30, 3793 + lG-to-A, in patient A, and the exon 3<
deletion mutation, 4776delG, in patient B, did not alte
a restriction enzyme site and therefore direct nucleotidi
sequencing was used to demonstrate the presence o
absence of these mutations in genomic DNA from thi
parents of both patients and the unaffected sibling o
patient A (see Results).
Results
Ultrastructural and immunohistochemical analysis o
skin specimens from patient A have been describee
previously.16 Electron microscopy of uninvolved skii
from patient A demonstrated dermal-epidermal separa
tion along the lamina lucida, whereas in patient B, there
were areas of separation with a very low plane o
cleavage in the basal keratinocytes above the hemi
desmosome plaques (Fig. 2a). Hemidesmosomes wen
sparse and poorly formed with loss of sub-basal dense
plates (Fig. 2b).
Immunohistochemical analysis using GB3 antibodj
against laminin-5 in skin biopsies from both proband;
revealed normal bright linear staining along the
dermal-epidermal junction relative to normal contro
human skin (Fig. 3a,b). Immunoreactivity to GoHT
antibody against the «6 integiiii subunit was marked!}
attenuated in patient B, but of near normal intensity in
patient A (Fig. 3c,d). In both probands, immunoreac¬
tivity with antibody 3E1 against the (34 integrin subunif
was greatly reduced relative to normal control skin, a;
was reactivity with the anti-(34 integrin antibodies G71,
in patient A, and 450-11A, in patient B (Fig. 3e,f). In
patient B, immunoreactivity to antibodies against the
180 kDa and 230 kDa BP antigens and plectin was
moderately reduced compared with normal skin (data
not shown).
In patient A, PCR amplification of ITGB4 followed by
CSGE revealed heteroduplex bands in the PCR products
spanning exons 30 and 36 (Fig. 4). Subsequent direct
nucleotide sequencing of exon 30 and flanking intronic
sequences demonstrated the presence of a heterozygous
G-to-A transition at the 5' donor consensus sequence at
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Figure 2. Electron microscopy of the dermal-epidermal junction in
patient B. (a) Intracellular plane of cleavage (asterisk) with basal cell
debris adherent to underlying basement membrane (arrows). Scale
bar= 1 p,m. (b) Poorly formed hemidesmosomes (arrows) with absent
sub-basal dense plates (scale bar = 0-5|xm). K, keratin intermediate
filaments; D, dermis.
the first nucleotide of intron 30 (3793 + lG-to-A)
(GenBank accession number U66529-U66541)
(Fig. 4). Direct nucleotide sequencing of the exon 30
PCR product in the proband's parents confirmed that
the mother was a carrier of this mutation. Sequencing
of the exon 36 PCR product in patient A demonstrated a
novel G-to-A transition at nucleotide position 4802,
which converts a tryptophan residue (TGG) to a stop
codon (TAG) (W1478X) (GenBank accession number
X51841) (Fig. 4). This mutation creates a Nhel restric¬
tion enzyme cut site and was used to confirm the
presence of this mutation in the proband, his father
and clinically unaffected sibling (Fig. 4), and to exclude
it from 100 normal chromosomes.
Heteroduplex analysis of ITGB4 PCR products in
patient B showed bandshifts in exons 3 and 36 (Fig. 5).
Direct nucleotide sequencing of the PCR product span¬
ning exon 3 revealed a novel heterozygous missense
mutation arising from a T-to-C transition at nucleotide
112, which converts a cysteine residue (TGC) to an
arginine (CGC) (C38R) (Fig. 5). This mutation abolishes
a BbvI restriction endonuclease cut site and therefore
this enzyme was used to confirm the presence of C38R
in the proband and his mother (Fig. 5), and to exclude it
from 100 normal chromosomes. Sequencing of the
proband's exon 36 PCR product demonstrated a hetero¬
zygous 1 bp deletion (4776delG), which results in a
premature termination codon of translation 20 bp
downstream (Fig. 5). Sequencing of this PCR product
from parental DNA confirmed that the proband's father
was a carrier for 4776delG. Heterozygous carrier
status for this mutation was excluded from 100
normal chromosomes by sequencing or heteroduplex
analysis.
Heteroduplex analysis of ITGB4 PCR products of the
probands and family members also showed heterodu¬
plex bands in some individuals in the PCR products
spanning exons 7 and 34. Direct nucleotide sequencing
of these PCR products disclosed two silent polymor¬
phisms: 579T-to-C in exon 7 and 4521G-to-C in
exon 34 (data not shown). The exon 7 polymorphism
abolished a Styl restriction site. Screening the exon 7
PCR product from 25 normal control subjects revealed
that this polymorphism occurred on 17 alleles, giving
an allelic frequency of 34% in this population. The
polymorphism within exon 34 abolishes a BstNI restric¬
tion site and was used to demonstrate this polymor¬
phism on 29 alleles in the 25 control subjects, giving an
allelic frequency of 58%.
Discussion
In this report, we have described two unrelated, British
patients with EB-PA in whom pathogenetic mutations
in the (34 integrin gene were identified. Both probands
were unusual in that following surgical correction of
pyloric atresia, they had survived into early childhood
with minimal cutaneous involvement whereas the
majority of patients with this disease die within the
first few weeks or months of life from sepsis or other
complications of the disease.
Integrin a 6 (34 is predominantly expressed in strati¬
fied squamous and transitional epithelia, and within the
cutaneous BMZ is localized to hemidesmosomes
which rely on the presence of this integrin for their
© 1998 British Association of Dermatologists, British Journal of Dermatology, 139, 862-871
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Figure 3. Indirect immunofluorescence of normal human control skin (a, c and e), and skin from patient B (b, d and f). Bright linear dermal-
epidermal junction staining with GB3 antilaminin-5 antibody in both normal skin (a) and uninvolved skin from patient B (b). The dermal-epidermal
junction in normal skin shows bright staining with GoH3 antibody against the a6 integrin subunit, and 450-11A against the (34 integrin subunit (c
and e, respectively). Immunoreactivity with GoH3 and 450-11A is markedly reduced in uninvolved skin from patient B (d and f, respectively)
(arrows) (scale bar = 25 p,m).
formation.8,35-39 The a6(34 heterodimer is involved in
maintaining basal cell-matrix adhesion through inter¬
action of the large intracytoplasmic tail of the (34
subunit with the keratin intermediate filament network,
at least in part through its binding with plectin and the
180 kDa BP antigen.40-42 Also, the extracellular
domain of a6(34 integrin serves as a receptor for
laminin-5 and interacts with the 180 kDa BP antigen,
both of them being components of the lamina lucida.43-45
The importance of integrin a6 (34 in maintaining BMZ
integrity has been demonstrated by mouse knock-out
studies which resulted in dermal-epidermal separation
with absent hemidesmosomes, associated with severe
mucocutaneous fragility and gastrointestinal and uro¬
genital tract abnormalities.38,46,47
The mutations identified in patients A and B, and
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Figure 4. Mutation analysis in the family of patient A. (a) Conformation-sensitive gel electrophoresis (CSGE) analysis of polymerase chain reaction
(PCR) products spanning exon 36 reveals heteroduplex bands in DNA from the father, proband and clinically unaffected sister, whereas the mother's
and control DNA shows homoduplex bands only. The mutation W1478X creates a Nhel restriction enzyme site which digests the mutant allele to
173bp and 154bp fragments, while the 327bp normal fragment resists digestion. Restriction analysis with Nhel of the exon 36 PCR products
demonstrates that the father, proband and sibling are heterozygous forW14 78X. CSGE analysis ofexon 3 0 PCR products in this family demonstrates
heteroduplex bands in the mother and proband, and homoduplex bands in the father, sibling and control DNA. (b) Direct nucleotide sequencing of
the exon 36 PCR products reveals heterozygosity for a G-to-A transition at nucleotide position 4802, converting a tryptophan residue (TGG) to a stop
codon (TAG) (W1478X) in patient A, his father, and unaffected sibling. Nucleotide sequencing of his mother's exon 36 PCR product is normal, (c)
Direct nucleotide sequencing ofexon 30 PCR products demonstrates a heterozygous G-to-A transition at the 5' donor consensus sequence at the first
nucleotide of intron 30 (3793 -I- lG-to-A) in patient A and his mother, and normal sequence in his father and sibling. M, <J>X174 HhcIII molecular
weight marker.
previously published ITGB4 mutations in EB-PA, are
shown diagrammatically in Figure 6. In our study, we
found that patient Awas a compound heterozygote for a
splice site mutation (3793 + 1G-to-A) and a non-sense
mutation (W1478X) in ITGB4, inherited on the mater¬
nal and paternal alleles, respectively. The splice site
mutation has been demonstrated previously in a homo¬
zygous patient with EB-PA in whom mRNA studies
suggested that two splice variants arose from the use
of two cryptic splice sites which result in frameshifts and
downstream premature termination codons and a
markedly reduced mRNA level.17 Compound hetero¬
zygosity for 3793 + 1G-to-A and the novel stop codon
mutation, W1478X, in patient A might be expected to
result in the synthesis of (34 polypeptides truncated in
the intracytoplasmic tail domain, although non-sense-
mediated mRNA decay is likely to result from these
mutations and thereby the synthesis of little if any (34
integrin subunit.48~,() Despite this, patient A has a
milder phenotype than observed in another EB-PA
patient homozygous for the same splice site mutation,
as well as in most previously reported cases with ITGB4
mutations identified. lf>~18'20'21 The reasons for this
remain unclear, although mRNA studies of the proband
might reveal the use of other, less disruptive cryptic
splice sites arising from the 379 3 -f lG-to-A mutation.
If the W1478X allele is expressed at the protein level,
the truncated polypeptide is expected to retain the
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of exon 3 136bp
112bp
(b) Paternal mutation (c) Maternal mutation
TGC (Cys)
CGC (Arg)
Heterozygous 4776delG Heterozygous C38R
Normal sequence Normal sequence
Figure 5. Mutation analysis in the family of patient B. (a) Conformation-sensitive gel electrophoresis (CSGE) analysis of polymerase chain reaction
(PCR) products spanning exon 36 reveals heteroduplex bands in the proband and his father whereas PCR products from the mother and control
show homoduplex bands only. Exon 3 PCR products demonstrate heteroduplex bands on CSGE analysis in the proband and his mother, but
homoduplexes in his father's and control DNA. The mutation C38R in exon 3 abolishes a BbvI restriction endonuclease site, digesting the normal
allele into 112bp and <40bp fragments while digesting the mutant allele into 136bp and <40bp fragments. Bbvl analysis demonstrates the
presence ofC38Ron one ITGB4 allele in the proband and his mother, (b) Direct nucleotide sequencing of exon 36 PCR products in this family reveals
a heterozygous 1 bp deletion (4776delG) in the proband and his father. Maternal sequence of this exon is normal, (c) Sequencing of the proband's
and mother's exon 3 PCR products demonstrates a heterozygous missense mutation arising from a T-to-C transition at nucleotide 112. converting a
cysteine residue (TGC) to an arginine (CGC) (C38R). This mutation is not detected in the paternal PCR product. M, <j>X174 Hnelll molecular weight
marker.
binding site for plectin, while the binding site for the
cytoplasmic domain of the 108 kDa BP antigen is
deleted.41'42
Mutational analysis in patient B revealed compound
heterozygosity for two novel mutations, 4776delG and
C38R, on the paternal and maternal alleles, respec¬
tively. 4776delG results in a frameshift and downstream
premature termination codon, also predictive of an
unstable mRNA transcript from this allele. The missense
mutation, C38R, arises in an exon of ITGB4 encoding
part of the extracellular amino-terminal domain of the
(34 integrin subunit. This amino acid substitution
occurs in a region of the protein which is highly
conserved between different (3 integrin polypeptides
and between different species, and therefore might be
expected to disrupt heterodimer formation with the a 6
integrin subunit or interactions with ligands within the
lamina lucida.,1~,i Perturbation rather than abolition
of (34 subunit function by C38R may explain the mild
phenotype of this proband with only minimal cuta¬
neous involvement and no evidence of other sequelae.
Recently, compound heterozygosity for a missense and a
non-sense or premature termination codon mutation
has been described in both lethal21 and non-lethal-- EB-
PA, suggesting that both the position and nature of the
amino acid substitution may influence phenotypic severity.
Ultrastructural analysis of uninvolved, gently rubbed
skin from patient A revealed an intralamina lucida
plane of cleavage. However, in patient B, the separation
was intracellular and at, or just above, the level of the
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Figure 6. Database of mutations in ITGB4. Mutations described in this study are shown in blue. 1150delG, 3793 + 2insT;,(' 3793 + lG-to-A:1,
3434dclT. 4050del8;20 4501delTC, 120delTG, C245G. 073X;21 L156P, R554X/ ' TM, transmembrane domain.
hemidesmosome plaques. Most cases of EB-PA reported
have had a level of separation along the lamina
lucida;6'7,12-14,16,17,19-21,54 however, splits within the
basal cell, and even below the lamina densa, have been
reported in some patients,1 ,21'2 ' 6 as well as in knock¬
out mice with ablation of ITGB4 or ITGA6-46'4' As
integrin a6[34 comprises intracellular, transmembrane
and extracellular domains, it is possible that mutations
in ITGA6 or ITGB4 might give rise to a junctional or
intracellular plane of cleavage at the BMZ. Further,
the normal stable connections between the keratin
filament network and hemidesmosomes are reduced in
the skin of patients with EB-PA,2 7 possibly rendering
this peripheral cytoplasmic zone liable to rupture after
trauma.
Immunohistochemical studies on skin from both
patients demonstrated reduced immunoreactivity to
antibodies against the (34 integrin subunit, and reduced
immunoreactivity to the a6 subunit in patient B. The
reduced a 6 subunit expression in patient B relative to
patient A may result from the C38R missense mutation
which, causing an amino acid substitution in the
extracellular domain of the (34 subunit, may greatly
disrupt a6(34 heterodimer formation.4" Similar findings
with reduced expression of both integrin subunits have
been demonstrated by other groups and underscore the
close association with which this heterodimer is
expressed at the basal epithelial cell surface.7'9'16'21
Perturbed hemidesmosome assembly resulting from
pathogenetic ITGB4 mutations is likely to account for
the reduced immunoreactivity to the hemidesmosomal
proteins plectin and the 180 kDa and 230kDa BP
antigens observed in patient B.
In addition, mutational analysis was undertaken
to establish the frequency of two ITGB4 intragenic
polymorphisms in a Caucasian European population.
Both polymorphisms occur with a high allelic
frequency (34% and 58%), which means that they
may be useful markers for linkage studies, including
DNA-based prenatal diagnosis, in other families with
EB-PA.
In summary, we report two cases of mild EB-PA with
mutations in ITGB4. Identification of these mutations
increases our understanding of pathogenetic mechan¬
isms in this disease and underscores the role of a6(34
integrin in maintaining epithelial-matrix adherence.
Precise molecular classification in both affected families
also has direct clinical relevance in that first trimester
DNA-based prenatal diagnosis can be made available in
subsequent at-risk pregnancies if requested.
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Laryngeal involvement in the Dowling-Meara variant of
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Summary The clinical features of the Dowling-Meara variant of epidermolysis bullosa simplex (EBS-DM) can,
in an infant, be indistinguishable from other severe forms of epidermolysis bullosa (EB). Two
unrelated infants with no family history of skin disease are described who, within hours of birth,
developed extensive blistering of skin and oral mucosae and who both subsequently developed
hoarse cries. Despite this superficial resemblance to other forms of EB, electron microscopy revealed
a basal cell rupture and keratin aggregates characteristic of EBS-DM in the skin of both infants and
in the vocal cord epithelium of one. Molecular analysis confirmed the diagnosis by identification of
mis-sense point mutations in basal cell keratin genes in both cases. One patient carries a point
mutation in keratin 14 (converting arginine at position 125 to histidine) and the other has a novel
point mutation in keratin 5 (converting serine at position 181 to proline). Hoarseness is not a well
documented feature of EBS-DM and is usually associated with junctional EB. These two patients
demonstrate that the presence of a hoarse cry in an infant affected by severe EB does not necessarily
indicate a poor prognosis.
Key words: Dowling-Meara, epidermolysis bullosa simplex, hoarseness, junctional epidermolysis
bullosa, keratin 14, keratin 5, laryngeal blisters
Epidermolysis bullosa simplex (EBS) is a member of a
larger EB family of disease which includes junctional EB
(JEB) and dystrophic EB (DEB), which can be distin¬
guished from each other histologically by the level of
cleavage through the epidermis and by the fact that
defects in distinct genes are responsible for each
subtype.
EBS-Dowling-Meara (EBS-DM) is the most severe
form of the three major EBS variants (DM, Koebner and
Weber-Cockayne). The mutations that are responsible
for the DM phenotype of EBS are at the ends of the
helical rod domains of keratins 5 and 141 or more
Correspondence: C.Shemanko, Institute for Biomedical Research,
Germany.
rarely with mutations in the intermediate filament-
associated protein plectin.2 4 These regions at the
beginning and the end of the keratin rod domain (helix
initiation and termination motifs) are highly conserved
and have been shown to be critical for filament
formation.5-11 The severity of EBS is apparently
dependent upon the nature of the mutation, its location
in the protein and its effect upon keratin filament
formation.
fn the neonatal period, when there is often extensive
blistering of the skin and mucous membranes, EBS-DM
is clinically indistinguishable from both JEB and severe
recessive DEB, which are associated with mutations in
laminin 5,12-1 ^ bullous pemphigoid antigen-2lf> and
type VII collagen,1' respectively. By 12 months of age,
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clinical features characteristic of EBS-DM begin to
emerge.18 In common with all severe forms of EB,
EBS-DM may be fatal during early infancy due to
overwhelming sepsis but if this early stage is survived,
life expectancy is normal. This is in contrast with the
Herlitz type of JEB in which survival beyond 5 years is
rare. A hoarse cry in a blistering infant has until
now been considered indicative of JEB with a poor
prognosis.19-2
We report two neonates with extensive blistering and
hoarse cries who were shown by molecular and
ultrastructure analysis to be suffering from EBS-DM.
Mutations were found in keratin 14 in one patient and
keratin 5 in the other. The mutation in the helix
initiation motif of keratin 5 is the first reported at this
site for a DM patient, and these are the first keratin
mutations associated with laryngeal involvement.
Case reports
Patient 1
A male infant, born at term to non-consanguineous
parents with no family history of skin disorders,
developed widespread blistering of the skin and buccal
mucous membranes within 24 h of birth. He was
noted to have a persistently hoarse cry. A modestly
raised maternal serum alpha-fetoprotein (2-05
multiples of the median) had been detected at
17 weeks of gestation, but a subsequent detailed
ultrasound scan was reported as normal. Blistering
remained widespread but became progressively more
herpetiform (Fig. 1) with periungual involvement and
nail dystrophy. The cry remained hoarse. At 7 months
of age, direct laryngoscopy was undertaken and
irregular thickenings were seen on both vocal cords.
Figure 1. Herpetiform blistering with central clearing. Left thigh of
patient 1 at 4 months of age, showing herpetiform blistering.
Hoarseness persisted until the age of 2 years. The child
is now 6 years old and developing normally. Blisters
remain widespread and herpetiform.
Patient 2
A female infant was born at term to healthy unrelated
parents with no family history of skin disease. At birth
there were blisters on the palms and soles and within
hours blistering had spread to involve the tongue,
buccal mucosa, periungual regions and large areas of
skin. By 3 weeks of age she had developed stridor and a
hoarse cry which was present until about the age of
2 years. Laryngoscopy was not undertaken. At the age
of 19 months, the child developed a widespread
cutaneous herpes simplex infection, requiring inpatient
treatment with systemic aciclovir. She is now 5 years




Fresh blisters from both infants, biopsied during the
first week of life, and a biopsy taken at 7 months of age
from the mucosa overlying the right vocal cord of
patient 1, were processed for transmission electron
microscopy.24
Mutation analysis
Genomic DNA was extracted from peripheral blood
lymphocytes isolated from blood samples taken from
both children, patients 1 and 2, and their parents for
sequencing of the genes coding for keratins 5 and 14.
The keratin 14 genomic DNA for exon 1 was
polymerase chain reaction (PCR) amplified using the
sense primer 5'-TAC CCG AGC ACC TTC TCT TC-3'
(257-276 bp, EMBL accession number J00124), and
the anti-sense primer 5'-TGC TGG AGA ACA AGT
AGC TGC-3' (1223-1202 bp). The cycle parameters
for PCR amplification consisted of an incubation at
94 °C for 2 min followed by 30 cycles of 30 s at 94 °C,
1 min at 55 °C and 2 min at 72 °C, followed by 7 min
at 72 °C. Approximately 500 ng of DNA was used per
100 |xL reaction containing 60 mmol/L Tris-HCl
pH 9-5, 15 mmol/L (NH4)2S04, and 2-5 mmol/I
MgCl2, 0-2 mmol/L each dNTP, 0-5 pg/mL each
primer and 2-5 U Taq polymerase (Perkin Elmer
Applied Biosystems, Warrington, U.K.). The PCR
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Figure 2. Electron microscopic analysis of a laryngeal biopsy from
patient 1. Electron micrograph of a biopsy taken at 7 months of age
from the right vocal cord, showing subnuclear cytolysis of basal
keratinocytes. the lamina densa (arrowhead), blister cavity (asterisk)
and clumped keratin tonofilaments (t). (Scale bar = 1 pm, original
magnification x 3600.)
product of 967 bp was cloned directly into the pCRIMII
vector (Invitrogen. Abingdon, U.K.). The mutation was
discovered in patient 1 in genomic DNA by dsDNA T7
sequencing (Pharmacia, Little Chalfont, U.K.) with
[a-55S]dATP (Amersham, Little Chalfont, U.K.), using
the sense primer 5'-GGG GGA GCC TAT GGG TTG
GGG-3' (496-516 bp). The samples were resolved on
6% denaturing sequencing gels (National Diagnostics),
and autoradiographed.
The keratin 5 genomic DNA (EMBL accession
number M21389) for exon 1 was PCR amplified
using the sense primer 5'-AAC AAG CCA CCA TGT
CTC GCC AGT CAA GTG TGT CC-3' (381-415 bp) and
an intron 1 anti-sense primer 5'-CTC TTT GGC ATT
TAT TTC AGA CCC-3' under the same conditions as
above. This fragment was used in sequencing and in
the restriction analysis. The 623-bp fragment was
cloned directly into the pCR™II vector (Invitrogen) and
the mutation was detected, in patient 2, by cycle
sequencing, using the above anti-sense primer end-
labelled with [y32P]ATP (New England Biolabs,
Hitchin, U.K.).
To prepare DNA fragments for restriction analysis,
the PCR conditions were as above except for the
addition of 0-7 ng of labelled anti-sense primer. One-
tenth of the product was incubated at 60 °C for 15 min
in a reaction consisting of 5 mmol/L spermidine,
100 (xg/mL bovine serum albumin, 50 mmol/L NaCl,
10 mmol/L Tris-HCl. 10 mmol/L MgCl2, 1 mmol/L
dithiothreitol pH 7-9, and digested using 5 U of the




Ultrastructural examination of freshly blistered skin
from both patients showed a cleavage plane through
the subnuclear cytoplasm of basal keratinocytes, with
tonofilament clumping and cytolysis (data not shown)
characteristic of EBS-DM.18 Ultrastructural examina¬
tion of a biopsy taken from the mucosa overlying the
right vocal cord of patient 1 showed features identical
to those present in the skin (Fig. 2).
Identification of causative mutations
In most cases of EBS-DM. the mutations underlying the
disease can be found in either keratin 5 or keratin 14,
with most occurring in the helix initiation motif of
keratin 14.1 Using PCR. we amplified a fragment of the
genomic keratin 14 DNA from patient 1 and subcloned
it for sequencing. Sequencing of the individual alleles
revealed a G to A substitution at the second nucleotide
position in codon 125 of one allele of the keratin 14
gene, resulting in a predicted arginine to histidine
substitution within the helix initiation motif of keratin
14 (K14R125H: Fig. 3). Parental DNA was unchanged
at this position in keratin 14. This mutation is identical
to several mutations already identified at this position
in unrelated families with EBS-DM.23,26
When a keratin 14 mutation in patient 2 was not









































Figure 3. A mutation in keratin 14 encoding the a-helix 1A
domain. Shown is the DNA sequence and predicted amino acid
sequence of a portion of the region encoding the helix termination
motif. The normal (right-hand side) and mutant allele (left) sequences
from genomic DNA subclones. The G to A mutation (arrowhead) at
codon 125 changes the predicted amino acid from arginine to
histidine. Sequences were consistent in several clones. The asparagine
codon shows a previously reported T to C silent heterozygous
polymorphism.4'
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Figure 4. DNA sequence and predicted amino acid sequence of a
portion of the region encoding the keratin 5 helix 1A domain. The
DNA sequence shows the normal (left-hand side) and mutant allele
(right-hand side) sequences from genomic DNA clones. The T to C
mutation (arrowhead) at codon 181 changes the predicted coding
amino acid from a serine to a proline. Sequences were consistent
within several clones.
subcloned and sequenced. Figure 4 shows the sequence
change identified in one allele of patient 2, as a T to C
substitution at the second nucleotide position at codon
181. The substitution predicts a change of the amino
acid encoded from a serine to a proline (K5S181P).





Mnl I and Ava II
Figure 5. The restriction digest screen demonstrating that the
keratin 5 (SI81P) mutation is not present in the normal population.
Digestion with Arall of a 3'-end-labelled polymerase chain reaction
product was used to remove numerous Mnl I sites present in the full-
length fragment (62 3 bp). The resulting 116 bp labelled fragment
was then cleaved with Mnl I to produce a 60-bp fragment in normal
sequences, and a 77 bp fragment (arrowhead) in DNA carrying the T
to C mutation which knocked out the Mnl I site.
keratin 5 for a DM patient. More than 50 non-EBS
individuals, plus the parents, were screened and found
negative for the mutation, indicating that it is not a
common polymorphism in the population (Fig. 5).
Discussion
Both neonates presented, within hours of birth, with
extensive blistering indistinguishable clinically from JEB
and severe recessive DEB. The principal point of clinical
interest in these two infants was their hoarseness.
Hoarseness is well recognized in JEB in which laryngeal
involvement may be an important cause of death.2'
This has not been a well documented feature of EBS-
DM, although it has been noted in one previous
report28 and in two patients with plectin defects
associated with EBS and muscular dystrophy.29
In our patients, identification of point mutations in
keratins 5 and 14 as well as the typical ultrastructural
defects were diagnostic, thus enabling an accurate
assessment of the prognosis in each case. An incidental
finding in patient 1 was the detection of a raised
maternal serum alpha-fetoprotein on routine screening
at 17 weeks of gestation. Although most often
associated with open neural tube defects this has
been described in association with severe fetal
dermatoses30 33 including EBS 34
The R12 5H mutation in the helix initiation motif of
keratin 14 identified in patient 1 is one of the most
common causes of EBS-DM, and this codon is the most
commonly affected in all of the keratin disorders. This
reflects not only a high mutability of this codon, as it
contains a CpG dinucleotide, but it also reflects a great
functional sensitivity of this region of the protein to any
amino acid sequence variation.
In EBS-DM cases, mutations in keratin 5 have been
reported less frequently to date than mutations in
keratin 14. They include E475G, E477K,
36
E477stop3/ and I466T38 in the helix termination
motif, and L174F,39 N176S.36'40 F179S36 and a splice
site mutation41 in the helix initiation motif.
The serine at position 181 in keratin 5 is a highly
conserved amino acid across keratins and other
intermediate filament proteins (Fig. 6), indicating the
important role of this residue. A similar mutation at
this position has been reported in keratin 1 for a
case of bullous congenital ichthyosiform erythro¬
derma,42 although it has not before been reported with
EBS-DM. A proline residue is predicted to be very
disruptive to the a-helix, and thus to keratin dimer or
filament formation 9.42 Here it is believed to have
© 2000 British Association of Dermatologists, British Journal ofDermatology, 142. 315-320






























Figure 6. Conservation of the keratin 5 serine residue 181 across
intermediate filaments. A schematic representation of type 1 and type
2 keratin intermediate filament proteins which shows the central rod
domain and a comparison of a portion of the amino acid sequence of
the helix initiation motif. The italic lettering refers to positions within
the heptad repeat. Also shown are the amino acid sequences at the
helix initiation motif of several other intermediate filament proteins
including GFAP (glial fibrillary associated protein). NF-L (neuro¬
filament light). NF-M (neurofilament moderate) and the cephalo-
chordate Brcmchiostomci lanceolatum (Brlf-l).
contributed to severe EBS-DM (patient 2), with
involvement of the larynx. The high degree of
conservation of the serine residue, its position in the
helix initiation motif, and the amino acid change from
serine to proline predict that this would produce a
severe phenotype.
By electron microscopy, sporadic electron dense
aggregates of keratin were clearly seen in the basal
keratinocytes of the stratified squamous epithelium of
the vocal folds. Keratins 5 and 14 are the major keratin
proteins of basal layer cells in this type of tissue, and the
aggregates here are consistent with the observed
mutations. Disruptive dominant negative mutations in
these keratins give rise to keratin aggregates instead of
correctly assembled filaments, and as in the epidermis,
this leads to an inherent fragility in the affected cells,
and subsequent cytolysis on trauma (Fig. 2) due to the
lack of an effective intracellular supportive cyto-
skeleton. As vocal cords contain a stratified squamous
epithelium, it is perhaps surprising that hoarseness and
laryngeal blisters have been described so infrequently in
EBS. The keratin 5 and 14 mutations reported here are
potentially very disruptive to the keratin intermediate
filament, which may, perhaps in combination with
other genetic factors of the individual,43,44 have
resulted in the detection of rarely reported laryngeal
involvement in EBS-DM.
These two neonates, with extensive blistering, nail
involvement and hoarse cries, have features clinically
indistinguishable from JEB, but have been shown by
keratin gene sequence analysis, ultrastructural exami¬
nation of the larynx of one and the skin of both, to be
suffering from the EBS-DM.
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Summary As part of the U.K. National Epidermolysis Bullosa Register, we have systematically recorded clinical
information on 130 (77%) of the 168 known Scottish epidermolysis bullosa simplex (EBS) sufferers.
Three subtypes of EBS were recognized; Dowling-Meara (EBS-DM), Weber-Cockayne (EBS-WC) and
Kobner (EBS-Kb), seen in 5%. 42% and 53% of patients, respectively. As there is considerable
overlap between EBS-WC and EBS-Kb, with both phenotypes frequently seen within the same
pedigree, EBS-WC is best regarded as a milder variant of EBS-Kb rather than a separate disorder.
Improvement with age is common in all variants of EBS, but is not invariable. Pain due to acral
blistering in EBS-Kb/EBS-WC has a more marked impact on life-style than the blisters of EBS-DM.
Oral blistering, nail involvement and aplasia cutis congenita occur in all EBS subtypes and laryngeal
involvement is a feature of EBS-DM. Seasonal variation is not seen in EBS-DM but is common in
EBS-Kb/EBS-WC.
Key words: epidermolysis bullosa simplex, epidermolysis bullosa
Since 1992, as part of the U.K. National Epidermolysis
Bullosa Register,1 clinical details of all known Scottish
epidermolysis bullosa (EB) patients have been system¬
atically recorded. In view of a relative paucity of
documentation of clinical features in the more common
milder forms of EB, we have attempted to record the
complete clinical spectrum of EB simplex (EBS) within
the Scottish population.
EBS, characterized by a cleavage plane through basal
keratinocytes, is caused by mutations of genes encoding
keratins 5 and 14, and plectra.2"' It is often regarded
as the least severe form of EB. Although usually not life
threatening, EBS-Dowling-Meara (EBS-DM), the most
severe subtype,8 can, like both junctional and recessive
dystrophic EB, be fatal during infancy.9 In 1886,
Kobner described seasonal blistering of predominantly
the palms and soles, but occurring, in addition, at
other sites of friction from clothing such as beneath
sock garters, in the groin and under corsets.10 His
name is often used to describe EBS in which
blisters are generalized,9 but in this paper we use
the term EBS-Kobner (EBS-Kb) to describe patients
who fit Kobner's original description, and EBS-Weber-
Cockayne (EBS-WC) to describe blistering confined
exclusively to the palms and soles.1112
Patients and methods
One hundred and sixty-eight individuals in Scotland
are known to suffer from EBS. One hundred and
forty-nine were identified and assessed during
compilation of the EB Register.1 and a further 19
were subsequently referred to the Department of
Dermatology at the Royal Infirmary of Edinburgh.
Detailed clinical information has been recorded on
130 patients from 33 families. Of the remaining 38
patients. 30 are affected relatives, identified by the
probands, who have not yet been interviewed.
Incomplete information exists on a further five
unrelated patients. The remaining three patients
have been diagnosed at other Scottish hospitals as
suffering from EBS, but have not yet been seen by
the authors. We report the clinical features seen in
the group of 130 patients for whom information is
complete.
Results
The three most common subtypes of EBS were
encountered in. this group of Scottish patients:
EBS-DM (5%), EBS-WC (42%) and EBS-Kb (53%).
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The Dowling-Meara subtype of epidermolysis bullosa
simplex
This was the most severe variant of EBS and was
identified in seven patients aged between 3 weeks and
49 years at initial interview. The two youngest were
identical twins, but the remaining five patients were
unrelated. None had an affected parent. The eldest (and
only patient over 18 years of age) had an affected son,
for whom no clinical information is available and who
was therefore not included in the study. Blisters were
congenital in four, and appeared during the first week
after birth in the other three (Table 1). One of the seven
was born with an area of absent epidermis on one leg.
All experienced widespread blistering which, after the
first few months of postnatal life, took on the clustered
herpetiform appearance characteristic of EBS-DM.13
The severity of blistering lessened during childhood and
adolescence in all patients. The four infants in the study
had intraoral blistering and hoarse cries. Two have
been followed up for several years; their hoarseness
resolved during their third year. All subjects had nail
involvement. In the case of the infants, this consisted of
periodic shedding of finger and toe nails which
subsequently regrew. The adults had thickened great
toe nails. None experienced any seasonal variation of
the blistering tendency. Mild hyperkeratosis of the
weight-bearing areas of the soles was seen in the two
oldest patients, aged 17 and 49 years. Although
friction from close-fitting clothing was an important
cause of blisters in all patients with EBS-DM, many
blisters appeared to arise spontaneously. Scarring was
not seen in any subjects, although widespread post¬
inflammatory pigmentation was present in one of the
two adolescents. This patient also had several atypical
naevi, apparently at the sites of previous blisters.
Table 1. Age at onset of blistering in patients with epidermolysis
bullosa simplex (EBS)
Age at onset All patients EBS-WC EBS-Kb EBS-DM
Birth 9 1 4 4
1-7 days 16 3 10 3
1-4 weeks 10 2 8 0
1-6 months 22 2 20 0
7 months-2 years 34 20 14 0
2-5 years 8 7 1 0
6-10 years 6 4 2 0
11-20 years 2 2 0 0
Adult 0 0 0 0
Unknown 23 13 10 0
Total 130 54 69 7
EBS-WC, Weber-Cockayne subtype of EBS; EBS-Kb. Kobner subtype
of EBS. EBS-DM, Dowling-Meara subtype of EBS.
Ultrastructural examination of fresh blisters from
one twin and four others showed, in each case,
characteristic cytolysis of basal and suprabasal kera-
tinocytes and clumping of keratin tonofilaments.13
Identical changes were seen in a biopsy from the vocal
cord of one infant.14 The seventh and oldest patient, for
whom no ultrastructural information is available, has
been shown to carry a mutation of a keratin 14 allele
identified previously in other EBS-DM sufferers
(K14Leu122Phe).15 Analysis of keratin genes has been
undertaken in the remaining patients and, in each
case, a causative mutation has been identified
(K5Ser1SiPro, a novel mutation not previously
reported; Professor E.B.Lane, personal communication;
K14Arg125Cys;16-20 and K14Arg125His,16'17'21 found
in two patients).
The Kobner subtype of epidermolysis bullosa simplex
Sixty-nine individuals, while experiencing blisters
predominantly on the palms and soles, also blistered
at other sites. Seventeen families were represented.
Four patients had parents who had never blistered.
Patients were aged between 1-3 and 75-5 years at
interview (mean 29-2, median 29-5). All experienced
blisters on the feet and other sites. Sixty-three (91%)
suffered blisters on the palms. Intraoral blisters
occurred in 17 subjects (24%), and the great toe
nails were thickened in 10 patients (14%) aged
between 1-5 and 57-1 years. Mild hyperkeratosis of
the weight-bearing areas of the soles was present in
eight adults (12%), four of whom were members of one
family. Sixty subjects (87%) indicated that their
blistering tendency was worst in warm weather. Only
11 (16%) were completely free of blisters during the
winter. Three patients (4%), two of whom were mildly
affected, denied seasonal variation in severity of
blistering. Six children (9%) were too young to allow
assessment of seasonal variation.
Friction from clothing and jewellery was identified by
patients as an important cause of blisters, with heat a
contributory factor, sometimes apparently causing
blisters even in the absence of friction. Improvement
with age was noted by 20 patients (29%), only two of
whom (aged 3 and 11 years) were under 20 years old.
Fourteen patients (20%), aged 5-57 years, felt there
had been no improvement in blistering as they had
grown older. Of these, seven were over 20 years old.
Eight children were too young to allow any assessment
of improvement, and no information is available for the
remaining 27 patients (39%) whose ages range from 4
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to 67 years (mean 26-8). While the age at onset of
blistering in EBS-Kb varied between birth and 10 years
of age, 81% developed their first blisters before the
age of 2 years (Table 1). Two patients, mother and
daughter, were each born with a single absent area of
epidermis on one leg, which subsequently healed
leaving subtle atrophic scarring. In one family, all
three affected children experienced blisters in the
anogenital region.
There were six families, none exceeding four
sufferers, in which all affected individuals had the
EBS-Kb pattern of blistering. In each of the remaining
11 pedigrees, ranging in size from two to 2 5 affected
individuals, there was a mixed pattern of blistering,
with both EBS-WC and EBS-Kb phenotypes represented.
The Weber-Cockayne subtype of epidermolysis bullosa
simplex
EBS-WC was seen in 54 patients from 20 families.
Patients were aged between 1-3 and 78-3 years (mean
27-8, median 24-6) at interview. Six patients had
unaffected parents. Blisters were confined to the hands
and feet, although four individuals (7%) from three
families also experienced intraoral blistering. Only two
sufferers did not have sole involvement: one (aged
15 • 5 years) had mild involvement of the palms in early
childhood and the other (aged 24 years) experienced
palmar blisters which were exacerbated by his manual
occupation. Palmar blistering was a feature in only 31
patients (57%). Thickened great toe nails were present
in seven individuals (12%), three of whom were aged
under 4 years. No fungus was found in any nail
clippings submitted for mycological examination. Five
patients (9%), all adults, had mild hyperkeratosis of the
soles. Seasonal variation of blistering, worst during the
summer, was noticed by all but four very mildly affected
adults (93%). Twenty-seven individuals (50%) con¬
tinued to experience blisters to a lesser extent during
the winter, while 11 (20%) were completely free of
blisters during the colder months. Three children were
too young to allow assessment of seasonal variation,
and information is incomplete for the remaining 13
(24%) patients.
As in EBS-Kb, blisters were attributed to friction and
heat. In 19 patients (35%), the blistering tendency had
improved with age, all but one being over 20 years old.
Seventeen (31%) had not improved, although only
three were over the age of 20 years. One child (aged
1-3 years) was too young to allow assessment of
improvement, and no information was available for
the remaining 17 patients (31%), aged 3-5-51 years.
The age at onset of blistering was slightly later than
that seen in EBS-Kb, varying between birth and
the teenage years (Table 1). Fifty-three per cent had
experienced their first blisters by the age of 2 years.
One child was born with a localized area of absent
epidermis on one leg.
There were nine pedigrees, none exceeding four
patients, in which all affected individuals demonstrated
exclusively the EBS-WC phenotype.
Effect of epidermolysis bullosa simplex on life-style
In both EBS-WC and EBS-Kb, foot blisters frequently
resulted in pain sufficient to require transport even over
short distances, and to limit walking during the
summer months. At home, it was common for affected
children and teenagers to avoid walking; they preferred
to crawl or 'bottom shuffle'. One adult EBS-Kb patient
used a wheelchair during the summer months. Some
parents carried their affected children to primary
school. Teenagers often found coping with frequent
changes of classroom during their school day difficult,
the less motivated regularly missing school because of
pain due to blisters. Two families had persuaded their
local education authorities to provide taxis to take their
affected children to school. Fourteen sufferers (8%; nine
with EBS-Kb, four with EBS-WC and one with EBS-DM)
were receiving social security benefits which in 11
cases was a mobility allowance. Seven of 67 adults
of employable age (10%) were unemployed, five of
whom suffered from EBS-Kb and two from EBS-WC.
Both adults affected by EBS-DM were in full-time
employment.
Discussion
Comparison with other EB databases suggests that this
population-based study is equally if not more rigorous
than other national surveys.1'22-27 We have tried to
minimize any bias towards more severely affected
patients by actively seeking out EBS sufferers, approxi¬
mately one-third of whom proved to be previously
unknown to dermatologists.1 It is inevitable that some
patients will remain undetected. Extrapolation and
analysis of data for the Lothians, the catchment area of
the Royal Infirmary of Edinburgh, suggests the national
prevalence of EBS to be appreciably higher than
recorded in any studies to date.1
Localized areas of congenital aplasia cutis, originally
termed 'Bart's syndrome'28 and since recorded in all
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major EB subtypes,29 are seen in all three variants of
EBS. Early onset and intraoral blisters, features typically
associated with recessive dystrophic and junctional
EB,9 all occur in each variant of EBS. Widespread
blistering during infancy in those few affected by
EBS-DM necessitates intensive nursing care, but over
the longer term, pain has a greater and more prolonged
effect on the life-style of those affected by EBS-Kb and
EBS-WC.
EBS is a spectrum, being a potentially life-
threatening condition for those few affected by
EBS-DM, a painful disability for many and little more
than an inconvenience for some. There is considerable
overlap within this spectrum, to such an extent that
EBS-WC and EBS-Kb should no longer be considered
different disorders. Both phenotypes are seen in family
members carrying identical causative mutations, and
this is apparent in all Scottish families of five or more
EBS sufferers. Thus, both EBS-Kb and EBS-WC appear
to represent variations of the same condition. Similar as
yet unexplained phenotypic variation is seen in other
single gene disorders, e.g. cystic fibrosis, neurofibro¬
matosis and ichthyosis bullosa of Siemens.30-32 It
appears the causative mutation, although important, is
not the only factor determining clinical severity.
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Summary Background Dystrophic epidermolysis bullosa (DEB) is a genodermatosis resulting from mutations in
COL7A1, the gene encoding type VII collagen. The site and specific nature of the underlying
mutation determine the clinical phenotype, which ranges widely from a severe mutilating condition
to a relatively mild disorder.
Objectives To document the clinical spectrum of DEB within a defined complete population.
Methods Since 1992, when compilation of the U.K. epidermolysis bullosa register began, an
exhaustive search for DEB sufferers within the Scottish population has been undertaken and their
clinical features comprehensively recorded.
Results One hundred and twenty-eight DEB sufferers have been identified within the Scottish
population. In descending order, the frequencies of the different forms of DEB were dominant DEB
(DDEB) in 88 individuals (68%), DEB of uncertain inheritance in 24 (19%) and recessive DEB
(RDEB) in 16 patients (13%). Within this latter group, nine (7%) had the mutilating Hallopeau-
Siemens subtype (RDEB-HS), five (4%) had localized (RDEB-loc) and two (2%) had a predominantly
flexural (inverse) form of RDEB. During the study, two patients with RDEB died from squamous cell
carcinomas (SCCs), one originating in the skin and the second arising in the oesophagus. Gastro¬
intestinal problems such as dysphagia, constipation and anal fissures, and restriction of mouth
opening were experienced by the majority of patients with RDEB and by a significant minority of
DDEB sufferers. Pseudosyndactyly was most severe in RDEB-HS, all those over 9 years of age having
mitten deformities of the hands. Milder pseudosyndactyly or flexion contractures of the fingers were
present in younger patients with this subtype, in most adults suffering from other subtypes of RDEB
and in 6% of those with DDEB. External ear involvement, a feature not often reported in DEB, was
common in RDEB and also occurred in a minority of those with DDEB. Pruriginous lesions and
albopapuloid lesions were each present in both DDEB and RDEB.
Conclusions Most patients with DEB have relatively mild dominantly inherited disease, only a
minority suffering from severe recessive subtypes. Scarring, gastrointestinal involvement, albo¬
papuloid lesions and a pruriginosa-like pattern each occur in both DDEB and RDEB. With increasing
age, SCC is a major cause of morbidity and mortality.
Key words: albopapuloid lesions, dystrophic epidermolysis bullosa, epidermolysis bullosa prurigi-
nosa, epidermolysis bullosa register
Dystrophic epidermolysis bullosa (DEB) is a genoder¬
matosis resulting from mutations in COL7A1, the gene
encoding type VII collagen. The site and specific nature
of the underlying mutation determine the clinical
phenotype, which ranges widely from a severe muti¬
lating condition to a relatively mild disorder.
Correspondence: Dr H.M.Horn. E-mail: hmhorn@doctors.org.uk
Because of its unique characteristics, Scotland was
selected for compilation of the first section of the U.K.
epidermolysis bullosa (EB) register. This part of Britain
has the advantages of being both politically and
geographically well defined: its population of 5 million1
is small enough to permit thorough assessment while
being large enough to reveal the full clinical spectrum
of EB. Those affected by severe variants of EB are well
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Table 1. Prevalences of epidermolysis bullosa (EB) (per million)
EBS JEB DEB
Scotland" 32-0 0-4 24-4
Norway2 24-3 - 9-3
N. Ireland3 280 0-7 3-3
Finland4 15-1 0-2 8-8
Croatia1 1-5 1-5 6-6
Japan6 40 0-2 3-5
Saudi Arabia' 1-7 00 3-7
S. Africa8 0-8 0-7 1-2
U.S.A.9 4-6 0-4 2-4
EBS, EB simplex: JEB, junctional EB: DEB. dystrophic EB. "Point
prevalences in Scotland on 1 January 2001. Figures based on Scot¬
tish population size in June 2000 of 5 114 600 (data supplied by the
General Register Office for Scotland).
known to the medical profession and are readily
included in EB registers but. unless they are actively
sought, sufferers with mild disease may not come to the
attention of researchers. Assessments of the epidemiol¬
ogy of EB in other countries2-9 suggest incomplete
sampling, pronounced regional variation or differing
genetic susceptibilities (Table 1). Although the ambi¬
tious U.S. national EB registry has so far published
valuable information on the largest EB cohort,9'10 the
large size of the American population hinders complete
sampling, thus resulting in a tendency to assess only
more severely affected EB sufferers. The smaller Scottish
population has been actively searched for EB sufferers,
resulting in compilation of the most complete EB
register of any published to date.
Details of the clinical features of EB simplex and the
prevalence and incidence of EB in Scotland have been
published previously.11'1" Between I960 and 1999.
the incidence in Scotland of EB simplex and of DEB was
34-3 and 26-0 per million, respectively i.e. 103 cases of
EB simplex and 78 of DEB out of 2 995 052 live births
during this period (data supplied by the General
Register Office for Scotland). We now present data
relating to the clinical features of DEB.
Patients and methods
Since 1992, 128 Scottish individuals have been iden¬
tified by the authors as suffering from DEB. Methods of
identification and assessment of patients have been
published previously.11 Diagnosis was made on the
basis of clinical features, family history and, in cases of
doubt, by antibody mapping and ultrastructural exam¬
ination using the recently published revised classifica¬
tion system of Fine et al.w Dominant DEB (DDEB) was
diagnosed when typical clinical features were present
in two or more individuals spanning at least two
generations. All patients with severe clinical features,
and many with milder disease, underwent skin biopsy
and ultrastructural assessment. Nine patients with very
mild disease and lacking a family history did not have
skin biopsies and were classified as having DEB of
uncertain inheritance (DEB-unc). DNA from selected
patients was analysed (Dr J.McGrath) for the presence
of COL7A1 mutations. We continue to record newly
diagnosed EB sufferers, both those referred to our
department and those diagnosed at other Scottish
hospitals.
The authors have examined 97 DEB sufferers from
50 families on at least one occasion and systematically
recorded their clinical findings at initial presentation.
Of the remaining 31 patients, 20, who have not been
clinically assessed, were identified by affected relatives
in whom the diagnosis of DEB had been confirmed.
Nine were diagnosed at the Royal Infirmary of Edin¬
burgh as suffering from DEB. However, clinical infor¬
mation is incomplete, and none is available for the two
patients diagnosed at other Scottish hospitals—one an
adult suffering from DDEB and the second a neonate
suffering from recessive DEB (RDEB-loc) of Hallopeau-
Siemens subtype (RDEB-HS). This study reports the
clinical findings at initial assessment of the 97 patients
seen by the authors.
Results
Four clinical variants of DEB were identified. DDEB
occurred in 88 patients (68%). Twenty-four patients
(19%) had no family history of DEB and clinical
features of mild to moderate severity (DEB-unc). On
the basis of individual pedigrees, recessive inherit¬
ance was judged to have occurred in 16 patients
(13%): nine (7%) with RDEB-HS and seven non-
Hallopeau-Siemens RDEB (RDEB-HS).
Dominant dystrophic epidermolysis bullosa
Detailed clinical information is available for 64 of the
88 individuals from 18 families. Subjects were aged
between 2 days and 76 years at interview (mean
2 7 years). Thirty-six were female. Age at onset of
blistering was known in 43 of the 64 patients and
varied between birth and 5 years (Table 2). Clinical
features are summarized in Table 3. With the exception
of seven children, four of whom were under 1 year old,
scars were present over bony prominences in all
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Tabic 2. Age at onset of blisters in dystrophic epidermolysis bullosa (DEB)
Age at first RDEB-HS RDEB-loc RDEB-inv DDEB DEB-unc
blister n = 8 n = 4 n = 2 n = 64 n = 19 Total
Birth 7 3 1 6 4 21
1-7 days 1 0 0 12 5 18
1-4 weeks 0 1 10 2 4
1-6 months 0 0 0 11 6 17
7-24 months 0 0 0 10 0 10
2-5 years 0 0 0 4 0 4
Unknown 0 0 0 21 2 23
RDEB-HS, recessive DEB of Hallopeau-Siemens subtype; RDEB-loc, localized RDEB; RDEB-inv, inverse form of RDEB; DDEB, dominant DEB; DEB-
unc, DEB of uncertain inheritance.
Table 3. Clinical features of dominant dystrophic epidermolysis
bullosa in adults and children
Children aged 12
years or under Adults
(n = 25), % (n = 39), %





Nail loss/dystrophy 44 85
Otitis externa 8 8
Constipation 12 21
Anal fissures 12 21
Dysphagia 4 23
Oral blisters 28 36
Dental disease 8 51
Microstomia 0 5
patients. Milia were noted in 17 subjects (27%), both
adults and children. Nail dystrophy, present in 44
patients (69%), was not seen below the age of 3 years.
Of the 22 individuals (34%) with significant dental
abnormalities, i.e. excessive dental caries or its seque¬
lae, three were under 20 years of age and 13 reported
oral blistering. A further nine patients with oral blisters
had normal dentition. Only two of the 12 (19%)
subjects with anal fissures were children, the youngest
being 2 years old.
Nine adults and one child aged 9 years (16%)
complained of dysphagia. All but one also had anal
fissures (seven patients) and/or constipation (five
patients). A further six patients complained of trouble¬
some constipation and two had some restriction of
mouth opening. A recent barium examination in one
adult with long-standing dysphagia and who intermit¬
tently produced oesophageal casts, did not reveal any
abnormality. Although pseudosyndactyly was not
observed in any individuals, flexion contractures of
the fingers were seen in four adults (6%). No patients
had eye involvement. Two adults (3%) had itchy
pretibial plaques, and 'EB pruriginosa' and albopapu-
loid lesions were apparent in 23 (36%) patients. Two
heterozygous glycine substitution mutations of
COL7A1 (one reported previously15) were detected in
patients from three families.
Dystrophic epidermolysis bullosa of uncertain inheritance
Clinical information is available for 19 unrelated
subjects. One man with mild DEB limited to the skin
and oral mucosa was the cousin of a patient with
RDEB-HS who died before analysis of COL7A1 muta¬
tions was available.14 The remaining patients in
this group had no family history of DEB. Ages at
interview ranged from 6 months to 39 years (mean
13-9 years). Nine (47%) had mild DEB while the
remainder had more troublesome DEB of varying
severity. All had scars, 13 (63%) had milia and 11
(58%) had nail loss or dystrophy. The youngest child
to have abnormal nails was 21 months old. She was
the only individual in this group born with a localized
area of absent skin ('Bart's syndrome') and the only
one to suffer from recurrent corneal erosions. Pseu¬
dosyndactyly was not observed but mild flexion
contractures of the fingers were seen in one adult.
Nine subjects (47%) had albopapuloid lesions and two
(11%) had EB pruriginosa. Both individuals with this
clinical variant of DEB also had involvement of the
external ear. Ten patients (53%) experienced oral
blisters. Dental disease was present in five (26%), all
but one of whom suffered oral blistering. One adult
with normal dentition had both restriction of mouth
opening and limitation of tongue protrusion (ankylo-
glossia). Anal fissures occurred in five individuals
(26%), both adults and children, and were associated
with constipation in four. A further three subjects
also complained of constipation. Oesophageal stric¬
tures were demonstrated in two of the four patients
(21%) who experienced dysphagia, which in a third
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was associated with the regular production of
oesophageal casts.
Recessive dystrophic epidermolysis bullosa
of Hallopeau-Siemens subtype
All nine individuals in this group were unrelated and
had unaffected parents. One had a cousin suffering
from mild localized DEB-unc: details of this family have
been reported previously.14 The parents of one child
were cousins but there was no evidence of consan¬
guinity in the other families. Clinical information is
available for eight patients who were aged between
3 days and 34 years at interview. Three were less than
1 year old, two were children aged 3 and 10 years and
three were adults aged 20, 23 and 34 years. Blisters
were present at birth in all but one, in whom they
appeared during the following 24 h. Two neonates also
had congenital localized areas of absent skin. Although
not a prominent feature, milia were visible in all
patients and scars were seen on all but the youngest
infant. Some features typical of RDEB-HS, including
dysphagia, dental disease and the consequences of
scarring (i.e. flexion contractures of the limbs, micro¬
stomia, ankyloglossia and mitten deformity of the
hands), were age related, being present in all adults
and the elder but not the younger child nor the infants.
Mild flexion contractures of the fingers and some loss of
interdigital web spaces were present in the 3-year-old
child. All subjects, including the infants, had nail loss
or dystrophy. Each adult had very sparse scalp hair and
none had experienced puberty. Involvement of the
external ear was seen in three patients. Five subjects,
infants and adults, experienced corneal erosions and
one adult had ectropion. Constipation proved trouble¬
some in six patients, being associated in three with anal
fissures. Only one subject, an infant, did not have oral
blisters. Neither EB pruriginosa nor albopapuloid
lesions were observed. Barium studies in two adults
confirmed the presence of oesophageal strictures.
Analysis of DNA from one patient identified compound
heterozygous mutations of COL7A1. Since the onset of
this study, the effects of scarring have become more
apparent in the infants and dysphagia has become
troublesome to such an extent that two have now
received gastrostomies. Two adults died during the
study period—one from metastatic squamous cell
carcinoma (SCC) arising in the skin and the second
from aspiration of gastric contents during an influenza¬
like illness. The eldest adult has recently developed her
first cutaneous SCC.
Non-Hallopeau—Siemens recessive dystrophic epidermolysis
bullosa
Localized recessive dystrophic epidermolysis bullosa. In
five adults, the clinical features were relatively mild and
the pedigrees suggestive of recessive inheritance. Four
were siblings and have been previously reported.'1
There was no evidence of consanguinity in either
family. Clinical information is available for three of the
four siblings and for the unrelated patient. Blisters had
been present at birth in three patients and had
appeared during the following 4 weeks in one; there
had been congenital absence of a localized area of skin
in three. All blistered readily in response to minor
trauma during childhood and teenage years, but
reported marked improvement of skin fragility during
adult life. When interviewed for this study the four
subjects were aged between 3 b and 47 years. They had
all experienced normal puberty and had unaffected
children. All had atrophic scars over bony prominences
and either nail loss or dystrophy. Milia. mild finger
flexion contractures, albopapuloid lesions and external
ear involvement were each seen in individual patients.
Pseudosyndactyly and corneal erosions did not occur.
Two sisters experienced pruritus, which in the first was
accompanied by pruriginous change over the pretibial
areas and posterior shoulders and in the second
affected the perineum. A number of contact sensitivities
had been identified by the referring hospital in this
latter patient. Oral blisters, dental disease and anal
fissures were present in every patient and constipation
was troublesome in three of the four. Two had some
restriction of mouth opening and protrusion of the
tongue. Oesophagoscopy and barium swallows had
previously revealed the presence of oesophageal webs
in all four and, in addition, oesophageal strictures had
been seen in two."' The siblings had required repeated
oesophageal dilatations from the late teenage or early
adult years, but after 10 years, dysphagia resolved in
two, at the age of 26 and 36 years.
Inverse form of recessive dystrophic epidermolysis bullosa.
Two unrelated woman aged 48 and 57 years at
interview were affected by flexural erosions in addition
to blisters and scarring over bony prominences. The
parents of the elder, an only child, shared a common
ancestor from a remote part of Scotland. Milia. finger
flexion contractures, loss of nails and oral blisters were
seen in both patients. They also both had dental
disease, ankyloglossia, mild microstomia and anal
fissures. Constipation was troublesome only in one.
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Both patients experienced dysphagia as a consequence
of oesophageal strictures, and underwent repeated
oesophageal dilatations. Both also suffered blistering
of the pinnae and one had bilateral stenosis of the
external auditory meatus associated with deafness. The
elder of the two patients died during the study from an
SCC arising in the oesophagus.
Albopapuloid lesions
In a significant minority of patients with DDEB (20
patients, i.e. 31%, from 10 families), examination of the
lumbar area revealed multiple slightly depressed areas
resembling subtle atrophic scars, each measuring
about 1 cm in width and having a finely wrinkled
surface (Fig. 1).
These were found in DDEB of all severities but were
not universally present in adult members of any
pedigree. They were also seen in DEB-unc (eight
unrelated patients) and in one patient with localized
RDEB (RDEB-loc). The youngest subject in whom they
were present was 6 years old.
In some cases, albopapuloid lesions were represented
by small ivory-white papules16 (Fig. 2), which occurred
on the upper trunk, arms and buttocks of six patients
(two with mild DEB-unc and four unrelated individuals
suffering from DDEB of a wide range of severity). The
youngest affected was 14 years old. Two patients
complained of associated itching. Both variants of
albopapuloid lesions were visible simultaneously on the
skin of two individuals.
'Epidermolysis bullosa pruriginosa'
Intense itching, associated with the formation of
pretibial lichenified nodules or plaques, is a distinctive
Figure 1. Albopapuloid lesion on the lumbar area.
Figure 2. Albopapuloid lesions on the trunk.
clinical picture that is genetically diverse.17,18 In our
study it was seen in DDEB, RDEB and DEB-unc. The
appearance may be confused clinically with both
hypertrophic lichen planus and nodular prurigo.
Among the Scottish families, itchy pretibial lesions were
present in two unrelated adults with DDEB and two with
DEB-unc. In each of these latter patients, the lesions
were remarkably extensive and linear (Fig. 3). Onset of
hypertrophic scarring was delayed until adult life.
Perineal itching in DEB has been reported previous¬
ly,19 and was seen in one Scottish adult woman with
RDEB-loc. Her affected sister also experienced itching
but the clinical appearance in her case was that of
nodular prurigo.
Discussion
By actively seeking EB sufferers within a population we
have found that the prevalence of DEB in Scotland
(now 24 per million) far exceeds any previous reports.
The high Scottish prevalence of DDEB, although
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Figure 3. Hypertrophic linear plaques on pretibial skin in epi¬
dermolysis bullosa pruriginosa.
undoubtedly an underestimate, is particularly striking
when compared with data from the U.S.A.9 (Table 4)
where it is likely that the large population and different
health care system may hinder full detection of EB
sufferers. Despite these apparent differences, our clin¬
ical findings are broadly in agreement with those of the
U.S. national EB registry. Milia, a non-specific feature of
most blistering disorders, were less common in Scottish
DDEB sufferers, perhaps reflecting inclusion in the U.K.
EB register of patients with mild disease who were not
actively blistering at the time of clinical examination.
Otitis externa was found more frequently in all
subtypes of DEB in Scotland, but the difference was
particularly marked in those with RDEB-HS (37% in
Scotland, 9% in the U.S.A.) and RDEB-loc (25% in
Scotland and 4-1% in the U.S.A.). Other clinical
features (corneal erosions, nail involvement, scarring,
contractures, pseudosyndactyly, constipation, dyspha¬
gia, oral blistering, ankyloglossia and microstomia)
occurred with similar frequencies to those reported
from the U.S.A.9'10
With the exception of one individual, all Scottish
RDEB-HS sufferers had blisters at birth, the remaining
patient developing blisters within the following 24 h.
However, early blistering does not inevitably indicate
either recessive inheritance or a poor prognosis. Eight¬
een of the 43 DDEB patients in whom the age at onset
of blistering is known, started to blister within the first
week postpartum (Table 2). Although eight (44%) of
this early onset group experienced a variety of trou¬
blesome extracutaneous features, the remaining 10
(56%) had mild disease confined to the skin. At least 37
(58%) Scottish DDEB sufferers had no blisters at birth,
and 25 (39%) did not develop blisters until after the
fourth week of life. This finding contrasts with the
recently published revised classification of EB, which
states that in DDEB it is usual for blisters to be present
at birth.10 This apparent discrepancy probably reflects
more complete sampling of Scottish DDEB patients and
inclusion of more patients with mild disease.
For most sufferers, DDEB does not impose serious
difficulties, and many experience improvement of the
blistering tendency during early adult life; some even
consider their skin to be normal. Consequently, there is
considerable under-reporting leading to the misleading
impression that DEB is inevitably a severe disorder. For
many the cosmetic consequences of scarring are the
most troublesome aspect of their disease, causing
psychological difficulties and social embarrassment
rather than physical disability. A significant minority
of DDEB sufferers, in both Scotland and the U.S.A.,9
have a more severe phenotype, experiencing contrac¬
tures, microstomia, dysphagia and anal fissures, clinical
features that are more often associated with RDEB.
Gastrointestinal manifestations of DEB can occur even
Table 4. Prevalences of dystrophic epidermolysis bullosa (DEB) subtypes per million in the U.S.A. and Scotland
DDEB (n) DEB-unc (n) All RDEB (n) RDEB-HS (n) RDEB-nHS (n)
Scotland 17-2 (88) 4-7 (24) 2-54 (13) 1-36 (7) 1-17 (6)
U.S.A. 0-87 (216) 0-37(91) 0-8 (98) 0-36(90) 0-43(108)
DDEB, dominant DEB; DEB-unc, DEB of uncertain inheritance; RDEB, recessive DEB; RDEB-HS, RDEB of Hallopeau-Siemens subtype; RDEB-nHS,
non-Hallopeau-Siemens RDEB.
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in the absence of active blistering and, unless cutaneous
signs of DDEB are sought in such patients, EB may not
be apparent as the cause of anal disease or dysphagia. In
both Scotland and the U.S.A., dysphagia is apparently
more common than oesophageal webs or strictures. Not
all our patients underwent barium studies, but it is
significant that in some with troublesome dysphagia
and a history of producing oesophageal casts, no
structural abnormality could be demonstrated.
Because scarring and its sequelae become more
apparent with increasing age, some of the hallmarks of
DEB may not be found in infants or children. The
mitten deformity, a characteristic feature of RDEB-HS,
was not seen in any child aged under 4 years, although
finger flexion contractures and some loss of digital web
spaces were apparent by the age of 3 years. Nail loss or
dystrophy, one of the most common physical signs in
DEB, was absent in those DDEB sufferers under 3 years
old and occurred in only 15% of children with this
subtype aged 5 years or under (data not shown).
Contractures, uncommon in DDEB, occurred solely in
adults, and dysphagia was present in only one child
with this subtype.
Dental disease due to caries occurs in all subtypes of
DEB and is preventable. The teeth are structurally
normal,20 but restricted access as a result of microsto¬
mia and pain from oral blisters contributes to poor oral
hygiene. In those suffering from dysphagia, a high
carbohydrate diet may also contribute to dental decay.
Of those with DDEB in this study, none of the 15
children under 5 years old and only three subjects
under 20 years old had evidence of dental disease.
Albopapuloid lesions (Figs 1 and 2) are a striking
clinical finding in DEB, but they do not appear to be of
diagnostic or prognostic significance. Although most
common in DDEB, they also occur in other subtypes of
DEB and have been reported in junctional EB.21
As yet, there is no explanation for the development of
the EB pruriginosa phenotype. Molecular studies have
revealed a range of both heterozygous and compound
heterozygous COL7A1 mutations in this distinctive
clinical variant.18 Identical mutations have been found
in DEB sufferers with a non-pruriginous phenotype,
indicating that additional genetic or environmental
factors, perhaps atopy, may be implicated.18
The reason for improvement of the blistering ten¬
dency or dysphagia with age is not known. Phenotypic
variation within individual pedigrees is also difficult to
explain. Analysis of COL7A1 mutations or of genes
encoding structurally or functionally related proteins
may provide some of the answers. When these inves¬
tigations become more readily accessible, accuracy of
diagnosis of EB subtype will be improved. Like previous
studies of EB, we have demonstrated overlap of clinical
features between the subtypes of DEB. It is important
that diagnosis of EB subtype should not rely on clinical
features alone but should be aided by ultrastructural
studies, antibody mapping and, where appropriate, by
mutational analysis. Determination of COL7A1 muta¬
tions is essential if accurate genetic counselling is to be
given to families at risk of having a severely affected
child and to those patients with moderately severe DEB-
unc. These latter patients usually prove to have mild
RDEB or, less commonly, de novo sporadic dominant
mutations. More unusual inheritance patterns such as
uniparental disomy have been reported,22 with pro¬
found implications when assessing risks to future
pregnancies.
Challenges for the future25 include preventing the
devastating effects of scarring both in the small
proportion of severely affected DEB sufferers and in
those with milder disease for whom scars are a
cosmetic embarrassment. Prevention and better treat¬
ment of SCCs, the major cause of death in RDEB,10 are
of great importance, and frequent total skin inspections
are an essential part of the management of those with
severe DEB. Although DEB can be a devastating
disorder, presenting numerous and difficult challenges
to patients, clinicians and researchers, for most DEB
sufferers it is not a severe disease.
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Quality of life in epidermolysis bullosa
H. M. Horn and M. J. Tidman
Royal Infirmary of Edinburgh, Edinburgh, UK
Summary The quality of life of people with epidermolysis bullosa (EB) living in Scotland was
assessed by postal questionnaire using the Dermatology Life Quality Index (DLQI) and
the Children's Dermatology Life Quality Index (CDLOI). There were 143 people with EB
simplex (EBS) and 99 individuals with non-Hallopeau-Siemens subtypes of dystrophic
EB (DEB). A further six individuals had the severe Hallopeau-Siemens subtype of DEB
(RDEB-HS). The overall response was 48% (EBS 52%, DEB 40% and RDEB-HS 83%).
Impairment of quality of life (OOL) was greatest in those with RDEB-HS, mean scores
(adults, 18; children, 22) exceeding those of any skin disorder previously assessed. The
effect on OOL of EBS and other subtypes of DEB was similar to that ofmoderately severe
psoriasis and eczema. EBS had a greater impact on 00L than the non-Hallopeau-
Siemens subtypes of DEB (EBS adults mean score, 10.7; EBS children mean score, 15;
DEB adults mean score, 7.5; DEB children mean score, 11.5).
Introduction
Skin disease can have a profound impact on many
aspects of daily life. Pain, itch, odour and time-consu¬
ming dressings are problems which impinge on self
confidence, social activities personal relationships, edu¬
cation and employment. The Dermatology Life Quality
Index (DLQI)1 (Fig. 1) and the Children's Dermatology
Life Quality Index (CDLOI)2 (Fig. 2) have emerged as
useful tools for assessing the quality of life of those with
skin diseases, comparing severities of different disorders
and judging the effectiveness of treatments.1-10 Our aim
was to document the impact of variants of epidermolysis
bullosa (EB) on quality of life.
Methods
Details of all EB sufferers living in Scotland were derived
from the EB Register.11 In the first of three diagnostic
groups (group A), there were 143 EB simplex (EBS)
sufferers. One-hundred and eleven adults and 2 7 children
had either EBS Weber-Cockayne or EBS-Kobner and five
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patients (three adults and two children) had the Dowling-
Meara subtype of EBS (EBS-DM). Adults were aged
between 16 and 86 years (mean 41 years) and children
between 1 and 15 years (mean 10 years). In group B
there were 99 dystrophic EB (DEB) sufferers comprising
53 adults and 20 children with dominant DEB, 12 adults
and eight children with DEB of uncertain inheritance
(DEB-unc) and six adults with non-Hallopeau-Siemens
recessively inherited DEB (RDEB-nHS). Adults were aged
between 16 and 84 years (mean 44 years) and the ages
of the children ranged from 3.5 to 15 years (mean
10 years). Six patients with RDEB-HS were considered in
group C, an adult aged 40 years and five children aged
from 3.5 to 15 years (mean 6 years, median 3.5 years).
The DLQI and an explanatory letter stressing the
anonymity of replies were posted in early May to every
Scottish EB sufferer aged 16 years or over. Parents of
those aged under 16 were sent a copy of the CDLQI for
each of their affected children. After an interval of
2 weeks, a reminder was posted to every patient. To
enable correlation of replies with subtype of EB, ques¬
tionnaires were colour coded, different colours corres¬
ponding to each of the three diagnostic groups.
The (C)DLOI contains 10 questions relating to
experiences during the previous week.1,2 Each question
has five possible answers (very much, a lot, a little, not
at all or not relevant) which score 3, 2, 1, 0 or 0,
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1 Over the last week, how itchy, sore, painful or stinging has your skin been?
2 Over the last week, how embarrassed or self conscious have you been because ofyour skin?
3 Over the last week, how much has your skin interfered with you going shopping, or looking after your home or garden?
4 Over the last week, how much has your skin influenced the clothes you wear?
5 Over the last week, how much has your skin affected any social or leisure activities?
6 Over the last week, how much has your skin made it difficult for you to do any sport?
7 Over the last week, has your skin prevented you from working or studying?
If "No", over the last week, how much has your skin been a problem at work or studying?
8 Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?
9 Over the last week, how much has your skin caused any sexual difficulties?
10 Over the last week, how much of a problem has the treatment of your skin been, for example by making your home messy or
by taking up time?
Figure 1 The DLQI.
1. Over the last week, how itchy, "scratchy", sore or painful has your skin been?
2. Over the last week, how embarrassed or self conscious, upset or sad have you been because ofyour skin?
3. Over the last week, how much has your skin affected your friendships?
4. Over the last week, how much have you changed or worn different or special clothes/ shoes because ofyour skin?
5. Over the last week, how much has your skin trouble affected going out, playing or doing hobbies?
6. Over the last week, how much have you avoided swimming or other sports because of your skin trouble?
7. Last week, was it either: If school time: over the last week, how much did your skin affect your school work?
school D
or (answer only one)
holiday time 0 If holiday time: how much over the last week, has your skin interfered with your holiday plans?
8. Over the last week, how much trouble have you had because of your skin trouble, with other people calling you names, teasing,
bullying, asking questions or avoiding you?
9. Over the last week, how much has your sleep been affected by your skin problem?
10. Over the last week, how much of a problem has the treatment of your skin been?
Figure 2 The CDLQI.
respectively. Patients are asked to tick one answer for
each question.
Results
Replies were received from 75 patients in group A (57
adults and 18 children), a response of 52% (adults 50%,
children 62%). In group B, there were 32 replies from
adults (45%) but only eight replies (29%) from children,
an overall response of 40%. Only one of the patients in
group C, a child, did not reply (83% response). Overall,
the response was 48%.
Adults - EBS
The mean total score in group A was 10.7 (range, 0-26:
median, 10). Question 1 (which enquired about symp¬
toms) and question 6 (relating to sport) had the highest
mean scores (1.6 and 1.5: median, 2 in each case)
(Fig. 3). The lowest mean score (0.3) was for question 9
which asked about sexual difficulties. Four patients aged
708 © 2002 Blackwell Science Ltd • Clinical and Experimental Dermatology, 27, 707-710




Figure 3 Mean DLQI scores in adult EB patients.
between 23 and 39 each scored a total of zero. The
question answered 'very much' most often (20 patients.
35%) was number 6.
highest mean score (2.1, median 2), followed by
question 5 (play and hobbies; mean. 1.9; median, 2)
(Fig. 4). The lowest score was for question 8 (teasing
and bullying; mean 0.9, median 0.5). Only one patient
(aged 8.5 years) recorded a total score of 0. In keeping
with adult responses, the question awarded 'very much'
by the greatest number of children (nine children, 50%)
was number 6 (sport).
Children - DEB
The mean total CDLOI score for children with DEB was
11.5 (median, 12.5; range, 0-23). Question 2 (embar¬
rassment and sadness) recorded the highest mean score
(1.7; median, 2), followed by question 1 (symptoms;
mean, 1.6; median, 2) (Fig. 4). The lowest mean score
was for question 3, which asked about friendships
(mean, 0.5; median, 0). Question number 1 was
awarded the maximum score by the most patients
(three patients, 37.5%). One child, aged 8 years, scored
a total of zero.
Adults - DEB
The mean total score was 7.5 (median, 4; range, 0-28).
Questions 1. 2 and 4 (symptoms, embarrassment and
clothing) achieved the highest mean scores of 1.2, 1.0
and 1.0 (median scores of 1 in each case) and question
8 (relationships) had the lowest mean score (0.4;
median, 0) (Fig. 3). Like EBS, the question awarded
'very much' by the greatest number of patients was
number 6 (sport), which was selected by seven (23%)
patients. Five patients, three aged between 67 and 84
and two of unknown age, recorded total scores of zero.
Children - EBS
Children with EBS recorded a mean total score of 15










Figure 4 Mean CDLQI scores for children with EB.
RDEB-HS
The one adult with RDEB-HS recorded a total score of
18. Question numbers 3 (household chores), 6 (sport), 7
(work), and 9 (sexual difficulties) were each awarded a
score of 0, remaining questions scoring 3.
The four children with RDEB-HS scored a mean total
of 22.0 (median, 21; range, 17-29). All patients
answered 'very much' to question 6 (sport). Question
3 (friendships) recorded the lowest mean score (mean,
1.0; median, 1).
Discussion
Despite the limitations of a postal survey and the
possibility of a biased response, our results reflect the
wide variety of problems encountered by EB sufferers.
Adults and children with both EBS and DEB experience
an impairment of quality of life (QOL) equivalent to
that caused by moderate to severe psoriasis and atopic
Table 1 Mean (C)DLQI scores in skin disorders.
Adults Children
Atopic eczema 4.143—16.24 7.72-12.75
Psoriasis 4.53-13.94 -
Hidradenitis suppurativa 8.95 -
Urticaria 7.5-157 -
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eczema (Table 1). Like most other skin disorders,
question 1, relating to symptoms, was scored most
highly by those in groups A and B. Comparison with
other studies suggests that RDEB-HS causes greater
impairment of QOL than any skin disease previously
assessed (Table 1). This impairment is further empha¬
sized by the fact that scores from some of these patients
were artificially lowered by responses 'not at all' or 'not
relevant' to questions on matters entirely incompatible
with the lifestyle of RDEB-HS sufferers. These include
sport, sexual difficulties, and domestic duties.
EBS is often considered to be the mildest subtype of EB
but this survey indicates that it has a more marked
effect on OOL than the non-Hallopeau-Siemens variants
of DEB. Patients' replies reflect the greater restriction of
physical, social and sporting activities caused by EBS
compared to DEB and also its greater impact on
employment and education. Despite the often visible
lesions of DEB. children with EBS, whose blisters are
usually concealed by footwear, find more difficulties
with friendships. Pain prevents participation by those
with EBS in the more physical aspects of normal
childhood and in our experience, this can lead to social
isolation or psychological problems. Undoubtedly, some
DEB sufferers do experience great difficulties, but the
majority of those with dominant DEB and even some
with RDEB-nHS, have only mild disease.13
Although some patients with EBS and DEB experience
an improvement of the blistering tendency during adult
life, many do not12 and for them impairment of OOL is
lifelong.
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